<SEC-DOCUMENT>0001047469-13-004692.txt : 20130423
<SEC-HEADER>0001047469-13-004692.hdr.sgml : 20130423
<ACCEPTANCE-DATETIME>20130423081739
ACCESSION NUMBER:		0001047469-13-004692
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130612
FILED AS OF DATE:		20130423
DATE AS OF CHANGE:		20130423
EFFECTIVENESS DATE:		20130423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		13775209

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2214489zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#13ZAC72001_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Celldex Therapeutics, Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=628658,FOLIO='blank',FILE='DISK126:[13ZAC1.13ZAC72001]BA72001A.;4',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>119 FOURTH AVENUE<BR>
NEEDHAM, MA 02494  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<BR>
To be held on June&nbsp;12, 2013  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To the Stockholders of<BR>
Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOTICE IS HEREBY GIVEN</B></FONT><FONT SIZE=2> that the Annual Meeting of Stockholders of Celldex Therapeutics,&nbsp;Inc. (the "Company" or "we" or "us") will
be held at the offices of Lowenstein Sandler LLP, 65 Livingston Avenue, Roseland, New Jersey 07068, on June&nbsp;12, 2013 beginning at 9:00&nbsp;a.m. local time. At the meeting, stockholders will
act on the following matters to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>elect seven directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall
have been duly elected and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the
year ending December&nbsp;31, 2013; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by
137,500 to 200,000; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in this proxy
statement; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
stockholders of record at the close of business on April&nbsp;15, 2013 are entitled to receive notice of and to vote at the Annual Meeting or any postponement or adjournment
thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. Whether you plan to attend the meeting or not, you may vote your shares by marking, signing, dating and mailing the enclosed proxy card in the envelope provided.
If you attend the meeting and prefer to vote in person, you may do so even if you have already voted your shares. You may revoke your proxy in the manner described in the proxy statement at any time
before it has been voted at the meeting. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Avery W. Catlin<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer and Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:times;"><FONT SIZE=2>April&nbsp;25,
2013<BR>
Needham, MA </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=436435,FOLIO='blank',FILE='DISK126:[13ZAC1.13ZAC72001]BE72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>119 FOURTH AVENUE<BR>
NEEDHAM, MA 02494  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement contains information related to the Annual Meeting of Stockholders to be held on June&nbsp;12, 2013 at 9:00&nbsp;a.m.
local time, at the offices of Lowenstein Sandler&nbsp;LLP, 65 Livingston Avenue, Roseland, New Jersey 07068, or at such other time and place to which the Annual Meeting may be adjourned or
postponed. The enclosed proxy is solicited by the Board of Directors of Celldex Therapeutics,&nbsp;Inc. The proxy materials relating to the Annual Meeting are being mailed to stockholders entitled
to vote at the meeting on or about April&nbsp;25, 2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Important Notice of Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June&nbsp;12, 2013.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Our proxy materials, including our Proxy Statement for the 2013 Annual Meeting, 2012 Annual Report to Stockholders (which contains our Annual Report on
Form&nbsp;10-K) and proxy card, are available on the Internet at www.proxyvote.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc72001_about_the_meeting"> </A>
<A NAME="toc_dc72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THE MEETING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Why are we calling this Annual Meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are calling the Annual Meeting to seek the approval of our stockholders to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>elect seven directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall
have been duly elected and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the
year ending December&nbsp;31, 2013; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by
137,500 to 200,000; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in this proxy
statement; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> What are the Board's recommendations?  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors recommends that you vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the election of each of the seven director nominees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the ratification of the appointment of
PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2013; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the approval of an amendment to our 2004 Employee Stock Purchase Plan
to increase the shares reserved for issuance thereunder by 137,500 to 200,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> an advisory vote on the compensation of the named executive officers
as described in this proxy statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Who is entitled to vote at the meeting?  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date, April&nbsp;15, 2013, are entitled to receive notice of the
Annual Meeting and to vote the shares of common stock that they held on that </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=31240,FOLIO='blank',FILE='DISK126:[13ZAC1.13ZAC72001]DC72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dc72001_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>date
at the meeting, or any postponement or adjournment of the meeting. Holders of our common stock are entitled to one vote per share on each matter to be voted upon. As of the record date, we had
80,870,320 outstanding shares of common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Who can attend the meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All stockholders as of the record date, or their duly appointed proxies, may attend the Annual Meeting. Please note that if you hold
your shares in "street name" (that is, through a broker or other nominee), you will need to bring a copy of your proxy card delivered to you by your broker or a legal proxy given to you by your broker
and check in at the registration desk at the meeting. For security reasons, you must comply with our pre-registration requirements, you must present a form of government issued photograph
identification on the day of the Annual Meeting and you must arrive at least thirty minutes prior to the meeting in order to attend the Annual Meeting. If you are a stockholder of record and plan to
attend the Annual Meeting, please contact Kathy Reamer by email at kreamer@celldextherapeutics.com or by phone at 908-454-7120 ext. 308 to register to attend the Annual
Meeting. If you hold shares through an intermediary, such as a bank or broker, and you plan to attend, you must send a written request to attend either by regular mail or email, along with proof of
share ownership, such as a bank or brokerage firm account statement, confirming ownership to: Celldex Therapeutics,&nbsp;Inc., 222 Cameron Drive, Suite&nbsp;400, Phillipsburg, NJ 08865, Attn:
Kathy Reamer or kreamer@celldextherapeutics.com. Attendance at the Annual Meeting will be limited to persons who pre-registered on or before June&nbsp;7, 2013, who present a form of
government-issued photograph identification on the day of the Annual Meeting, and who arrive by 8:30 am local time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> What constitutes a quorum?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of our common stock outstanding on the record
date will constitute a quorum for our meeting. Signed proxies received but not voted and broker non-votes will be included in the calculation of the number of shares considered to be
present at the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> How do I vote?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You can vote on matters that come before the Annual Meeting by completing, dating and signing the enclosed proxy card and returning it
in the enclosed postage-paid envelope. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
shares will be voted as you indicate on your proxy card. If you vote the enclosed proxy but you do not indicate your voting preferences, and with respect to any other matter that
properly comes before the meeting, the individuals named on the proxy card will vote your shares FOR the matters submitted at the meeting, or if no recommendation is given, in their own discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a stockholder of record, to submit your proxy by telephone or via the Internet, follow the instructions on the proxy card. If you hold your shares in street name, you may vote
by telephone or via the Internet as instructed by your broker, bank or other nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you attend the Annual Meeting and prefer to vote in person, you may do so even if you have already voted your shares by proxy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> What if I vote and then change my mind?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may revoke your proxy at any time before it is exercised by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>filing with the Secretary of the Company a notice of revocation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>sending in another duly executed proxy bearing a later date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>attending the meeting and casting your vote in person. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
latest vote will be the vote that is counted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=97347,FOLIO='2',FILE='DISK126:[13ZAC1.13ZAC72001]DC72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dc72001_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><B><I> What is the difference between holding shares as a stockholder of record and as a beneficial owner?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our stockholders hold their shares through a stockbroker, bank or other nominee rather than directly in their own name. As
summarized below, there are some distinctions between shares held of record and those owned beneficially. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Stockholder of Record  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you are considered,
with respect to those shares, the stockholder
of record. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote in person at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Beneficial Owner  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares
held in street name, and these proxy materials are being forwarded to you by your broker, bank or nominee which is considered, with respect to those shares, the stockholder of record. As the
beneficial owner, you have the right to direct your broker as to how to vote and are also invited to attend the Annual Meeting. However, because you are not the stockholder of record, you may not vote
these shares in person at the Annual Meeting unless you obtain a signed proxy from the record holder giving you the right to vote the shares. If you do not vote your shares or otherwise provide the
stockholder of record with voting instructions, your shares may constitute broker non-votes. The effect of broker non-votes is more specifically described in "What vote is required to approve each
proposal?" below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> What are "broker non-votes"?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broker non-votes occur when nominees, such as banks and brokers holding shares on behalf of beneficial owners, do not
receive voting instructions from the beneficial holders at least ten days before the meeting. If that happens, the nominees may vote those shares only on matters deemed "routine", such as the
ratification of auditors. Nominees cannot vote on non-routine matters unless they receive voting instructions from beneficial holders, resulting in so-called "broker
non-votes." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
election of directors (Proposal No.&nbsp;1), the approval of an amendment to our 2004 Employee Stock Purchase Plan (Proposal No.&nbsp;3) and the advisory vote on the compensation
of our named executive officers (Proposal No.&nbsp;4) are not considered to be "routine" matters and brokers are not permitted to vote on those matters if the broker has not received instructions
from the beneficial owner. Accordingly, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares. The ratification of our independent registered
public accounting firm (Proposal No.&nbsp;2) is considered to be a "routine" matter, and hence your brokerage firm will be able to vote on Proposal No.&nbsp;2 even if it does not receive
instructions from you, so long as it holds your shares in its name. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business. Abstentions and
broker non-votes are not counted for the purpose of determining the number of votes cast and will therefore not have any effect with respect to any of the proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> What vote is required to approve each proposal?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of a majority of the outstanding shares entitled to vote must be present, in person or by proxy, at the Annual Meeting in order
to have the required quorum for the transaction of business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=247305,FOLIO='3',FILE='DISK126:[13ZAC1.13ZAC72001]DC72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dc72001_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2>Pursuant
to Delaware corporate law, abstentions and broker non-votes will be counted for the purpose of determining whether a quorum is present. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that a quorum is present, the following votes will be required:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>With respect to the election of directors (Proposal No.&nbsp;1), the seven nominees receiving the highest number of FOR
votes (from the holders of shares present in person or represented by proxy) will be elected as directors. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>With respect to the ratification of the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered
public accounting firm (Proposal No.&nbsp;2), approval will require the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>With respect to the approval of an amendment to our 2004 Employee Stock Purchase Plan (Proposal No.&nbsp;3), approval
will require the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>With respect to the advisory vote on the compensation of our named executive officers as disclosed in this proxy statement
(Proposal No.&nbsp;4), approval will require the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of the common stock will not have any dissenters' rights of appraisal in connection with any of the matters to be voted on at the meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> How are we soliciting this proxy</I></B></FONT><FONT SIZE=2>? </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are soliciting this proxy on behalf of our Board of Directors by mail and will pay all expenses associated therewith. Some of our officers and other
employees also may, but without compensation other than their regular compensation, solicit proxies by further mailing or personal conversations, or by telephone, facsimile or other electronic means.
We will also, upon request, reimburse brokers and other persons holding stock in their names, or in the names of nominees, for their reasonable out-of-pocket expenses for forwarding proxy materials to
the beneficial owners of the capital stock and to obtain proxies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=993927,FOLIO='4',FILE='DISK126:[13ZAC1.13ZAC72001]DC72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de72001_1_5"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de72001_proposal_1__to_elect_seven_dir__pro05596"> </A>
<A NAME="toc_de72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1: TO ELECT SEVEN DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING<BR>  AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY<BR>  ELECTED AND QUALIFIED    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de72001_(proposal_no._1)"> </A>
<A NAME="toc_de72001_2"> </A></FONT> <FONT SIZE=2><B>  (Proposal No.&nbsp;1)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, seven directors are to be elected. All directors of the Company hold office until the next Annual Meeting of
Stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is the intention of the persons named in the proxies for the holders of common stock to vote the proxies for the election of the nominees named below, unless otherwise specified in
any particular proxy. Our management does not contemplate that the nominees will become unavailable for any reason, but if that should occur before the meeting, proxies will be voted for another
nominee, or other nominees, to be selected by our Board of Directors. In accordance with our by-laws and Delaware law, a stockholder entitled to vote for the election of directors may
withhold authority to vote for certain nominees for directors or may withhold authority to vote for all nominees for directors. The director nominees receiving a plurality of the votes of the holders
of shares of common stock present in person or by proxy at the meeting and entitled to vote on the election of directors will be elected directors. Broker non-votes will not be treated as
a vote for or against any
particular director nominee and will not affect the outcome of the election. Stockholders may not vote, or submit a proxy, for a greater number of nominees than the seven nominees named below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Nominees for Election  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The persons listed below are our current directors and have been nominated for re-election (the "Director Nominees") to
fill the seven director positions to be elected by the holders of the common stock. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:33pt;"><FONT SIZE=1><B>Directors

<!-- COMMAND=ADD_SCROPPEDRULE,33pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year First<BR>
Became<BR>
Director </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger (Chairman of the Board)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2003</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci (Chief Executive Officer)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George O. Elston</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Timothy M. Shannon, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following biographical descriptions set forth certain information with respect to the Director Nominees, based on information furnished to Celldex by each Director Nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Director Nominees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Larry Ellberger</B></FONT><FONT SIZE=2> was appointed Chairman of the Board of Directors in September 2009 and
has been a director of Celldex since August 2003. From 2003 to July 2012, Mr.&nbsp;Ellberger was Founding Partner of HVA,&nbsp;Inc. a consulting firm specializing in business development, product
acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery, and medical device companies. From October 2005 to May 2006, Mr.&nbsp;Ellberger was Interim
Chief Executive Officer of PDI,&nbsp;Inc., a provider of sales and marketing services to the biopharmaceutical industry. Previously, he was a member of the Board of Directors of PDI and Chairman of
the Audit Committee. From 2000 to 2003, Mr.&nbsp;Ellberger was Senior Vice President of Powderject&nbsp;PLC, a U.K. vaccine company. He was also a member of the Board of Directors of Powderject.
From 1995 to 1999, Mr.&nbsp;Ellberger held several </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=7,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=335754,FOLIO='5',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2>positions
at W.R. Grace&nbsp;&amp;&nbsp;Co. including Interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development. From 1975 to 1995,
Mr.&nbsp;Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. Mr.&nbsp;Ellberger currently serves
on the Board of Directors of The Jewish Children's Museum. Mr.&nbsp;Ellberger was formerly Chairman of the Board of Omrix BioPharmaceuticals,&nbsp;Inc. until its acquisition by Johnson&nbsp;&amp;
Johnson in 2008. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed as permanent President and Chief Executive Officer of Celldex in September 2008 and as a director of
Celldex in December 2008. From May 2008 to September 2008 Mr.&nbsp;Marucci served as the Chief Executive Officer and President on an interim basis in addition to his role as Executive Vice
President, Corporate Development which he assumed upon consummation of the merger of Celldex Research Corporation (formerly known as Celldex Therapeutics,&nbsp;Inc.) ("Celldex Research") and Celldex
(formerly known as AVANT Immunotherapeutics,&nbsp;Inc.) (the "AVANT Merger") in March 2008. Prior to the AVANT Merger, Mr.&nbsp;Marucci had been Celldex Research's Acting Chief Executive Officer
since October 2007 and its Vice President, Chief Financial Officer, Treasurer and Secretary since May 2003. In addition, he was Treasurer of Medarex,&nbsp;Inc. from December 1998 to March 2004.
Mr.&nbsp;Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. Mr.&nbsp;Marucci is a member of the Board of Trustees of BioNJ&nbsp;Inc. and also served
as its Treasurer through 2010. Mr.&nbsp;Marucci received his M.B.A. from Columbia University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Herbert J. Conrad</B></FONT><FONT SIZE=2> became a director of Celldex in March 2008 upon consummation of the AVANT Merger. Mr.&nbsp;Conrad had been a director
of Celldex Research since March 2004. Mr.&nbsp;Conrad was President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche,&nbsp;Inc., a pharmaceutical company, from 1982 until his
retirement in 1993. Mr.&nbsp;Conrad currently serves as Chairman of the Board of Matinas BioPharma, a privately held biopharmaceutical company. In
addition to serving on the board of directors of privately held biotechnology companies, Mr.&nbsp;Conrad has served as Chairman of the Board of Directors of Pharmasset,&nbsp;Inc.,
GenVec,&nbsp;Inc. and Bone Care International,&nbsp;Inc. Mr.&nbsp;Conrad has also served as director of Savient Pharmaceuticals,&nbsp;Inc. and was a director and co-founder of
Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company. He received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long
Island University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>George O. Elston</B></FONT><FONT SIZE=2> became a director of Celldex in March 2008 upon consummation of the AVANT Merger. Mr.&nbsp;Elston had been a director
of Celldex Research since March 2004. Mr.&nbsp;Elston has served as the managing partner of Chatham Street Partners, a strategic advisory firm to the Life Science industry since January 2010. From
January 2008 to January 2010, Mr.&nbsp;Elston was Chief Financial Officer of Optherion,&nbsp;Inc., a privately held biopharmaceutical company. From May 2000 to September 2007, Mr.&nbsp;Elston
was Vice President of Finance and Government Affairs of Elusys Therapeutics,&nbsp;Inc., a privately held biopharmaceutical company. Before joining Elusys, Mr.&nbsp;Elston was Chief Financial
Officer of Trillium USA,&nbsp;Inc. Prior to Trillium, Mr.&nbsp;Elston was with C.R. Bard,&nbsp;Inc., an international manufacturer and distributor of medical devices, and with
PricewaterhouseCoopers. Mr.&nbsp;Elston serves as a Trustee and is a member of the Audit and Nominating Committees of the Deutsche Bank DBX ETF Trust, an investment management company.
Mr.&nbsp;Elston received his B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Harry H. Penner, Jr.</B></FONT><FONT SIZE=2> has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT
Merger. Mr.&nbsp;Penner has served as Chairman and Chief Executive Officer of Nascent BioScience,&nbsp;LLC, a firm engaged in the creation and development of new biotechnology companies since
2001. From 1993 to 2001, Mr.&nbsp;Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, Mr.&nbsp;Penner was an Executive Vice President of
Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President
and General Counsel in Denmark. He has served as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=8,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=69917,FOLIO='6',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2>BioScience
Advisor to the Governor and the State of Connecticut, as Co-Chairman of Connecticut United for Research Excellence, and as Chairman of the Connecticut Board of Governors of
Higher Education and the Connecticut Technology Council. Mr.&nbsp;Penner is currently on the Board of Directors of New Haven Pharmaceuticals, Inc. (of which he is Executive Chairman), Prevention
Pharmaceuticals, Inc., Affinimark Technologies,&nbsp;Inc. and Marinus Pharmaceuticals,&nbsp;Inc., all privately held companies. In addition to having served on the board of directors of privately
held life science companies, Mr.&nbsp;Penner served on the Board of Directors and Audit Committee of Altus Pharmaceuticals, Inc. until October 2009. Mr.&nbsp;Penner received a B.A. from the
University of Virginia, a&nbsp;J.D. from Fordham University, and an L.L.M. in International Law from New York University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Timothy M. Shannon, M.D.</B></FONT><FONT SIZE=2> became a director of Celldex in October 2009 upon the acquisition of CuraGen Corporation ("CuraGen") by Celldex
(the "CuraGen Acquisition"). Since December 2009, Dr.&nbsp;Shannon has been a Venture Partner at Canaan Partners, a global venture capital firm. Since September 2011, Dr.&nbsp;Shannon has been a
member of the Board of Directors and interim President and CEO of ALDEA Pharmaceuticals,&nbsp;Inc., a privately held biotechnology company. From September 2007 to October 2009, Dr.&nbsp;Shannon
served as CuraGen's President and Chief Executive Officer and a member of its board of directors. From January 2004 until September 2007, Dr.&nbsp;Shannon served as CuraGen's Executive Vice
President and Chief Medical Officer. From September 2002 until December 2003, Dr.&nbsp;Shannon served as CuraGen's Senior Vice President of Research and Development. Prior to joining CuraGen,
Dr.&nbsp;Shannon worked in positions of increasing responsibility for Bayer's Pharmaceutical Business Group, where his last position was Head and Senior Vice President of Global Medical Development.
Dr.&nbsp;Shannon currently serves as a director of Civitas Therapeutics,&nbsp;Inc., Novira Therapeutics&nbsp;Inc. and CytomX Therapeutics,&nbsp;Inc., all privately held biotechnology
companies. Dr.&nbsp;Shannon earned his B.A. in Chemistry from Amherst College and his M.D. from the University of Connecticut School of Medicine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Karen L. Shoos</B></FONT><FONT SIZE=2> has been a director of Celldex since May 2001. Ms.&nbsp;Shoos has been Chief Executive Officer of AABB since October
1994. AABB is a professional standards setting and accrediting organization in the fields of blood and cellular therapies. Prior to AABB, from 1984 to 1994, Ms.&nbsp;Shoos held senior positions at
the American Red Cross, including Acting Senior Vice President, Biomedical Services (1993-1994) and Secretary and General Counsel (1990-1993). Prior to the American Red Cross,
Ms.&nbsp;Shoos was a lawyer in private practice. Ms.&nbsp;Shoos earned her B.A. from Yale University and her J.D. from Case Western Reserve University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Family Relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no family relationships among our Director Nominees, management and other key personnel. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> The Board of Directors and Its Committees  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently managed by a seven member Board of Directors, a majority of whom are "independent" as that term is defined in the
applicable NASDAQ listing standards. Other than Mr.&nbsp;Marucci, each of our directors is deemed "independent" as that term is defined in the applicable NASDAQ listing standards. Our Board of
Directors met four times in 2012. Each of the directors attended at least 75% of the aggregate of (i)&nbsp;the total number of meetings of our Board of Directors (held during the period for which
such directors served on the Board of Directors) and (ii)&nbsp;the total number of meetings of all committees of our Board of Directors on which the Director served (during the periods for which the
director served on such committee or committees). Our annual meeting of stockholders is generally held to coincide with one of the Board's regularly scheduled meetings. We do not have a formal policy
requiring members of the Board of Directors to attend our annual meetings, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=9,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=729493,FOLIO='7',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2>although
our directors typically attend the annual meeting. Each of the then current directors attended the 2012 annual meeting of stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger, and Harry
H. Penner, Jr. The Audit Committee makes recommendations concerning the engagement of independent public accountants, reviews with the independent public accountants the scope and results of the audit
engagement, approves professional services provided by the independent public accountants, reviews the independence of the independent public accountants, considers the range of audit and
non-audit fees, and reviews the adequacy of our internal accounting controls. Each member of the Audit Committee is "independent" as that term is defined in the rules of the SEC and the
applicable NASDAQ listing standards. The Board has determined that each Audit Committee member has sufficient knowledge in financial and auditing matters to serve on the Committee. The Board has
designated George O. Elston as an "audit committee financial expert," as defined under the applicable rules of the SEC and the applicable NASDAQ listing standards. The Audit Committee met six times
during 2012. Our Board has adopted an Audit Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Compensation Committee currently consisting of Karen&nbsp;L. Shoos, Chair, George O. Elston
and Harry H. Penner, Jr. The primary function of the Compensation Committee is to assist the Board in the establishment of compensation for the Chief Executive Officer, to approve the compensation of
other officers and senior employees and to approve certain other personnel and employee benefit matters. Each member of the Compensation Committee is "independent" as that term is defined in the rules
of the SEC and the applicable NASDAQ listing standards. In 2012, the Compensation Committee engaged Radford, an Aon Hewitt Company, to provide guidance on various aspects of the company's executive
compensation programs. The Compensation Committee has assessed the independence of Radford and concluded that no conflict of interests exists under applicable SEC rules. The Compensation Committee met
ten times during 2012. Our Board has adopted a Compensation Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldextherapeutics.com.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Herbert J. Conrad, Chair, Larry
Ellberger and Karen L. Shoos. The primary function of the Nominating and Corporate Governance Committee is to assist the Board in reviewing, investigating and addressing issues regarding Board
composition, policy and structure; membership on Board committees; and other matters regarding our governance. Each member of the Nominating and Corporate Governance Committee is "independent" as that
term is defined in the rules of the SEC and the applicable NASDAQ listing standards. The Nominating and Corporate Governance Committee met three times during 2012. Our Board has adopted a Nominating
and Corporate Governance Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldextherapeutics.com</I></FONT><FONT SIZE=2> . </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Scientific Advisory Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Scientific Advisory Committee consisting of Dr.&nbsp;Timothy Shannon, Chair. The primary
function of the Scientific Advisory Committee is to assist the Board in undertaking periodic reviews of our research and development efforts, and clinical trials, and reporting to the Board about
developments and strategy, at such times as the Committee determines to be appropriate. The sole member of that Committee shall also be invited to attend meetings of our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=10,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=669840,FOLIO='8',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2>Scientific
Advisory Board (the "</FONT><FONT SIZE=2><I>SAB</I></FONT><FONT SIZE=2>") and shall serve as the primary liaison between the Board and the SAB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Director selection criteria  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee is responsible for reviewing, on an annual basis, the appropriate mix of professional
competencies, key attributes, skills and experiences required of board members to work together as a team to properly oversee our strategies and operations. The process followed by the Nominating and
Corporate Governance Committee to evaluate any candidates whether identified or recommended by board members, management, members of the Nominating and Corporate Governance Committee, stockholders or
other external sources, includes meetings from time to time to evaluate biographical information and background material relating to potential candidates to the Board and interviews of selected
candidates by members of the Committee and the Board. All nominees must have, at a minimum, high personal and professional integrity, exceptional ability and judgment, and be effective in collectively
serving the long-term interests of all stockholders, all as described above. Other qualifications that may be considered by the Committee are described in the Nominating and Corporate
Governance Committee's Charter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
board members are expected to possess certain key attributes necessary to creating a functional board: high personal and professional ethics, integrity and values; practical wisdom
and mature judgment; an inquisitive and objective perspective; professional experience at a policy-making level in business, government, education or medicine; time availability for
in-person participation at board and committee meetings; and a commitment to representing the long-term interests of our stockholders. We look for directors with professional
competencies that include senior management operational experience, accounting and finance capabilities, deep industry-related experience, biologic development and manufacturing expertise, business
development leadership, medical and scientific proficiencies, and government and public policy experience. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of our directors brings unique perspectives and experiences to the Board of Directors and contributes in guiding and directing our strategies to meet our business objectives and to
provide value to our stockholders. For example, Messrs.&nbsp;Conrad, Ellberger, Marucci, Penner, Shannon and Ms.&nbsp;Shoos have all either currently or formerly been chief executive officers of
life sciences or healthcare-related companies and have experienced the challenges of such a position. Similarly, Dr.&nbsp;Shannon has formerly been chief medical officer of a biotechnology company
and has the experience of guiding and directing the research and development efforts at that company. Messrs.&nbsp;Ellberger, Elston and Marucci have all formerly been chief financial and chief
corporate development officers at pharmaceutical and life sciences companies and have completed a significant number of financing and business development transactions. Ms.&nbsp;Shoos has experience
in the highly regulated blood supply sector which is similar to
our regulated biologics industry. Mr.&nbsp;Penner has been the chief legal officer at a large public pharmaceutical company and for that company and for life sciences companies has completed a
significant number of financing and business development transactions. Messrs.&nbsp;Conrad and Ellberger have many years of experience on the boards of directors of larger public pharmaceutical and
life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independence
also is an important selection criterion for nomination to our Board. Independent directors should be free of any relationship with us, our management, other directors or
other parties that may impair, or appear to impair, the director's ability to make independent judgments. Independent directors must satisfy the criteria for independence established by NASDAQ.
Currently all of our directors are independent except for our Chief Executive Officer, Mr.&nbsp;Marucci. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
all board members are expected to act in our best interests and the best interests of our stockholders and to avoid any conflicts of interest in accordance with our Code of
Business </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=11,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=151825,FOLIO='9',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2>Conduct
and Ethics. In selecting director nominees, the Nominating and Corporate Governance Committee seeks individuals who are free from conflicts of interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
candidates should be enthusiastic and excited about their service on our Board and working collaboratively with existing board members to create value for all of our
stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Stockholder nominations for directorships  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders may propose a potential director candidate for consideration by the Nominating and Corporate Governance Committee by
submitting their names and background to the Secretary of Celldex at 119 Fourth Avenue, Needham, Massachusetts 02494. All such recommendations will be forwarded to the Nominating and Corporate
Governance Committee, which will review and consider only such recommendations if appropriate biographical and other information is provided, as described below, on a timely basis. All security holder
recommendations for director candidates must be submitted to us not less than 120 calendar days prior to the date on which our proxy statement is released to stockholders in connection with our annual
meeting, and must include the following information:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the name and address of record of the security holder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a representation that the security holder is a record holder of our securities, or if the security holder is not a record
holder, evidence of ownership in accordance with Rule&nbsp;14a-8(b)(2) of the Securities Exchange Act of 1934; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the name, age, business and residential address, educational background, current principal occupation or employment, and
principal occupation or employment for the preceding five (5)&nbsp;full fiscal years of the proposed director candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a description of the qualifications and background of the proposed director candidate which addresses the minimum
qualifications and other criteria for Board membership approved by the Board from time to time and set forth in the Nominating and Corporate Governance Committee's written charter; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a description of any arrangements or understandings between the security holder and the proposed director candidate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the consent of the proposed director candidate to be named in the proxy statement relating to our annual meeting of
stockholders and to serve as a director if elected at such annual meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that appropriate information is provided for candidates recommended by stockholders, the Nominating and Corporate Governance Committee will evaluate those candidates by
following substantially the same process, and applying substantially the same criteria, as for candidates submitted by Board members or other persons, as described above and as set forth in its
written charter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Board Leadership Structure  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to
provide independent oversight of management. The Board understands that there is no single, generally accepted approach to providing Board leadership and that given the dynamic and competitive
environment in which we operate, the right Board leadership structure may vary as circumstances warrant. Consistent with this understanding, the Nominating and Corporate Governance Committee considers
the Board's leadership structure on an annual basis. This consideration includes the pros and cons of alternative leadership structures in light of the Company's operating and governance environment
at the time, with the goal of achieving the optimal model for effective oversight of management by the Board. Currently, the roles of Chief Executive Officer and Chairman of the Board are separate.
Mr.&nbsp;Marucci, our Chief Executive Officer, is a member of our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=12,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=374841,FOLIO='10',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2>Board.
Mr.&nbsp;Ellberger, an independent director, serves as Chairman of the Board. The Board believes that its current leadership structure provides independent board leadership, engagement, and
oversight. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our independent committee chairs are responsible for leading committee meetings, determining committee meeting schedules, agenda and information flow, and reporting to the
full Board on the committee's actions and areas of responsibilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Risk Oversight  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for assessing and managing risk and the Board of Directors oversees and reviews certain aspects of our
risk management processes. The Board of Directors is involved in risk oversight through direct decision-making authority with respect to significant matters and the oversight of management by the
Board of Directors and its committees. The Board is responsible for overseeing risks related to our overall strategy, including, among others, product development, potential asset acquisitions,
financial reporting, business continuity (including succession planning) and reputational risks faced by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
committees of the Board execute their oversight responsibility for risk management as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The Audit Committee is responsible for overseeing our internal financial and accounting controls and the work performed by
the independent registered public accounting firm. As part of its oversight function, the Audit Committee regularly discusses with management and the independent registered public accounting firm our
major financial and controls-related risk exposures and steps that management has taken to monitor and control such exposures. The Audit Committee also reviews our risk management insurance programs. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The Compensation Committee is responsible for overseeing risks related to our cash and equity-based compensation programs
and practices. As part of its oversight function, the Compensation Committee periodically discusses with the President and Chief Executive Officer as well as the Board of Directors, as necessary, the
compensation plan for both executive officers and the independent directors, performance goals and objectives for the period and related achievement, peer group and other relevant compensation
benchmarks and practices and other matters to ensure our compensation practices are in our best interest and that of our shareholders. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The Nominating and Corporate Governance Committee is responsible for overseeing risks related to the composition and
structure of the Board of Directors and its committees and our corporate governance. In this regard, the Nominating and Corporate Governance Committee assesses the qualifications and independence of
members of the Board, makes annual recommendations regarding Board and committee membership, and reviews any transactions between us and our officers, directors, affiliates of officers and directors
or other related parties for conflicts of interest. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B> Stockholder Communications  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors will give appropriate attention to written communications that are submitted by stockholders, and will respond
if and as appropriate. Absent unusual circumstances or as contemplated by committee charters, and subject to advice from legal counsel, the Secretary of Celldex is primarily responsible for monitoring
communications from stockholders and for providing copies or summaries of such communications to the Board of Directors as he considers appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
from stockholders will be forwarded to all directors if they relate to important substantive matters or if they include suggestions or comments that the Secretary
considers to be important for the Board of Directors to know. Communication relating to corporate governance and corporate strategy are more likely to be forwarded to the Board of Directors than
communications </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=13,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=466771,FOLIO='11',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<A NAME="page_de72001_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2>regarding
personal grievances, ordinary business matters, and matters as to which Celldex tends to receive repetitive or duplicative communications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
who wish to send communications to the Board of Directors should address such communications to: The Board of Directors, Celldex Therapeutics,&nbsp;Inc., 119 Fourth
Avenue, Needham, Massachusetts 02494, Attention: Secretary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics that applies to our directors, officers, and employees. The purpose of the Code
of Business Conduct and Ethics is to deter wrongdoing and to promote, among other things, honest and ethical conduct and to ensure to the extent possible that our business is conducted in a
consistently legal and ethical manner. Our Code of Business Conduct and Ethics is publicly available on our website at www.celldextherapeutics.com. If we make any substantive amendments to the Code of
Business Conduct and Ethics or grant any waiver, including any implicit waiver from a provision of the Code of Business Conduct and Ethics to our Directors or Executive Officers, we will disclose the
nature of such amendments or waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Executive Officers  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding our current executive officers: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:69pt;"><FONT SIZE=1><B>Name of Individual

<!-- COMMAND=ADD_SCROPPEDRULE,69pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position and Office </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Business Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed as permanent President and Chief Executive Officer of Celldex in September 2008 and as a director of the
Company in December 2008. See Mr.&nbsp;Marucci's biography under </FONT><FONT SIZE=2><I>Director Nominees</I></FONT><FONT SIZE=2> above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Avery W. Catlin</B></FONT><FONT SIZE=2> joined Celldex in January 2000. Mr.&nbsp;Catlin has more than 20&nbsp;years of financial and business expertise in the
biotechnology and medical device industries. Prior to joining Celldex, he
served as Vice President, Operations and Finance, and Chief Financial Officer of Endogen,&nbsp;Inc., a public life science research products company, from 1996 to 1999. From 1992 to 1996,
Mr.&nbsp;Catlin held various financial positions at Repligen Corporation, a public biopharmaceutical company, serving the last two years as Chief Financial Officer. Earlier in his career,
Mr.&nbsp;Catlin held the position of Chief Financial Officer at MediSense,&nbsp;Inc., a Massachusetts-based medical device company. Mr.&nbsp;Catlin received his B.A. degree from the University
of Virginia and his M.B.A. from Babson College and is a Certified Public Accountant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Thomas Davis, M.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Medical Officer of Celldex in March 2008 upon consummation of the AVANT Merger.
Dr.&nbsp;Davis was Vice President of Clinical Development and Chief Medical Officer of Celldex Research since April 2006 and Chief Medical Officer at GenVec from July 2005 to April 2006.
Dr.&nbsp;Davis was also Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies at
the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr.&nbsp;Ron Levy on the development of rituximab and idiotype vaccines at Stanford University.
Dr.&nbsp;Davis received his B.A. degree in Biophysics from Johns Hopkins University, his M.S. degree in Physiology from Georgetown University and his M.D. from Georgetown University School of
Medicine. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=14,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=361366,FOLIO='12',FILE='DISK126:[13ZAC1.13ZAC72001]DE72001A.;11',USER='MALTRI',CD='22-APR-2013;17:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg72001_1_13"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Tibor Keler, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Scientific Officer of Celldex in March 2008 upon consummation of the AVANT
Merger. Dr.&nbsp;Keler had been Celldex Research's Vice President, Research and Discovery and Chief Scientific Officer since May 2003. In addition, he was Senior Director of Preclinical Development
and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the development of Celldex's technology and products, as well as for the preclinical
development and testing of numerous Medarex products now in clinical trials. Dr.&nbsp;Keler received his Ph.D. in Microbiology from the University of Pennsylvania. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ronald Pepin, Ph.D.</B></FONT><FONT SIZE=2>&nbsp;became Senior Vice President and Chief Business Officer of Celldex in July 2011. From June 2010 to April 2011, Dr.&nbsp;Pepin
served as Vice President at Shire Pharmaceuticals. From August 2000 to December 2009, Dr.&nbsp;Pepin was Senior Vice President, Business Development at Medarex,&nbsp;Inc. Earlier in his career,
Dr.&nbsp;Pepin was Executive Director of External Science and Technology at Bristol-Myers Squibb Company. Dr.&nbsp;Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from
Georgetown University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> EXECUTIVE COMPENSATION  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg72001_compensation_discussion_and_analysis"> </A>
<A NAME="toc_dg72001_1"> </A></FONT> <FONT SIZE=2><B>  Compensation Discussion and Analysis    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Introduction  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee oversees and administers our executive compensation programs. The Committee's complete roles and
responsibilities are set forth in the written charter of the Compensation Committee adopted by our Board of Directors, which can be found at our website, </FONT> <FONT SIZE=2><I>www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation programs are designed to deliver compensation that is competitive with our peer group and that allows us to
attract and retain superior talent who can perform effectively and succeed in a demanding business environment. Our compensation programs are also designed to reward performance against
pre-established goals and align the interests of our executives with our stockholders. We believe that the compensation of our executive officers should focus executive behavior on the
achievement of near-term corporate targets as well as long-term business objectives and strategies. We believe that pay-for-performance compensation
programs, which reward our executives when they achieve individual and/or corporate goals, create stockholder value and thus have emphasized company and individual performance in setting compensation.
We use a combination of base salary, annual cash incentive compensation programs, a long-term equity incentive compensation program and a broad based benefits program to create a
competitive compensation package for our executive management team. We describe below our compensation philosophy, policies and practices with respect to our Chief Executive Officer, Chief Financial
Officer and our other executive officers, who are collectively referred to as our Named Executive Officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a biopharmaceutical company focusing on the development of several immunotherapy technologies, we establish corporate goals that are designed to contribute to the development of our
lead programs, rindopepimut and CDX-011, to ensure that we manage our cash effectively and have sufficient funding to complete near term development activities for our lead drug candidates
and, where appropriate, to pursue partnerships and collaborations through which we can leverage the value of our drug candidates. We seek to link the financial interests of our Named Executive
Officers to those of our stockholders by tying compensation to the achievement of these strategic corporate goals,
which we believe will drive long-term stockholder value. Each year we establish corporate goals the achievement of which we believe are essential to the long-term success of
our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1048393,FOLIO='13',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2012, we engaged Radford, an Aon Hewitt Company, to review our executive compensation programs and to assess Celldex's base salaries, short-term incentive opportunities,
target total cash and long-term incentives from a competitive standpoint. The Compensation Committee has adopted a compensation philosophy of targeting our executive compensation to the
50<SUP>th</SUP>&nbsp;percentile of executive compensation of our peer group and the Radford Global Life Sciences Survey results. Executive compensation may be above or below the
50<SUP>th</SUP>&nbsp;percentile based on an executive's experience, scope of position, individual performance and company constraints. On Radford's recommendations, the Compensation Committee
increased annual base salary for our existing executive officers by 2% to 3% in 2012 and established new bonus targets ranging from 30% to 55% of annual base salary, depending on the position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee reviewed our performance relative to our 2012 corporate goals and concluded that we had achieved 100% of our business and financial operations goals, which
resulted in a payout of 100% of our executive officers' 2012 bonus target. Further, stock options granted to our executive officers in 2012 have exercise prices equal to 100% of the fair value on the
date of grant and vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter based on continued service. We believe that
stock options structured in this manner encourage our executive officers to focus on increasing stockholder value and stock price appreciation over the long term and limit unnecessary risk taking
behavior, while promoting retention. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2012, we (i)&nbsp;raised net proceeds of $83.6&nbsp;million through sales of our common stock and we ended 2012 with cash, cash equivalents and marketable securities of
$84.0&nbsp;million and (ii)&nbsp;accomplished the following significant clinical milestones during the year:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Presented positive final results from the Phase&nbsp;2b EMERGE study of CDX-011 in patients
with&nbsp;GPNMB-expressing, advanced, heavily pretreated breast cancer at the San Antonio Breast Cancer Symposium in December 2012. Progression free and overall survival benefits were demonstrated
in the subgroup of patients with triple negative disease that also over-expressed GPNMB, and strong trends towards benefits were seen in all patients with over-expression of&nbsp;GPNMB. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Announced impressive three-year survival data across three Phase&nbsp;2 studies of rindopepimut in
EGFRvIII-positive glioblastoma at the Society for Neuro-Oncology Annual Meeting in November 2012. In addition, Celldex announced a new contemporary historical control dataset compiled from the
Radiation Therapy Oncology Group (RTOG)'s Phase&nbsp;3 0525 study that continues to demonstrate that patients with EGFRvIII-positive glioblastoma fare worse than the general glioblastoma patient
population. Importantly, the data set provides further confidence in the ACT IV registration study design. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Continued to open clinical sites to support enrollment in the Phase&nbsp;3 ACT IV study and the Phase&nbsp;2 ReACT
study of rindopepimut in glioblastoma. As of early March 2013, there were more than 142 clinical sites around the world that were actively screening patients to participate in the ACT IV study. The
ReACT study is also well positioned, with all 25 study sites actively screening to date. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Presented positive results from the Phase&nbsp;1 study of CDX-1401 in solid tumors at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting in October 2012. The study identified a well-tolerated and immunogenic regimen. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Completed enrollment in the Phase&nbsp;1 portion of the CDX-1127 solid tumor arm. CDX-1127 was
determined to be well tolerated to date, including at the highest dose level. Celldex continues to enroll patients in the dose escalation portion of the lymphoma and leukemia arm. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Presented positive results from a Phase&nbsp;1 multi-dose study of CDX-301 (rhuFlt3L) in healthy
volunteers in a poster presentation at the American Society of Hematology 54th&nbsp;Annual Meeting </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=873746,FOLIO='14',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_15"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>and
Exposition in December 2012. The study demonstrated that CDX-301 was well-tolerated and can effectively mobilize hematopoietic cell populations in healthy volunteers. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Independent Compensation Consultants  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that independent advice is important in developing Celldex's executive compensation program and in
2012 engaged Radford as its independent compensation consultant. Radford reports directly to the Committee and provides guidance on trends in executive and non-employee director
compensation, the development of specific executive compensation programs, the composition of the Company's compensation peer group and other matters as directed by the Committee. During 2012, the
Company paid Radford approximately $49,100 in consulting fees directly related to these services. In 2012, Radford did not provide any other services to Celldex. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> Data Used to Make Compensation Determinations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In making decisions regarding the compensation of our executive officers, the Compensation Committee generally considers compensation
and survey data for similarly situated executives at a comparison group of companies it considers our peer group. These comparison data are primarily used to gauge the reasonableness and
competitiveness of executive compensation decisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
draw upon a pool of talent that is highly sought after by large and established pharmaceutical and biotechnology companies as well as by other development-stage life science
companies, both within and outside our geographic areas. We believe that the compensation practices of our industry in general and of our select peer group in particular provide useful information to
help us establish compensation practices that allow us to attract, retain, and motivate a highly talented executive team. We believe we must offer a compensation package to all of our officers and our
other employees that is competitive with our peer group, as well as larger pharmaceutical and biotechnology companies from whom we frequently recruit. In addition, the comparator companies should be
aligned with our current stage of development and have similar short and long-term growth objectives. In 2012, the
Compensation Committee set the target level of total executive compensation, as well as the key elements of compensation, at the 50<SUP>th</SUP>&nbsp;percentile of our peer group, but then
adjusted each of the elements based on an individual's performance and contribution to our strategic objectives. The Committee may need to adjust these levels in the future to attract or retain
specific individuals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
review the levels of cash, equity, and total compensation for all comparable officers in our peer group relative to the elements of compensation paid to our officers. In considering
how these data relate to our existing compensation structure, we take into account our size, stage of development, performance, and geographic location as compared to these peer companies, as well as
what we know about the comparable scope of responsibilities of our officers versus those of comparable executives at such peer group companies. With the assistance of our compensation consultant,
Radford, we used two primary market frames of reference (which we refer to as the "market") against which to compare our total executive compensation practices and levels and inform our decisions
regarding compensation of our officers as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Select Peer Group&#151;A select group of national biotechnology companies at a similar stage of development as our
company with similar headcount, market capitalization and in most cases, similar therapeutic targets, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Radford Global Life Sciences Survey&#151;A national survey of executive compensation levels and practices that
covers approximately sixty executive positions in over 600 multinational life sciences organizations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=336075,FOLIO='15',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not apply a specific weighting to either data source when making compensation comparisons. Instead, we work with Radford to develop competitive market guidelines using these data
sources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
peer group will be reviewed each year to ensure continued relevance as we grow and develop and is approved by the Compensation Committee prior to its adoption. The select peer group
as of September 2012 analyzed by Radford and used to inform our decisions affecting executive compensation based on 2012 performance consisted of the following companies: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Affymax,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Novavax&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Agenus,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Omeros Corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Amicus Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>OncoGenex Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ArQule,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Oncothyreon,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Dynavax Technologies Corporation</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Rigel Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ImmunoGen,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Synta Pharmaceuticals Corp.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Infinity Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Threshold Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>MAP Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vical Incorporated</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Neurocrine Biosciences,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Xoma Corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>NewLink Genetics Corporation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>ZIOPHARM Oncology,&nbsp;Inc.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
peer group consisted of public companies in the biopharmaceutical industry with product candidates generally in late-stage development, annual revenues generally less
than $100&nbsp;million (average of $27.3&nbsp;million), and market capitalization of at least $100&nbsp;million (average of $454&nbsp;million). We believe that, as of September 2012, this list
was representative of the companies with whom we generally compete for talent. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> Administration and Objectives of Our Executive Compensation Program  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors, which is comprised of independent, non-employee directors, is
responsible for establishing and administering the policies governing the compensation of our employees, including salary, bonus and stock option grants. The policy of the Compensation Committee is to
compensate our employees with competitive salaries based on their level of experience and job performance. All permanent employees, including executive officers, are eligible for annual bonus awards
based on achievement of our strategic corporate goals and participation in our stock option program. The stock option grants are made in accordance with our 2008 Stock Option and Incentive Plan, as
amended (the "2008 Plan"). The
Compensation Committee is also responsible for the administration of our 2004 Employee Stock Purchase Plan, as amended (the "2004 Plan"), in which employees participate on a voluntary basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee has designed our overall executive compensation program to achieve the following objectives:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>attract and retain talented and experienced executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>motivate and reward executives whose knowledge, skills and performance are critical to our success; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>provide a competitive compensation package that aligns the interests of our executive officers and stockholders by
including a significant variable component which is weighted heavily towards performance-based rewards, based upon achievement of pre-determined goals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>foster a shared commitment among executives by aligning our and their individual goals; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=669041,FOLIO='16',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_17"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>compensate our executives to manage our business to meet our near-term and long-term objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use a mix of short-term compensation (base salaries and cash incentive bonuses) and long-term compensation (equity incentive compensation) to provide a total
compensation structure that is designed to achieve these objectives. We determine the percentage mix of compensation structures that we think is appropriate for each of our executive officers. In
general, the Compensation Committee believes that a substantial percentage of the compensation of our executive officers should be performance based. The Compensation Committee uses its judgment and
experience and the recommendations of the chief executive officer (except for his own compensation) to determine the appropriate mix of compensation for each individual. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining whether to adjust the compensation of any of our Named Executive Officers, we annually take into account the changes, if any, in the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>market compensation levels; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the contributions made by each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the performance of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the increases or decreases in responsibilities and roles of each executive officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the business needs for each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the relevance of each executive officer's experience to other potential employers; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the readiness of each executive officer to assume a more significant role within the organization. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, with respect to new executive officers, we take into account their prior base salary and annual cash incentives, their expected contribution and our business needs. We
believe that our executive officers should be fairly compensated each year relative to market pay levels within our industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Executive Compensation Components  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to both attract and retain experienced and qualified executives to manage us, the Compensation Committee's policy on executive
compensation is to (i)&nbsp;pay salaries which are competitive with the salaries of executives in comparable positions in the biotechnology industry, and (ii)&nbsp;allow for additional
incentive-based compensation through the payment of annual cash bonuses and the grant of stock-based incentive awards. This policy is designed to have a significant portion of each executive's total
compensation be tied to our progress in order to incentivize the executive to fully dedicate himself or herself to achievement of corporate goals, and to align the executive's interest with those of
our stockholders through equity incentive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program is primarily composed of base salary, annual incentive cash compensation payable on an annual basis and equity compensation. In addition, we provide
our executives with benefits that are generally available to our salaried employees, including medical, dental, group life and accidental death and dismemberment insurance, short- and
long-term disability coverage and our 401(k) plan. Within the context of the overall objectives of our compensation programs, we determined the specific amounts of compensation to be paid
to each of our executives in 2012 based on a number of factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our understanding of the amount of compensation generally paid by similarly situated companies to their executives with
similar roles and responsibilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the roles and responsibilities of our executives; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=515467,FOLIO='17',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_18"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the individual experience and skills of, and expected contributions from, our executives; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amounts of compensation being paid to our other executives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>our executives' historical compensation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
discuss each of the primary elements of our executive compensation in detail below. While we have identified particular compensation objectives that each element of executive
compensation serves, our compensation programs complement each other and collectively serve all of our executive compensation objectives described above. Accordingly, whether or not specifically
mentioned below, we believe that, as a part of our overall executive compensation, each element to a greater or lesser extent serves each of our objectives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Base salary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each executive officer (except the chief executive officer whose performance is reviewed by the Compensation Committee) has an annual
performance review with the chief executive officer who makes recommendations on salary increases, promotions and stock option grants to the Compensation Committee. We have historically established
base salaries for each of our executives based on many factors, including average salary increases expected in the biotechnology industry in the Boston, Massachusetts and central New Jersey areas,
competition in the marketplace to hire and retain executives, experiences of our Board members and leadership team with respect to salaries and compensation of executives in similarly situated
companies in our industry and other similar industries, as well as additional factors which we believe enables us to hire and retain our leadership team in an extremely competitive environment. Our
Compensation Committee annually reviews salary ranges and individual salaries for our executive officers. For 2012, the Compensation Committee increased annual base salary for our existing executive
officers by 2% to 3%. For 2010 and
2011, we limited annual base salary increases for our existing named executive officers to only 1%. Dr.&nbsp;Pepin joined us in July 2011 and his base salary was the result of arms length
negotiations as part of his hiring process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Annual Performance-Based Cash Bonus  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designed our annual cash bonuses to reward our executive officers for their actual performance and contributions to our
corporate goals for each year, as approved in advance by our Compensation Committee and Board of Directors. The corporate goals are allocated between specific product and financial performance
targets. Achievement of our corporate goals was, in 2012, the primary factor considered by our Compensation Committee in determining the annual bonuses for our executive officers. However, the
Compensation Committee retains discretion to adjust any individual bonus as a result of exceptional individual performance. Our performance-based bonus plan emphasizes the contributions of each of our
executive officers to the achievement of our corporate goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the beginning of each calendar year, the Compensation Committee establishes annual corporate performance goals and target bonuses. In 2012 based on Radford's recommendation, the
Compensation Committee established new target bonuses of 55% of base salary for Mr.&nbsp;Marucci, 40% of base salary for Dr.&nbsp;Keler, 35% of base salary for each of Mr.&nbsp;Catlin and
Dr.&nbsp;Davis and 30% of base salary for Dr.&nbsp;Pepin. Corporate goals are proposed by management, reviewed and approved by the Compensation Committee and also approved by the Board of
Directors on an annual basis. The Compensation Committee considers and assigns a relative weight to appropriately focus efforts on corporate goals that are intended to enhance shareholder value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee reviewed the 2012 corporate goals at meetings held in March, June and September 2012, to gauge our levels of achievement and to assess whether the corporate
goals approved earlier in the year remained relevant and complete. In December 2012, prior to approving 2012 incentive bonuses, the Compensation Committee evaluated our 2012 performance by assessing
if, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=20,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=248894,FOLIO='18',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2>and
the extent to which, we achieved or failed to achieve the corporate goals approved by the Board of Directors for 2012. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
corporate goals for 2012 and the level at which the Compensation Committee determined they were achieved are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate Goal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Relative<BR>
Weight </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012<BR>
Achievement </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Rindopepimut Development Activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Open at
least 75% of the planned 150 worldwide clinical sites in the pivotal rindopepimut Phase&nbsp;3 ACT IV study</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Identify a
CMO partner and develop the commercial manufacturing plan for rindopepimut</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Complete
accrual of 75% of patients to the Phase&nbsp;2 ReACT study</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>CDX-011 Development Activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Present data
from the Phase&nbsp;2b randomized breast cancer study</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>CDX-1127 and CDX-1135 Development Activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Complete
accrual of at least 30 patients to the CDX-1127 Phase&nbsp;1 studies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>File an IND
for the CDX-1135 pilot study in Dense Deposit Disease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Complete
manufacture of CDX-1135 drug product in our Fall River facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Business and Financial Operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Provide
sufficient cash through either financings or partnerships and cost reductions to extend runway into 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2> </font> &#149; </font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"> <font size=2> </FONT><FONT SIZE=2>Position the
Company to complete a licensing transaction with respect to rindopepimut, CDX-011 and/or CDX-1127 in 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD style="font-family:times;">&nbsp;</TD>
<TD style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Totals:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD style="font-family:times;">&nbsp;</TD>
<TD style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Compensation Committee's December 2012 meeting, Mr.&nbsp;Marucci reviewed in detail the performance of each executive officer, excluding himself, and considered such
individual's contributions to our success in 2012. Mr.&nbsp;Marucci's bonus recommendations were primarily driven by the fact that the Company achieved 100% of its pre-determined
corporate goals in 2012 and each employee, including the executive officers, contributed to our success in achieving the 2012 corporate goals. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee discussed Mr.&nbsp;Marucci's recommendations for the Named Executive Officers and reviewed Mr.&nbsp;Marucci's performance for fiscal 2012. Based on
Mr.&nbsp;Marucci's recommendations for each of the Named Executive Officers, the Compensation Committee's review of Mr.&nbsp;Marucci's performance and the 100% achievement of the corporate goals
for 2012, the Compensation Committee determined that the annual cash incentives approved for each Named Executive Officer (including Mr.&nbsp;Marucci) should be set at 100% of the targets
established for each Named Executive Officer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determined that annual incentive bonuses paid to the Named Executive Officers for 2012, were fair, reasonable and appropriate based on the factors described
above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Equity Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also use stock options and equity-based incentive programs to attract, retain, motivate and reward our executive officers. Through
our equity-based grants, we seek to align
the interests of our executive officers with our stockholders, reward and motivate both near-term and long-term executive </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=21,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=275833,FOLIO='19',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2>performance
and provide an incentive for retention. Our decisions regarding the amount and type of equity incentive compensation and relative weighting of these awards among total executive
compensation have been based on our understanding of market practices of similarly situated companies and our negotiations with our executives in connection with their initial employment or promotion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have adopted an equity grant policy that formalizes how we grant equity awards by setting a regular schedule for granting equity awards in connection with the hiring or promotion of
any of our employees, granting annual equity awards and granting equity awards to non-employee directors. Such policy also outlines grant approval requirements and specifies the vesting
schedule and exercise prices for restricted stock units and stock option awards. We believe that this policy will mitigate the risk that issues or concerns would be raised in the future regarding the
timing of grants of equity awards to our officers, directors and employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such grants to our Named Executive Officers are subject to prior approval by the Compensation Committee at a regularly scheduled meeting during the year. The date of grant and the
fair market value of the award are based upon the date of the Compensation Committee meeting approving such grant. When granting equity-based awards, the Compensation Committee considers a number of
factors in determining the amount of equity incentive awards, if any, to grant to our executives, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the existing levels of stock ownership among the executive officers relative to each other and to our employees as a
whole; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>previous grants of stock options to such executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>vesting schedules of previously granted options; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the performance of the executives and their contributions to our overall performance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>an outside survey of stock option grants and restricted common stock awards in the biotechnology industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>an internally prepared survey of similarly situated biotechnology companies' proxy statements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>personal knowledge of the Compensation Committee members regarding executive stock options and restricted common stock
awards at comparable companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the financial statement impact of stock option awards on our results of operations; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amount and percentage of our total equity on a diluted basis held by our executives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
compensation awards to our Named Executive Officers primarily consist of stock option awards. Stock option awards provide our executive officers with the right to purchase shares
of our common stock at a fixed exercise price typically for a period of up to ten years, subject to continued employment with us. Stock options are earned on the basis of continued service to us and
generally vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter. All historical option grants were made at what our
Compensation Committee and Board of Directors determined to be the fair market value of our shares of our common stock on the respective grant dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;12, 2012, the Compensation Committee awarded stock options to all qualified employees, including stock options to purchase 280,000 shares, 115,000 shares, 115,000
shares, 90,000 shares and 90,000 shares of our common stock to each of Messrs.&nbsp;Marucci, Keler, Davis, Catlin and Pepin, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;6, 2013, the Compensation Committee of the Board of Directors approved an amendment to the 2004 Employee Stock Purchase Plan, or 2004 Plan, subject to approval at the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=22,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=139253,FOLIO='20',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dg72001_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2>Annual
Meeting by our stockholders, to increase the number of shares reserved for issuance thereunder by 137,500 to 200,000 shares. Approval of the amendment to the 2004 Plan is intended to ensure
that we have sufficient shares reserved for issuance under the 2004 Plan to provide incentives to our participant base and to fund anticipated employee participation for up to three years. The Board
of Directors believes that the approval of the amendment to the 2004 Plan is important to our continued success. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Other Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that establishing competitive benefit packages for our employees is an important factor in attracting and retaining highly
qualified personnel. Executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, group life and accidental death and dismemberment insurance, short-
and long-term disability coverage and our 401(k) plan, in each case on the same basis as other employees. We provide a matching contribution under our 401(k) plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Employment Agreements and Post-Termination Compensation and Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We depend greatly on the intellectual capabilities and experience of our key executives. Our success is dependent on our ability to
attract and retain highly skilled executives with significant experience in the biotechnology industry, particularly as we expand our activities in clinical trials, the regulatory approval process and
sales and manufacturing. Therefore we have entered into new employment agreements with our existing executives effective January&nbsp;1, 2013. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, each employment arrangement provides for cash severance, 100% acceleration of any unvested options, restricted stock and/or other equity awards and continuation of certain
employee
benefits in the event that an executive's employment is terminated without cause or is terminated by the executive for good reason within a one year period immediately following a change of control.
The cash severance consists of a single lump sum payment equal to (i)&nbsp;twenty-four (24)&nbsp;times Executive's highest monthly base compensation paid hereunder during the preceding
twenty-four month period, plus (ii)&nbsp;150% (200%, in the case of Mr.&nbsp;Marucci) of the highest one-year Annual Bonus actually received by the Executive during the
preceding two full fiscal years prior to the date of termination. We use a "double trigger" with respect to benefits that are to be provided in connection with a change of control. A change of control
does not itself trigger benefits; rather, benefits are paid only if the employment of the executive is terminated by us other than for cause, death or disability or by the executive for good reason
during a specified period before or after a change of control. We believe a "double trigger" benefit maximizes shareholder value because it prevents a windfall to executives in the event of a change
of control in which the executive retains significant responsibility as defined in his or her individual agreement, while still providing our executives appropriate incentives to cooperate in
negotiating any change of control that may put their jobs at risk. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the benefits that only accrue in connection with a change of control, our agreements with the Named Executive Officers provide for cash severance, 25% acceleration of
unvested options, restricted stock and/or other equity awards and continuation of certain employee benefits if we terminate their employment with us without cause or they terminate their employment
with us for good reason, as such terms are defined in the applicable agreement with the executive officer. The cash severance consists of a lump sum cash payment equal to twenty-four
months of the executive's then existing base salary. A further discussion of the terms and projected payments under each of these agreements is set forth below under the heading </FONT> <FONT SIZE=2><I>Potential Payments upon Termination of
Employment or Change in Control.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=23,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=169010,FOLIO='21',FILE='DISK126:[13ZAC1.13ZAC72001]DG72001A.;11',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di72001_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><B><I> Committee Consideration of the Company's 2012 Shareholder Advisory Vote on Executive Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our 2012 annual meeting of shareholders, approximately 90% of the shares voted at the meeting approved, on an advisory basis, the
compensation of the Named Executive Officers. Given that a majority of the shares voted approved the 'say on pay' advisory proposal, the Committee did not implement specific changes and continued with
its performance-based compensation philosophy and its balanced approach to various components of its compensation program. However, the Compensation Committee does monitor the results of the annual
advisory 'say-on-pay' proposal and refers to such results as one of many factors considered in connection with the discharge of its responsibilities, although the Committee
does not assign a quantitative weighting to any such factors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has determined that an advisory vote will be conducted on an annual basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di72001_summary_compensation_table"> </A>
<A NAME="toc_di72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary compensation table reflects certain information concerning compensation for services in all capacities awarded
to, earned by or paid during the years ended December&nbsp;31, 2012, 2011 and 2010 to each person who served as our Chief Executive Officer and Chief Financial Officer at any time during the year
ended December&nbsp;31, 2012 and the three other executive officers employed by us as of December&nbsp;31, 2012 (collectively, the "Named Executive Officers"). </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:96pt;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,96pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive<BR>
Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>478,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>290,913</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,001,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,643</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,780,504</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Executive</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>469,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>127,407</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>317,071</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>923,046</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>464,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>374,222</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>974,428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
299,986</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
85,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
321,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
5,643</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
712,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>295,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>140,608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,572</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>506,724</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>292,562</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>66,217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>195,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,665</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>559,933</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
378,120</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
155,182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
411,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
7,407</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
951,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>371,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>183,669</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,185</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>662,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Medical Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>367,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>83,179</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>223,416</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,345</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>681,513</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
356,835</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
162,924</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
411,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
3,627</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
934,672</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>350,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>174,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>624,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>346,881</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>94,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>209,453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,538</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>654,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ronald Pepin, Ph.D.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
303,461</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
80,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
321,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
5,924</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
711,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>145,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>223,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>405,724</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Business Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Bonus column include annual bonus amounts earned by each of our Named Executive Officers in 2012, 2011 and 2010.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Option Awards column reflect the dollar amounts for the aggregate grant date fair value of stock option awards made in fiscal years ended
December&nbsp;31, 2012, 2011 and 2010 for annual awards pursuant to the 2008 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts listed in the All Other Compensation column includes our matching contribution to the 401(k) Savings Plan of each named executive officer and
premiums paid for life insurance under our nondiscriminatory group plan for each named executive officer. In addition, Mr.&nbsp;Marucci's compensation includes the annual premium of $2,550 in 2012,
2011 and 2010 for a $1,000,000 term life insurance policy and $689, $352 and $408 for the personal use of a Company car in 2012, 2011 and 2010.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Dr.&nbsp;Pepin
joined us on July&nbsp;1, 2011 with an annual base salary of $300,000. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=34507,FOLIO='22',FILE='DISK126:[13ZAC1.13ZAC72001]DI72001A.;6',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk72001_1_23"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk72001_grants_of_plan-based_awards"> </A>
<A NAME="toc_dk72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Grants of Plan-Based Awards    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information on stock options and stock awards granted in 2012 to each of our Named Executive Officers. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=4 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Future<BR>
Payouts Under<BR>
Equity Incentive Plan Awards </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares or<BR>
Units<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair Value of<BR>
Stock and<BR>
Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base Price of<BR>
Option<BR>
Awards<BR>
($/Sh)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/12/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>280,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,001,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/12/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>321,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/12/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/12/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/12/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>321,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
exercise prices reflect the closing price of our common stock on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
grant date fair value is generally the amount we would expense in our financial statements over the award's service period, but does not include a
reduction for forfeitures. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk72001_outstanding_equity_awards_at_fiscal_year-end"> </A>
<A NAME="toc_dk72001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Outstanding Equity Awards at Fiscal Year-End    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the stock option grants and stock awards to our Named Executive Officers
at December&nbsp;31, 2012. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:18pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,18pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Market or<BR>
Payout<BR>
Value of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>280,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>124,025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>112,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>129,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>55,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>183,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>32,656</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,312</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>29,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>76,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>148,825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,063</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ronald Pepin, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ronald Pepin, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>31,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>25%
of the options vest on the first anniversary of the grant date and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=189851,FOLIO='23',FILE='DISK126:[13ZAC1.13ZAC72001]DK72001A.;9',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dk72001_1_24"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><A
NAME="dk72001_option_exercises_and_stock_vested"> </A>
<A NAME="toc_dk72001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Option Exercises and Stock Vested    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the number of option exercises in fiscal 2012 and the number of shares of
stock issued under the 2008 Plan that vested in fiscal 2012 and the corresponding amounts realized by our Named Executive Officers. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Exercise<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Exercise<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Vesting<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Vesting<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk72001_employment_agreements"> </A>
<A NAME="toc_dk72001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Employment Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and conditions of the employment agreements of Mr.&nbsp;Marucci, Mr.&nbsp;Catlin, Dr.&nbsp;Davis, Dr.&nbsp;Keler, and
Dr.&nbsp;Pepin are governed by written employment contracts which became effective on January&nbsp;1, 2013. The employment agreements provide, among other things, for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>annual base salary ($484,855 in the case of Mr.&nbsp;Marucci, $303,187 in the case of Mr.&nbsp;Catlin, $383,649 in the
case of Mr.&nbsp;Davis, $362,053 in the case of Mr.&nbsp;Keler and $307,500 in the case of Mr.&nbsp;Pepin) or such greater amount as may from time to time be determined by the Board of Directors
or the Compensation Committee thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>eligibility for an annual bonus with a defined bonus target (55% of base salary in the case of Mr.&nbsp;Marucci, 35% of
base salary in the case of Mr.&nbsp;Catlin, 35% of base salary in the case of Mr.&nbsp;Davis, 40% of base salary in the case of Mr.&nbsp;Keler and 30% of base salary in the case of
Mr.&nbsp;Pepin); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a lump sum severance payment equal to 100% (200% in the case of Mr.&nbsp;Marucci only) of the executive's
then-existing annual base salary in the event that his employment is terminated without cause or he resigns "for good reason" (as defined in the employment agreement) and 25% accelerated
vesting of any unvested equity awards; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment
equal to twenty-four (24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month period preceding the date of
termination plus 150% (200% in the case of Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal years preceding the
date of termination in the event of termination without cause or resignation "for good reason" by the executive within one year immediately following a change in control (as defined in the employment
agreement). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
employment agreements have an initial term through December&nbsp;31, 2015 and shall automatically renew for additional one year terms unless either party gives ninety
(90)&nbsp;days prior written notice of its intent not to renew. The Company may terminate the employment agreements without cause, on 90-days' prior notice, or for cause, subject to a
30-day cure period in certain circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk72001_pension_benefits"> </A>
<A NAME="toc_dk72001_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Pension Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers participate in qualified or nonqualified defined benefit plans sponsored by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk72001_nonqualified_deferred_compensation"> </A>
<A NAME="toc_dk72001_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Nonqualified Deferred Compensation    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers are covered by a defined contribution or other plan that provides for the deferral of compensation
on a basis that is not tax-qualified. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=66413,FOLIO='24',FILE='DISK126:[13ZAC1.13ZAC72001]DK72001A.;9',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm72001_1_25"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72001_potential_payments_upon_termin__pot02940"> </A>
<A NAME="toc_dm72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Potential Payments upon Termination of Employment or Change in Control    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Named Executive Officers have provisions in their employment agreements regarding severance upon certain termination events or
acceleration of stock options in the event of our change of control or termination following a change of control. These severance and acceleration provisions are described in "Employment Agreements,"
and certain estimates of these change of control benefits are provided in the tables below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table describes the potential payments and benefits upon employment termination for our Named Executive Officers as if their employment had terminated as of
December&nbsp;31, 2012. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:115pt;"><FONT SIZE=1><B>Executive benefits and payments<BR>
upon termination

<!-- COMMAND=ADD_SCROPPEDRULE,115pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for no good<BR>
reason </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for good<BR>
reason(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex not<BR>
for cause(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
for cause </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary termination<BR>
by the executive<BR>
for good reason<BR>
or termination by<BR>
Celldex without<BR>
cause in connection<BR>
with or following<BR>
change of control(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Anthony S. Marucci</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>581,826</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>220,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>883,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,230,073</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,230,073</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,474,749</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Avery W. Catlin</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>303,187</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>303,187</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>606,374</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>127,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>369,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>424,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>424,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,131,932</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Thomas Davis, M.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>383,649</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>383,649</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>767,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>232,773</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>463,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>539,017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>539,017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,503,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Tibor Keler, Ph.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>362,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>362,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>724,106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>244,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>111,396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>111,396</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>445,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>512,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>512,862</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,453,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=228713,FOLIO='25',FILE='DISK126:[13ZAC1.13ZAC72001]DM72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dm72001_1_26"> </A>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:115pt;"><FONT SIZE=1><B>Executive benefits and payments<BR>
upon termination

<!-- COMMAND=ADD_SCROPPEDRULE,115pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for no good<BR>
reason </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for good<BR>
reason(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex not<BR>
for cause(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
for cause </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary termination<BR>
by the executive<BR>
for good reason<BR>
or termination by<BR>
Celldex without<BR>
cause in connection<BR>
with or following<BR>
change of control(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Ronald Pepin, Ph.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>307,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>307,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>615,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,778</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,778</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>311,112</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>424,691</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>424,691</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,085,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
termination without cause or resignation for good reason, the employee is generally entitled to a lump sum payment equal to 100% (200% in the case of
Mr.&nbsp;Marucci only) of the employee's then annual base salary, continuation of certain employee benefits and 25% accelerated vesting of any unvested equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
employee is generally entitled to accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment
equal to twenty-four (24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month period preceding the date of
termination plus 150% (200% in the case of Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal years preceding the
date of termination in the event of termination without cause or resignation "for good reason" by the executive within one year immediately following a change in control (as defined in the employment
agreement).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value of each share subject to an option to purchase common stock that would be accelerated in the circumstances described above equals $6.71 per share
(the closing price on the last trading day of 2012), minus the exercise price per share; </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72001_director_compensation"> </A>
<A NAME="toc_dm72001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Director Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective March&nbsp;8, 2008, the following director non-equity compensation policy was adopted. Directors who are not
our employees are each entitled to receive a retainer fee of $50,000 each fiscal year ("Annual Retainer"). The Chairman of the Board is entitled to receive an annual retainer fee of $40,000 in
addition to his or her Annual Retainer and any retainer for committee service. The Chairperson of each committee of the Board of Directors is entitled to receive an annual retainer fee of $30,000 in
addition to his or her Annual Retainer. Each committee member (other than the Chairperson of a committee) will receive an annual retainer of $20,000 in addition to his or her Annual Retainer. Stipends
and retainers are paid in advance on a quarterly basis. The Directors shall be reimbursed for necessary travel and business expenses as incurred but will not receive any additional fees for attending
meetings or calls of the Board of Directors. To further align the interests of the members of the Board with the stockholders of the Company, the Board, at the recommendation of the Compensation
Committee, amended its non-equity compensation policy on December&nbsp;16, 2009 to provide that new board members will receive an initial stock option grant to purchase 8,000 shares of
the Company's common stock upon joining the Board and that all non-employee directors will receive an annual grant of 2,000 shares of restricted stock each year following the annual
stockholders' meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=641512,FOLIO='26',FILE='DISK126:[13ZAC1.13ZAC72001]DM72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_dm72001_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2012, our non-employee directors had the following stock options outstanding: Larry Ellberger&#151;29,728, Herbert J.
Conrad&#151;29,879, George O. Elston&#151;29,879, Harry H. Penner, Jr.&#151;29,728, Timothy M. Shannon, M.D.&#151;300,936 and Karen L. Shoos&#151;29,728. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the annual compensation for our non-employee directors during 2012. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned or<BR>
Paid in Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>130,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>139,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George O. Elston</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Timothy M. Shannon, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in the Stock Awards column reflect the grant date fair value of restricted stock awards of 2,000 shares made in 2012 to each of our
non-employee directors for awards pursuant to the 2008 Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject
to risk of forfeiture on each of September&nbsp;20, 2012, December&nbsp;20, 2012, March&nbsp;20, 2013 and June&nbsp;20, 2013 (so long as the director remains a member of the Board as of such
date). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72001_compensation_committee__dm702479"> </A>
<A NAME="toc_dm72001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors is currently composed of the following three non-employee directors:
Karen L. Shoos, Chair, George O. Elston and Harry H. Penner, Jr. None of these Compensation Committee members was an officer or employee of us during the year. No Compensation Committee interlocks
between us and another entity existed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm72001_risk_considerations"> </A>
<A NAME="toc_dm72001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Risk Considerations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not believe that our compensation practices and policies for our employees, including our executive officers, create risks or are
likely to create risks that are reasonably likely to have a material adverse effect on our results of operations or financial condition. The Compensation Committee considered our strategic goals and
operational practices and evaluated our incentive program design to assess whether these programs foster a business environment that might drive inappropriate decision-making or behavior. We are a
biopharmaceutical company that is generating a pipeline of drug candidates to treat cancer and other difficult-to-treat diseases and do not yet generate earnings. While a
significant portion of our executives' compensation is performance-based, we believe several features of our program mitigate inappropriate or excessive risk-taking that could harm
shareholder value: we set performance goals that we believe are reasonable and set targets with payouts at multiple levels of performance, rather than an "all or nothing" approach; and we cap payout
levels under our near- and long-term incentive plans, which is consistent with market
prevalent practice and does not provide disproportionate leverage for achievement of near- or long-term results. As discussed above in our Compensation Discussion and Analysis
section we use a mix of performance goals in our annual and long-term incentive programs to align incentive compensation with a broad set of measures important to the creation of
shareholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=476428,FOLIO='27',FILE='DISK126:[13ZAC1.13ZAC72001]DM72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do72001_1_28"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do72001_compensation_committee_report"> </A>
<A NAME="toc_do72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT*    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee has reviewed the Compensation Discussion and Analysis with management and based on a review of the Compensation Discussion Analysis, the Compensation Committee
recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Compensation
Committee:<BR>
Karen L. Shoos, Chair<BR>
George O. Elston<BR>
Harry H. Penner, Jr. </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Compensation Committee is not to be deemed "filed" with the SEC (irrespective of any general incorporation language in any
document filed with the SEC) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended, or to the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934,
except to the extent we specifically incorporate it by reference into a document filed with the SEC. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=93463,FOLIO='28',FILE='DISK126:[13ZAC1.13ZAC72001]DO72001A.;4',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq72001_1_29"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq72001_report_of_the_audit_committee"> </A>
<A NAME="toc_dq72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE*    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned members of the Audit Committee of the Board of Directors of Celldex submit this report in connection with the
committee's review of the financial reports for the fiscal year ended December&nbsp;31, 2012 as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has reviewed and discussed with management the audited financial statements for Celldex for the fiscal year ended December&nbsp;31,
2012.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with representatives of PricewaterhouseCoopers&nbsp;LLP the matters which are required to be discussed with them under
the provisions of SAS 61. That Statement of Accounting Standards requires the auditors to ensure that the Audit Committee received information regarding the scope and results of the audit.
PricewaterhouseCoopers&nbsp;LLP has also communicated with the Audit Committee on matters required by Rule&nbsp;2-07 of Regulation&nbsp;S-X.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with PricewaterhouseCoopers&nbsp;LLP, the independent registered public accounting firm, the auditors' independence from
management and Celldex including the matters in the written disclosures and the letter from the independent auditors required by PCAOB rule&nbsp;3526. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Audit Committee considered whether the provision of information technology services or other non-audit services by PricewaterhouseCoopers&nbsp;LLP is
compatible with maintaining its independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the Board of Directors has
approved) that the audited financial statements be included in Celldex's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2012 for filing with the Securities
and Exchange Commission. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Audit
Committee:<BR>
George O. Elston, Chair<BR>
Larry Ellberger<BR>
Harry H. Penner, Jr. </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Audit Committee is not to be deemed "soliciting material" or deemed to be "filed" with the Securities and Exchange Commission
(irrespective of any general incorporation language in any document filed with the Securities and Exchange Commission) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as
amended, or to the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into a document filed with the Securities
and Exchange Commission. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=661751,FOLIO='29',FILE='DISK126:[13ZAC1.13ZAC72001]DQ72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds72001_1_30"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Security Ownership of Certain Beneficial Owners and Management  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information as of April&nbsp;9, 2013 with respect to the beneficial ownership of common stock
of the Company by the following: (i)&nbsp;each of the Company's current directors; (ii)&nbsp;each of the Named Executive Officers; (iii)&nbsp;the current executive officers; (iv)&nbsp;all of
the executive officers and directors as a group; and (v)&nbsp;each person known by the Company to own beneficially more than five percent (5%) of the outstanding shares of the Company's common
stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the following table, beneficial ownership is determined in accordance with the applicable SEC rules and the information is not necessarily indicative of beneficial
ownership for any other purpose. Except as otherwise noted in the footnotes to the table, we believe that each person or entity named in the table has sole voting and investment power with respect to
all shares of the Company's common stock shown as beneficially owned by that person or entity (or shares such power with his or her spouse). Under the SEC's rules, shares of the Company's common stock
issuable under options that are exercisable on or within 60&nbsp;days after April&nbsp;9, 2013 ("Presently Exercisable Options") are deemed outstanding and therefore included in the number of
shares reported as beneficially owned by a person or entity named in the table and are used to compute the percentage of the common stock beneficially owned by that person or entity. These shares are
not, however, deemed outstanding for computing the percentage of the common stock beneficially owned by any other person or entity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of the common stock beneficially owned by each person or entity named in the following table is based on 80,870,320 shares of common stock outstanding as of
April&nbsp;9, 2013 plus any shares issuable upon exercise of Presently Exercisable Options held by such person or entity. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:180pt;"><FONT SIZE=1><B>Name and Business Address of Beneficial Owners*

<!-- COMMAND=ADD_SCROPPEDRULE,180pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount and Nature<BR>
of Beneficial<BR>
Ownership(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Common Stock(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Directors and Executive Officers</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>52,228</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>37,379</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George O. Elston</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>37,379</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>40,644</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Timothy M. Shannon, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>379,648</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>40,561</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>638,286</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>366,067</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>356,498</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>458,798</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>43,750</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Directors and Executive Officers as a group (11&nbsp;persons)</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,451,238</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the address is c/o Celldex Therapeutics,&nbsp;Inc., 119 Fourth Avenue, Needham, Massachusetts 02494-2725.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the persons shown have sole voting and investment power over the shares listed.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Common
stock includes all outstanding common stock plus, as required for the purpose of determining beneficial ownership (in accordance with
Rule&nbsp;13d-3(d)(1) of the Securities Exchange Act of 1934, as amended), all common stock subject to any right of </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=338557,FOLIO='30',FILE='DISK126:[13ZAC1.13ZAC72001]DS72001A.;8',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_ds72001_1_31"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>acquisition,
through exercise or conversion of any security, within 60&nbsp;days of the record date.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,728 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,879 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,879 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,728 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
300,936 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,728 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
595,418 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
352,458 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
348,130 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
442,930 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
43,750 shares of common stock underlying options which are or may be exercisable as of April&nbsp;9, 2013 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Please
refer to footnotes 3&nbsp;-&nbsp;13. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=403026,FOLIO='31',FILE='DISK126:[13ZAC1.13ZAC72001]DS72001A.;8',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_ds72001_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><B> Section&nbsp;16(a) Beneficial Ownership Reporting Compliance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, requires Celldex's directors and executive, officers, and
persons who are beneficial owners of more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission
(the "SEC"). These persons are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. To our knowledge, based solely on a review of the copies of such
reports furnished to us, and written representations that no other reports were required during the fiscal year ended December&nbsp;31, 2012, all reports required to be filed under
Section&nbsp;16(a) were filed on a timely basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Transactions with Related Persons  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is our policy that all employees and directors, as well as their family members, must avoid any activity that is or has the
appearance of conflicting with Celldex's business interest. This policy is included in our Code of Business Conduct and Ethics. All directors and officers of Celldex complete a directors and officers
questionnaire at the beginning of each year, in which they are asked to disclose family relationships and other related party transactions. Our Audit Committee must review and approve all related
party transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K. Our Audit Committee's procedures for reviewing related party transactions are not in writing. In fiscal 2012,
there were no related party transactions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>
FOR THE ELECTION OF THE DIRECTOR NOMINEES</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=197694,FOLIO='32',FILE='DISK126:[13ZAC1.13ZAC72001]DS72001A.;8',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_du72001_1_33"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du72001_proposal_2__ratify_the_appoint__pro06309"> </A>
<A NAME="toc_du72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 2: RATIFY THE APPOINTMENT OF<BR>  PRICEWATERHOUSECOOPERS&nbsp;LLP AS OUR INDEPENDENT REGISTERED    <BR>    PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2013    <BR>    <BR>    (Proposal No.&nbsp;2)
<BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has reappointed PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm to audit the
financial statements of the Company for the fiscal year ending December&nbsp;31, 2013, and has further directed that management submit their selection of independent registered public accounting
firm for ratification by our stockholders at the Annual Meeting of Stockholders. A representative of PricewaterhouseCoopers&nbsp;LLP is expected to attend the Annual Meeting and will have an
opportunity to make a statement, if he or she desires, and will be available to respond to appropriate questions. Neither the accounting firm nor any of its members has any direct or indirect
financial interest in or any connection with us in any capacity other than as public registered accounting firm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Principal Accountant Fees and Services  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the fees for professional services rendered by PricewaterhouseCoopers&nbsp;LLP, our independent
registered public accounting firm, for each of the last two fiscal years: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="13pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:46pt;"><FONT SIZE=1><B>Fee Category

<!-- COMMAND=ADD_SCROPPEDRULE,46pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>393</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>319</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>321</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Audit Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents fees, including out of pocket expenses, for professional services provided in connection with the audit of our annual
audited financial statements and of our internal control over financial reporting, the review of our quarterly financial statements included in our Forms&nbsp;10-Q, accounting
consultations or advice on accounting matters necessary for the rendering of an opinion on our financial statements, services provided in connection with the offerings of our common stock and audit
services provided in connection with other statutory or regulatory filings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Audit-Related Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit-related fees are for assurance and other activities not explicitly related to the audit of our financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Tax Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax fees are associated with tax compliance and tax planning related activities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> All Other Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All other fees consist of fees relating to an accounting research tool. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=126734,FOLIO='33',FILE='DISK126:[13ZAC1.13ZAC72001]DU72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<A NAME="page_du72001_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for appointing, setting compensation and overseeing the work of the independent auditors. The Audit Committee has established a policy regarding
pre-approval of all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section&nbsp;10A(g) of the
Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board) to be provided to Celldex by the independent auditor. However, the pre-approval
requirement may be waived with respect to the provision of non-audit services for Celldex if the "de minimus" provisions of Section&nbsp;10A(i)(1)(B) of the Exchange Act are satisfied. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has considered whether the provision of Audit-Related Fees, Tax Fees, and all other fees as described above is compatible with maintaining
PricewaterhouseCoopers,&nbsp;LLP's independence and has determined that such services for fiscal years 2012 and 2011 were compatible.
All such services were approved by the Audit Committee pursuant to Rule&nbsp;2-01 of Regulation&nbsp;S-X under the Exchange Act to the extent that rule was applicable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for reviewing and discussing the audit financial statements with management, discussing with the independent registered public accountants the matters
required in Auditing Standards No.&nbsp;61, receiving written disclosures from the independent registered public accountants required by the applicable requirements of the Public Company Accounting
Oversight Board regarding the independent registered public accountants' communications with the Audit Committee concerning independence and discussing with the independent registered public
accountants their independence, and recommending to the Board of Directors that the audit financial statements be included in our annual report of Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>
FOR THE RATIFICATION OF THE INDEPENDENT REGISTERED PUBLIC<BR>
ACCOUNTING FIRM  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=155555,FOLIO='34',FILE='DISK126:[13ZAC1.13ZAC72001]DU72001A.;5',USER='DPERRY',CD='22-APR-2013;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dw72001_1_35"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw72001_proposal_3__amend_the_2004_emp__pro04766"> </A>
<A NAME="toc_dw72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 3: AMEND THE    <BR>    2004 EMPLOYEE STOCK PURCHASE PLAN    <BR>    TO INCREASE THE SHARES RESERVED FOR ISSUANCE THEREUNDER BY 137,500 TO 200,000    <BR>    <BR>    (Proposal No.&nbsp;3)    <BR>
</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders are requested in this Proposal 3 to approve an amendment to our 2004 Employee Stock Purchase Plan (the "2004 Plan")
increasing the number of shares of our common stock reserved for issuance thereunder from 62,500 to 200,000, which was adopted by the Board of Directors on March&nbsp;6, 2013, subject to the
approval by our stockholders. As a result of the late-stage clinical development of our lead drug candidates, rindopepimut and CDX-011, we have expanded our employee base.
Approval of the amendment to the 2004 Plan is intended to ensure that we have sufficient shares reserved for issuance under the 2004 Plan to provide incentives to our expanded participant base. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
below is a summary of the existing 2004 Plan and a discussion of the federal income tax consequences of the issuance and exercise of options to purchase shares of our common
stock under the 2004 Plan to recipients and to us. This summary of the existing 2004 Plan is qualified entirely by reference to the complete text of the 2004 Plan, a copy of which is attached to this
proxy statement as </FONT><FONT SIZE=2><B><I>Appendix&nbsp;A</I></B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Description of the Existing 2004 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2004 Plan was approved by our stockholders on May&nbsp;13, 2004 and has subsequently been amended such that 62,500 shares of our
common stock are reserved for issuance thereunder. The closing price of our common stock as reported by the Nasdaq Global Market on April&nbsp;9, 2013 was $11.67. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2004 Plan, eligible employees may authorize Celldex to deduct amounts from their pay, which amounts are used to enable the employees to purchase shares of Celldex common stock.
The 2004 Plan is intended to be an "employee stock purchase plan" under Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended, (the "Code"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following description of material terms of the 2004 Plan is intended to be a summary only. This summary is qualified in its entirety by the full text of the 2004 Plan, which is
attached to this proxy statement as Appendix&nbsp;A. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan is administered by Celldex's Board of Directors or a person or persons appointed by the Board of Directors for such purpose. The 2004 Plan provides that all employees of
Celldex and certain of its subsidiaries whose customary employment is for more than 20&nbsp;hours per week and more than five months in any calendar year are eligible to participate in the 2004 Plan
following sixty days of active employment, provided, however, that persons who are deemed under Section&nbsp;423(b) of the Code to own five percent (5%) or more of Celldex's voting stock are
excluded from participation. As of December&nbsp;31, 2012, approximately 109 employees were eligible to participate in the 2004 Plan, of which 33% enrolled in the 2004 Plan for the purchase period
beginning January&nbsp;1, 2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan provides for two "purchase periods" each year, the first commencing on January&nbsp;1 of each year and continuing through June&nbsp;30 of such year, and the second
commencing on July&nbsp;1 of each year and continuing through December&nbsp;31 of such year. Eligible employees may elect to become participants in the 2004 Plan by enrolling prior to each
semi-annual purchase period. Shares are purchased through the accumulation of payroll deductions of not less than one percent (1%) nor more than fifteen percent (15%) of each participant's
compensation. No employee may be granted an option under the 2004 Plan which permits the right to purchase shares of common stock at a rate that exceeds $25,000 (determined on the date of grant) for
each calendar year the option is outstanding. In addition, no participant may purchase more than 500 shares of Common Stock pursuant to the Plan in any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=37,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=335801,FOLIO='35',FILE='DISK126:[13ZAC1.13ZAC72001]DW72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_dw72001_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2>calendar
year, unless otherwise determined by the Board of Directors. The number of shares to be purchased is determined by dividing the participant's balance in the plan account on the last day of
the purchase period by the purchase price per share for the stock. The purchase price per share will be the lower of 85% of the fair market value of the common stock as of either the beginning or
ending date of the semi-annual purchase period of shares for the participant's account. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
option granted under the 2004 Plan is not transferable by the participant except by will or by the laws of descent and distribution. Employees may cease their participation in the
offering at any time during a purchase period, and participation automatically ceases on termination of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares that are reserved for issuance under the 2004 Plan is subject to adjustment for stock splits and similar events. The proceeds received by Celldex from exercise under
the 2004 Plan will be used for the general purposes of Celldex. Shares issued under the 2004 Plan may be from authorized but unissued shares or shares reacquired by Celldex and held in its treasury,
or any other proper source. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan shall remain in full force and effect until suspended or discontinued by the Board of Directors. The Board of Directors may amend the 2004 Plan at any time and for any
purposes permitted by law, and may terminate the 2004 Plan at any time. Any amendment to the 2004 Plan that increases the number of shares available under the 2004 Plan and certain other amendments
that are required to be approved by stockholders to comply with Section&nbsp;423(b) of the Code must be approved by stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Federal Income Tax Considerations under the 2004 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the federal income tax consequences resulting from the issuance and exercise of options to purchase
shares of common stock under the 2004 Plan: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan is intended to qualify as an "employee stock purchase plan" as defined in Section&nbsp;423(b) of the Code. As a result, an employee will not recognize income for federal
income tax purposes at the time of the transfer of shares of common stock to the employee pursuant to the exercise of an option granted under the 2004 Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired under the 2004 Plan are sold more than two years after the first day of the purchase period pursuant to which the shares were purchased, no taxable income results if
the proceeds of the sale are equal to or less than the price paid for the shares. If the proceeds of the sale are higher than the purchase price, the employee will recognize ordinary income for the
year in which the sale occurs equal to the lesser of (a)&nbsp;fifteen percent (15%) of the fair market value of the common stock on the first day of the purchase period pursuant to which the shares
were purchased or (b)&nbsp;the excess of the amount actually received for the shares over the amount paid. In addition, the employee may recognize long-term capital gain or loss in an
amount equal to the difference between the proceeds of the sale and the employee's basis in the shares (i.e.,&nbsp;the employee's purchase price plus the amount taxed to the employee as ordinary
income). No deduction is allowed to the company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired under the 2004 Plan are sold within two (2)&nbsp;years of the first day of the purchase period pursuant to which the shares were purchased, the employee will
recognize ordinary income equal to the difference between the fair market value of the shares on the exercise date and the employee's purchase price. This amount is reportable as ordinary income even
if no profit was realized on the sale of shares or the shares were sold at a loss. Long-term or short-term (depending on the holding period for the shares) capital gain or loss
will be recognized in an amount equal to the difference between the proceeds of sale and the employee's basis in the shares (i.e.,&nbsp;the employee's purchase price plus the amount taxed to the
employee as ordinary income). The amount reportable as ordinary income from a sale made within two years of the first day of the purchase period pursuant to which the shares were purchased will
generally be allowed as a tax deduction to the company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=38,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=728685,FOLIO='36',FILE='DISK126:[13ZAC1.13ZAC72001]DW72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_dw72001_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><B> Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2012 regarding shares of our common stock that may be issued under
our existing equity compensation plans, including our 2008 Stock Option and Incentive Plan (the "2008 Plan") and our 2004 Plan. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="124pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon exercise<BR>
of outstanding options and<BR>
rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under equity<BR>
compensation plan<BR>
(excluding securities<BR>
referenced in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(a)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(b)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(c)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,349,810</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.98</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,390,528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan, 2004 Plan, Celldex Research's 2005 Equity Incentive Plan and CuraGen's 2007 Stock Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 Plan because the purchase price (and therefore the number of shares to be purchased) will not be
determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 Plan (other than the additional 137,500 shares covered by the amendment to
the 2004 Plan in this Proposal). </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> New Plan Benefits  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future benefits available under the 2004 Plan are subject to the participation level of our employees and to our stock price at the
time of any purchases and are, therefore, not determinable at this time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Vote Required  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting will be required to
approve the amendment to the 2004 Plan to increase the shares of common stock reserved for issuance thereunder to 200,000. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" APPROVAL OF THE AMENDMENT TO OUR 2004 EMPLOYEE STOCK PURCHASE PLAN.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=39,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=834164,FOLIO='37',FILE='DISK126:[13ZAC1.13ZAC72001]DW72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dy72001_1_38"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dy72001_proposal_4__advisory_vote_on_e__pro02564"> </A>
<A NAME="toc_dy72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION<BR>  <BR>    (Proposal No.&nbsp;4)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and
Section&nbsp;14A of the Securities Exchange Act of 1934, as amended, or the Exchange Act, our stockholders are entitled to vote to approve, on an advisory (nonbinding) basis, the compensation of our
Chief Executive Officer, Chief Financial Officer and our other Named Executive Officers as disclosed in this proxy statement in accordance with the Securities and Exchange Commission's rules. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in detail under the heading "Compensation of Executive Officers&#151;Compensation Discussion and Analysis", our executive compensation programs are designed to retain
and incentivize the high quality executives whose efforts are key to our long-term success. Under these programs, our Named Executive Officers are rewarded on the basis of individual and
corporate performance measured against established corporate and strategic goals. Please read the section of this proxy statement under the heading "Compensation of Executive
Officers&#151;Compensation Discussion and Analysis" for additional details about our executive compensation programs, including information about the fiscal year 2012 compensation of our Named
Executive Officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee of our Board of Directors continually reviews the compensation programs for our Named Executive Officers to ensure they achieve the desired goals of aligning
our executive compensation structure with our stockholders' interests and current market practices. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are asking our stockholders to indicate their support for our Named Executive Officer compensation as described in this proxy statement. This proposal, commonly known as a
"say-on-pay" proposal, gives our stockholders the opportunity to express their views on our Named Executive Officers' compensation. This vote is not intended to address any
specific item of compensation, but rather the overall compensation of our Named Executive Officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we are
asking our stockholders to cast a non-binding advisory vote "FOR" the following resolution at the Annual Meeting: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"RESOLVED,
that the compensation of the Named Executive Officers, as disclosed in the Company's Proxy Statement for the 2013 Annual Meeting of Stockholders pursuant to Item&nbsp;402 of
Regulation&nbsp;S-K, including the Compensation Discussion and Analysis, compensation tables and narrative disclosure is hereby APPROVED." </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
say-on-pay vote is advisory, and therefore not binding on Celldex Therapeutics, the Compensation Committee or our Board of Directors. Nevertheless, our Board
of Directors and our Compensation Committee value the opinions of our stockholders, whether expressed through this vote or otherwise, and, accordingly, the Board and Compensation Committee intend to
consider the results of this vote in making determinations in the future regarding executive compensation arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
approval of this Proposal No.&nbsp;4 will require the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD RECOMMENDS A VOTE FOR THIS PROPOSAL NO. 4  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=382651,FOLIO='38',FILE='DISK126:[13ZAC1.13ZAC72001]DY72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_dy72001_1_39"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dy72001_stockholder_proposals"> </A>
<A NAME="toc_dy72001_2"> </A>
<BR>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Stockholder Proposals for 2014 Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder proposals submitted pursuant to Exchange Act Rule&nbsp;14a-8 for inclusion in Celldex's proxy statement
and form of proxy for our 2014 Annual Meeting must be received by Celldex on or before December&nbsp;27, 2013 in order to be considered for inclusion in our proxy statement and form of proxy. Such
proposal must also comply with the requirements as to form and substance established by the SEC if such proposals are to be included in the proxy statement and form of proxy. Any such proposal shall
be mailed to: Celldex Therapeutics.&nbsp;Inc., 119 Fourth Avenue, Needham, MA&nbsp;02494-2725, Attn.: Secretary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
by-laws state that the stockholder must provide timely written notice of such nomination or proposal and supporting documentation as well as be present at such meeting,
either in person or by a representative. A stockholder's notice shall be timely received by Celldex at our principal executive office not less than seventy-five (75)&nbsp;days nor more
than one hundred twenty (120)&nbsp;days prior to the anniversary date of the immediately preceding annual meeting (the "Anniversary Date"); provided, however, that in the event the annual meeting is
scheduled to be held on a date more than thirty (30)&nbsp;days before the Anniversary Date or more than sixty (60)&nbsp;days after the Anniversary Date, a stockholder's notice shall be timely if
received by Celldex at our principal executive office not later than the close of business on the later of (1)&nbsp;the seventy-fifth (75<SUP>th</SUP>) day prior to the scheduled date of such
annual meeting or (2)&nbsp;the fifteenth (15<SUP>th</SUP>) day following the day on which such public announcement of the date of such annual meeting is first made by Celldex. Proxies solicited
by our Board of Directors will confer discretionary voting authority with respect to these proposals, subject to SEC rules and regulations governing the exercise of this authority. Any such proposal
shall be mailed to: Celldex Therapeutics.&nbsp;Inc., 119 Fourth Avenue, Needham, Massachusetts 02494-2725, Attn.: Secretary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> ANNUAL REPORT  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies of our Annual Report on Form&nbsp;10-K (including audited financial statements), as amended, filed with the
Securities and Exchange Commission may be obtained without charge by writing to Corporate Secretary, Celldex Therapeutics,&nbsp;Inc., 119 Fourth Avenue, Needham, MA 02494. A request for a copy of
our Annual Report on Form&nbsp;10-K must set forth a good-faith representation that the requesting party was either a holder of record or a beneficial owner of our common
stock on April&nbsp;15, 2013. Exhibits to the Form&nbsp;10-K will be mailed upon similar request and payment of specified fees to cover the costs of copying and mailing such materials. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
audited financial statements for the fiscal year ended December&nbsp;31, 2012 and certain other related financial and business information are contained in our 2012 Annual Report
to Stockholders, which is
being made available to our stockholders along with this proxy statement, but which is not deemed a part of the proxy soliciting material. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=564512,FOLIO='39',FILE='DISK126:[13ZAC1.13ZAC72001]DY72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_dy72001_1_40"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dy72001_other_matters"> </A>
<A NAME="toc_dy72001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this proxy statement, the Board of Directors does not intend to present at the Annual Meeting any matters other than
those described herein and does not presently know of any matters that will be presented by other parties. If any other matter requiring a vote of the stockholders should come before the meeting, it
is the intention of the persons named in the proxy to vote with respect to any such matter in accordance with the recommendation of the Board of Directors or, in the absence of such a recommendation,
in accordance with the best judgment of the proxy holder. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Needham,
MA<BR>
April&nbsp;25, 2013<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=620218,FOLIO='40',FILE='DISK126:[13ZAC1.13ZAC72001]DY72001A.;6',USER='DPERRY',CD='22-APR-2013;17:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_lc72001_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc72001_appendix_a"> </A>
<A NAME="toc_lc72001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix&nbsp;A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc72001_celldex_therapeutics,_inc._200__cel04208"> </A>
<A NAME="toc_lc72001_2"> </A></FONT> <FONT SIZE=2><B>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  2004 EMPLOYEE STOCK PURCHASE PLAN<BR>  As amended as of March&nbsp;6, 2013 (subject to stockholder approval)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Purpose.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Celldex Therapeutics,&nbsp;Inc. 2004 Employee Stock Purchase Plan (the "Plan")
is to provide eligible employees of Celldex Therapeutics,&nbsp;Inc. (the "Company") and certain of its subsidiaries with opportunities to purchase shares of the Company's common stock, par value
$.01 per share (the "Common Stock"). Two Hundred Thousand (200,000) shares of Common Stock in the aggregate have been approved and reserved for this purpose. The Plan is intended to constitute an
"employee stock purchase plan" within the meaning of Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan will be administered by the person or persons (the "Administrator") appointed by the
Company's Board of Directors (the "</FONT><FONT SIZE=2><I>Board</I></FONT><FONT SIZE=2>") for such purpose. The Administrator has authority to make rules and regulations for the administration of the
Plan, and its interpretations and decisions with regard thereto shall be final and conclusive. No member of the Board or individual
exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Offerings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company will make one or more offerings to eligible employees to purchase Common Stock under
the Plan ("Offerings"). Unless otherwise determined by the Administrator, each Offering will begin on the first business day occurring on or after each January&nbsp;1 and July&nbsp;1 and will end
on the last business day occurring on or before the following June&nbsp;30 and December&nbsp;31, respectively. The Administrator may, in its discretion, designate a different period for any
Offering, provided that no Offering shall exceed 27&nbsp;months in duration or overlap any other Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Eligibility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each individual classified as an employee (within the meaning of Section&nbsp;3401(c) of the
Code and the regulations thereunder) by the Company or a Designated Subsidiary (as defined in Section&nbsp;12) on the Company's or the Designated Subsidiary's payroll records during the relevant
participation period are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the "Offering Date") they are
customarily employed by the Company or a Designated Subsidiary for more than 20&nbsp;hours a week and more than five months in the calendar year during which the Offering Date occurs or in the
calendar year immediately preceding such year, and have completed at least 60&nbsp;days of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Participation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An employee eligible on any Offering Date may participate in such Offering by submitting an
enrollment form to his appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established for the Offering). The form will
(a)&nbsp;state a whole percentage to be deducted from his Compensation (as defined in Section&nbsp;12) per pay period, (b)&nbsp;authorize the purchase of Common Stock for him in each Offering in
accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in which shares of Common Stock purchased for him are to be issued pursuant to Section&nbsp;11. An employee who
does not enroll in accordance with these procedures will be deemed to have waived his right to participate. Unless an employee files&nbsp;a new enrollment form or withdraws from the Plan, his
deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he remains eligible. Notwithstanding the foregoing, participation in the Plan will neither
be permitted nor be denied contrary to the requirements of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Employee Contributions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each eligible employee may authorize payroll deductions at a minimum of one percent
(1%) up to a maximum of fifteen percent (15%) of his Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=363784,FOLIO='A-1',FILE='DISK126:[13ZAC1.13ZAC72001]LC72001A.;7',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_lc72001_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>made
by each participating employee for each Offering. No interest will accrue or be paid on payroll deductions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Deduction Changes.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may be determined by the Administrator in advance of an Offering, an employee
may not increase or decrease his payroll deduction during any Offering, but may increase or decrease his payroll deduction with respect to the next Offering (subject to the limitations of
Section&nbsp;6) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established for the Offering). The Administrator may,
in advance of any Offering, establish rules permitting an employee to increase, decrease or terminate his payroll deduction during an Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Withdrawal.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An employee may withdraw from participation in the Plan by delivering a written notice of
withdrawal to his appropriate payroll location. The employee's withdrawal will be effective as of the next business day. Following an employee's withdrawal, the Company will promptly refund to him his
entire account balance under the Plan (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. The employee may not begin
participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;5. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant of Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On each Offering Date, the Company will grant to each eligible employee who is then a
participant in the Plan an option ("Option") to purchase on the last day of such Offering (the "Exercise Date"), at the Option Price hereinafter provided for, (a)&nbsp;a number of shares of Common
Stock determined by dividing such employee's accumulated payroll deductions on such Exercise Date by the lower of (i)&nbsp;85% of the Fair Market Value of the Common Stock on the Offering Date, or
(ii)&nbsp;85% of the Fair Market Value of the Common Stock on the Exercise Date, or (b)&nbsp;such other lesser maximum number of shares as shall have been established by the Administrator in
advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each employee's Option shall be exercisable only to the extent of such employee's
accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option (the "Option Price") will be 85% of the Fair Market Value of the Common Stock on the
Offering Date or the Exercise Date, whichever is less. In addition, no Participant may purchase more than 500 shares of Common Stock pursuant to the Plan in any calendar year, unless otherwise
determined by the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, no employee may be granted an option hereunder if such employee, immediately after the option was granted, would be treated as owning stock possessing five
percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section&nbsp;12). For purposes of the preceding
sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of an employee, and all stock which the employee has a contractual right to purchase
shall be treated as stock owned by the employee. In addition, no employee may be granted an Option which permits his rights to purchase stock under the Plan, and any other employee stock purchase plan
of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year
in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into
account in the order in which they were granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Option and Purchase of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each employee who continues to be a participant in the Plan on
the Exercise Date shall be deemed to have exercised his Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his
accumulated payroll deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in an employee's account at the end of an
Offering will be refunded to the employee promptly. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=131371,FOLIO='A-2',FILE='DISK126:[13ZAC1.13ZAC72001]LC72001A.;7',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_lc72001_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Certificates representing shares of Common Stock purchased under the Plan may be
issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee
to be his, or their, nominee for such purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;The
term "Compensation" means the amount of base pay, prior to salary reduction pursuant to either Sections&nbsp;125, 132(f) or 401(k) of the Code, but excluding
overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company stock options,
and similar items. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;The
term "Designated Subsidiary" means any present or future Subsidiary (as defined below) that has been designated by the Board to participate in the Plan. The Board may
so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term "Fair Market Value of the Common Stock" on any given date means the fair market value of the Common Stock determined in good faith by the Administrator;
provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System ("NASDAQ"), NASDAQ National System or national
securities exchange, the determination shall be made by averaging the high and the low asked price on such date. If there are no market quotations for such date, the determination shall be made by
reference to the last date preceding such date for which there are market quotations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;The
term "Parent" means a "parent corporation" with respect to the Company, as defined in Section&nbsp;424(e) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e)&nbsp;&nbsp;&nbsp;&nbsp;The
term "Subsidiary" means a "subsidiary corporation" with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights on Termination of Employment.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If a participating employee's employment terminates for any reason
before the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the employee and the balance in his account will be paid to him or, in the case of his
death, to his designated beneficiary as if he had withdrawn from the Plan under Section&nbsp;8. An employee will be deemed to have terminated employment, for this purpose, if the corporation that
employs him, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An employee will
not be deemed to have terminated employment, for this purpose, if the employee is on an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if
the employee's right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides
in writing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Special Rules.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Administrator may adopt special rules
applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a
jurisdiction where such Designated Subsidiary has employees; provided that such rules are consistent with the requirements of Section&nbsp;423(b) of the Code. Such special rules may include (by way
of example, but not by way of limitation) the establishment of a method for employees of a given Designated Subsidiary to fund the purchase of shares other than by payroll deduction, if the payroll
deduction method is prohibited by local law or is otherwise impracticable. Any special rules established pursuant to this Section&nbsp;14 shall, to the extent possible, result in the employees
subject to such rules having substantially the same rights as other participants in the Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=11728,FOLIO='A-3',FILE='DISK126:[13ZAC1.13ZAC72001]LC72001A.;7',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_lc72001_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Optionees Not Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither the granting of an Option to an employee nor the deductions from his pay
shall constitute such employee a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Not Transferable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Rights under the Plan are not transferable by a participating employee other than
by will or the laws of descent and distribution, and are exercisable during the employee's lifetime only by the employee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Application of Funds.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All funds received or held by the Company under the Plan may be combined with other
corporate funds and may be used for any corporate purpose. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustment in Case of Changes Affecting Common Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a subdivision of outstanding shares of
Common Stock, or the payment of a dividend in Common Stock, the number of shares approved for the Plan, and the share limitation set forth in Section&nbsp;9, shall be increased proportionately, and
such other adjustment shall be made as may be deemed equitable by the Administrator. In the event of any other change affecting the Common Stock, such adjustment shall be made as may be deemed
equitable by the Administrator to give proper effect to such event. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment of the Plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time, and from time to time, amend the Plan in any respect,
except that without the approval, within 12&nbsp;months of such Board action, by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any
other change that would require stockholder approval in order for the Plan, as amended, to qualify as an "employee stock purchase plan" under Section&nbsp;423(b) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Insufficient Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the total number of shares of Common Stock that would otherwise be purchased on any
Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned
among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase Common Stock on such Exercise Date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination of the Plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan may be terminated at any time by the Board. Upon termination of the Plan,
all amounts in the accounts of participating employees shall be promptly refunded. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Regulations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligation to sell and deliver Common Stock under the Plan is
subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan shall be governed by Massachusetts law except to the extent that such law is preempted by federal law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shares may be issued upon exercise of an Option from authorized but unissued Common
Stock, from shares held in the treasury of the Company, or from any other proper source. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Participation in the Plan is subject to any minimum required tax withholding on income of
the participant in connection with the Plan. Each employee agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to deduct any such taxes from any payment of any
kind otherwise due to the employee, including shares issuable under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notification Upon Sale of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each employee agrees, by entering the Plan, to give the Company prompt
notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=812609,FOLIO='A-4',FILE='DISK126:[13ZAC1.13ZAC72001]LC72001A.;7',USER='DPERRY',CD='22-APR-2013;17:01' -->
<A NAME="page_lc72001_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effective Date and Approval of Shareholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan was adopted by the Board of Directors on
March&nbsp;31, 2004 and shall take effect on the date that it is approved by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=119915,FOLIO='A-5',FILE='DISK126:[13ZAC1.13ZAC72001]LC72001A.;7',USER='DPERRY',CD='22-APR-2013;17:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="680" height="880" src="g18202cai001.gif"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">THIS PROXY CARD
  IS VALID ONLY WHEN SIGNED AND DATED. KEEP THIS PORTION FOR YOUR RECORDS
  DETACH AND RETURN THIS PORTION ONLY TO VOTE, MARK BLOCKS BELOW IN BLUE OR
  BLACK INK AS FOLLOWS: Signature (Joint Owners) Signature [PLEASE SIGN WITHIN
  BOX] Date Date To withhold authority to vote for any individual nominee(s),
  mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line
  below. 0 0 0 0 0 0 0 0 0 0 0 0 0000173570_1 R1.0.0.51160 For Withhold For All
  All All Except The Board of Directors recommends you vote FOR the following:
  1. Election of Directors Nominees 01 Larry Ellberger 02 Anthony S. Marucci 03
  Herbert J. Conrad 04 George O. Elston 05 Harry H. Penner, Jr. 06 Timothy M.
  Shannon 07 Karen L. Shoos CELLDEX THERAPEUTICS, INC. 119 FOURTH AVENUE
  NEEDHAM, MA 02494 VOTE BY INTERNET - www.proxyvote.com Use the Internet to
  transmit your voting instructions and for electronic delivery of information
  up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting
  date. Have your proxy card in hand when you access the web site and follow
  the instructions to obtain your records and to create an electronic voting
  instruction form. Electronic Delivery of Future PROXY MATERIALS If you would
  like to reduce the costs incurred by our company in mailing proxy materials,
  you can consent to receiving all future proxy statements, proxy cards and
  annual reports electronically via e-mail or the Internet. To sign up for
  electronic delivery, please follow the instructions above to vote using the
  Internet and, when prompted, indicate that you agree to receive or access
  proxy materials electronically in future years. VOTE BY PHONE -
  1-800-690-6903 Use any touch-tone telephone to transmit your voting
  instructions up until 11:59 P.M. Eastern Time the day before the cut-off date
  or meeting date. Have your proxy card in hand when you call and then follow
  the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return
  it in the postage-paid envelope we have provided or return it to Vote
  Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. The Board of
  Directors recommends you vote FOR proposals 2, 3 and 4. For Against Abstain 2
  To ratify the appointment of PricewaterhouseCoopers LLP as our independent
  registered public accounting firm for the year ending December 31, 2013. 3 To
  approve an amendment to our 2004 Employee Stock Purchase Plan to increase the
  shares reserved for issuance thereunder by 137,500 to 200,000. 4 To approve,
  on an advisory basis, the compensation of the Company's named executive
  officers as disclosed in this proxy statement. NOTE: In their discretion,
  upon such other business as may properly come before the annual meeting or
  any adjournment or postponement. Please sign exactly as your name(s)
  appear(s) hereon. When signing as attorney, executor, administrator, or other
  fiduciary, please give full title as such. Joint owners should each sign
  personally. All holders must sign. If a corporation or partnership, please
  sign in full corporate or partnership name, by authorized officer. </font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=48,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=573114,FOLIO='',FILE="DISK127:[13ZAC2.13ZAC72002]1820-2-CA_ZAC72002.CHC",USER="JVANGB",CD='Apr 16 19:09 2013' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="92%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="680" height="880" src="g18202cai002.gif"></font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:4.0%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">0000173570_2
  R1.0.0.51160 Important Notice Regarding the Availability of Proxy Materials
  for the Annual Meeting: The Notice &amp; Proxy Statement and Annual Report on
  Form 10-K is/are available at www.proxyvote.com . CELLDEX THERAPEUTICS, INC.
  Annual Meeting of Stockholders June 12, 2013 9:00 AM This proxy is solicited
  by the Board of Directors The undersigned hereby appoints Avery W. Catlin and
  Anthony S. Marucci, and each of them, as the true and lawful attorneys,
  agents and proxies of the undersigned, with full power of substitution, and
  hereby authorizes them to represent and to vote, as designated on the
  reverse, all shares of common stock of Celldex Therapeutics, Inc. held of
  record by the undersigned on April 15, 2013 at the Annual Meeting of
  Stockholders to be held at the offices of Lowenstein Sandler LLP, 65
  Livingston Avenue, Roseland, NJ 07068, on June 12, 2013 at 9:00 a.m. local
  time, or at any adjournment or postponement thereof. This proxy, when
  properly executed, will be voted in the manner directed herein. If no such
  direction is made, this proxy will be voted in accordance with the Board of
  Directors' recommendations. Continued and to be signed on reverse side </font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=49,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=563858,FOLIO='',FILE="DISK127:[13ZAC2.13ZAC72002]1820-2-CA_ZAC72002.CHC",USER="JVANGB",CD='Apr 16 19:09 2013' -->


<BR>
<P><br><A NAME="13ZAC72001_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc72001_1">ABOUT THE MEETING</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de72001_1">PROPOSAL 1: TO ELECT SEVEN DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY ELECTED AND QUALIFIED</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de72001_2">(Proposal No. 1)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg72001_1">Compensation Discussion and Analysis</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di72001_1">Summary Compensation Table</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_1">Grants of Plan-Based Awards</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_2">Outstanding Equity Awards at Fiscal Year-End</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_3">Option Exercises and Stock Vested</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_4">Employment Agreements</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_5">Pension Benefits</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk72001_6">Nonqualified Deferred Compensation</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm72001_1">Potential Payments upon Termination of Employment or Change in Control</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm72001_2">Director Compensation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm72001_3">Compensation Committee Interlocks and Insider Participation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm72001_4">Risk Considerations</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do72001_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq72001_1">REPORT OF THE AUDIT COMMITTEE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_du72001_1">PROPOSAL 2: RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2013 (Proposal No. 2)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw72001_1">PROPOSAL 3: AMEND THE 2004 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE SHARES RESERVED FOR ISSUANCE THEREUNDER BY 137,500 TO 200,000 (Proposal No. 3)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dy72001_1">PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION (Proposal No. 4)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dy72001_2">STOCKHOLDER PROPOSALS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dy72001_3">OTHER MATTERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lc72001_1">Appendix A</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lc72001_2">CELLDEX THERAPEUTICS, INC. 2004 EMPLOYEE STOCK PURCHASE PLAN As amended as of March 6, 2013 (subject to stockholder approval)</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JVANGB,SEQ=,EFW="2214489",CP="CELLDEX THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g18202cai001.gif
<DESCRIPTION>G18202CAI001.GIF
<TEXT>
begin 644 g18202cai001.gif
M1TE&.#EAJ`)P`_0```$!`0P,#!04%!P<'",C(RPL+#0T-#P\/$-#0TM+2U14
M5%M;6V-C8VQL;'1T='M[>X2$A(R,C)24E)N;FZ2DI*NKJ[.SL[R\O,/#P\O+
MR]/3T]S<W./CX^OKZ_3T]/[^_B'Y!```````+`````"H`G`#``7^X">.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__P*!P2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZ
MO^"P>$PNF\_HM'K-;KO?\+A\3J_;[_B\?L_O^_^`@8*#A(6&AXB)BHN,C8Z/
MD)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\
MO;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CI
MZNOL[>[O\/'R\_3U]O?X^?K[_/W^_P`#"AQ(L*#!@P@3*ES(L*'#AQ`C2IQ(
ML:+%BQ@S:MS(L:,T#R9`DA#I0:0(D"3^3Y8P^0&E2I,P5[:<R=*CS4(UU]3,
M>8+G29\C=HZ<>;,H#@X40':8X$$#!`X?*$B@$.%"!0D1)"B=@%7#!PD=HF;X
M@!1I20H8)'"E<$&"!`@:VD:@\.'"A0\:*D3%.J'MVB@PO1H=3*1#``L?'AR8
M$(!```P+`@`(P&```0,'0&(`4*!```X('FP0@*$N:0`,/@BH'"#``06N!UA`
MX#H`!0<`-D@@\*%Q@00,6@=($%1$!@\=O&;PJJ&#!PP<FN*%ND'#\:;'.5P(
MF_W"AI89QG+XCL%K@LP=+'P7T>&"T@O4-V#HL)RP_1;`/QAX4&#"AP8'?(!!
M`"4%X``%27W^D$$`7`W``0<$$`"!"!@,<$%C&)#VP0`1?*!``5=Q8$`"&1#0
MP`,`-+!;;P?2Y<%C1(VPV`0#>#!`C01,0`$`#F@`@`<%T+6```,PD`$`"EA`
M@``&?(```Z\1X`$%`@"@P0(+-!"``!48<%@""Q@PE@<&F$@FD2(2<,``L`EV
MWYLF8)`C`1O`&,$`=1'X(@$%9"8@`&4J((*6(F5HP0`0)#!`:1Q^L```:\X&
M```(>*@`E$WZEMF+I8GP0`+?36!`F`LDH`"I3Q[`0`$,&!`6F*-=Z,&*,`;0
MP`<%7*#`!`XD8(`%`6S```,-+,`!``\$($&>'<A'(`$2&#!5C3#^PFEM4(%^
M<!X%`SP@H)X!/("@9@!,,`$`I47`FV8"7-B!`0",U>B'%D@`85\`=("ECP&&
MBV!+,(($X'<="(!`!`!84`$`$=#F`0(Y\HA!!E!.T"X`'UA\@947&/Q!!040
MP(&/E3)X0`,,*."C!`Q04,&`7!W9,04&F,L;NC%>^R8$`>C%P9`/@)2!`26M
M.4`!(&E`P``">!M5I<8=@`'1)9KG'P0".&;!`OXE<.*M#2C@@=%(DSG6"0P\
MP$'9!7#P0&H2$%>`L`\T<!D%&R#M:--.4K!K;ZDYZ1^-F1UZ002JRND!ULL^
M(,`"VEI@`7%BZFPY%4"E(%1Q0XV@@*#^FI^$]7J7E[[#YJ?[Q-+J1$B><TZ+
M(\9Z"ZJ;;FU,H<_^$N<]A<3[4+C'R'I)K^?\>^]A=?Z3\31ICASS*@$O?%#.
M'9\Y\<&C5'M0SX]T_0C1V8Z+`E!=D!I//W<`N@D<K$^6^RM@$+CY.=,_`P:W
MW774`AXX[?N_,;$?"B[0``YTZ`8,N,O#$I"YNIPO1NU;003&5(((SB0K]IK!
M;A0HOEH@`"H68``&$(``#UC```=<&`8.D``&GO"`'&!@J;@&``Z<4"L*.)$"
M#J"7"!@``U@#B>,^H"ZZ?,`!!-!`:#*@@`1HP`$[U(VJ--!""AS`.Q`@@`,^
MT('4M.4"!(C^@`=2`P'S\<\#M\)`508@`0N@"P*3.YBCO"8"!$$@BA(X@`.0
MF($$0*`!4Z+`VDY$`#4^K(014(`![(*`!$`E*L#9P`*:^+0"E&9A%%"2&"\E
M$A]B`#+:$EL'$+"K`&1@`0S80`(0N4,UQD5",V$`"?]S@`Z\90(-&$L#-O"Y
M6>W0*PT(RR@_J*8&=G`5"/B.!1P``0100`,%>(`!OJ.!`T"(EU;DSW=BV`$Z
M+2!NW82`F.:V``A0()7=2H#?ZLB`:@XM+.>$YI2P-@$$6.`!$KB4Y)RIS@;(
MKV4B6,`%\(F`#/#3430[F\H<,($#&'0"H%I`(C6@``DLX(0B@$#^!!)PSWP*
M])P90%IF(A`!KEU@`B)L@`,B`(&W0:`")W(F5&;E``%88&X*L&(&KHB7`VQ`
M3`CHTME*]*D*..`!393`42\P&PAQ@`$LK=M+55K/"QC1HI,3%;&P`E4'4`R*
M"4`I'(T$.HE&H`$-\,\Q/?B="D`NGQ!"JG@2,,H/M,P`4)QK71DP@05T\P$7
M)<X"PM,`#2"J98&S0"X%]<$/*):)VBJI13U`TO\\@(`4RZP#&H"8#VR`E$JT
MZP0$M8!U@H0"J`PM7XUE5@^8U4DB("G_L&)9S$)NI"559B[1^DF53@QN#&S)
M`2B@3D&UC+2(X6:`^"HHS1R6`@]PP)/^<)E<N@9H`;UU0&\?,%J5:-0#%=W/
M`TC:SI1AH`'3Y:Q=?Q70#)Q7O6N5!4B:":##)8``%%/``X19R$H)-&5!(XMU
M[4H!<BH`+O[]Y&VY)B<17*``'3B``4!W@45"[DD%R"=E(P#%X>;22$9"V19!
M,BP/849$E5GG"*1E8I_F"JIB3.:(`O0!C8J-I%`T0`4.L#5M+6``5"%`DG[%
MV9"9[Y,,R"=^N8A7(`OV`@M`@(9`TV(JCB#"7`MAA7-9`34]&`/$*7`!0MC;
M!IAO5,8I``DU8(`$DE1L$RA`5*;(`,1D8`#)$[/Y.AO?66@`;RVAP)@`W9+Y
M,.<LZVF*=#;^T('Y3(F:>"G)-I/B`?>TY"X<J`!)X+/-"C3'*QSH0`?PYH$-
ME/K4&ZC."`#:@0I`10/J20X)PN<!5]=E/*$N]08H``$:/\C4H1ZUJ:'3:0V`
M4`//:9:`2F/J4PMZ!'EA]*$KC>R6>*76KYXUI;UB%PJ59CN"^62D=7V61RH(
M`]2DRZ]+DKQN,]JQ@7,PLY/79V,8LPKS)0X*OB>3%2)`?\?CPKVAYSV9*(\$
M>>L4P>L=BY0$/'JA^YW#80?QYE6\=S@8.`MX0O&`=SQZ'4<=R'>W[XM'_.$'
M9S@LJ@WMLQG<!*9FN<950,T.F+O4)R'=<RR@&9=KQSO03EYS$&[^E^UT3M0O
M#\K$/CETCT='YS(Q=0H>9+SRF'P$P-8XSD,"'>C0Q-QD^;C*<;%?LN!%`%M,
M7DG63CRRA,6:$!#F2:I'\K8WC]T?\.E4("<"!\CYB'+63`$*>`%2ZL6N!0B3
M8/KD60`L2R2O8<`"MHD2J#S`6TAO";M)LJH",',LSL$>W3\+FN[1?007#3OV
M0,+2H$"%2OY1.TC")P(%G%?3[*&WYHFR`1JC)"P-Z!,!`.Y6LD!%`7K)_/+6
M/G9:%/D`"W"`*1D@``D8%JEM7D"`+*!(QL#TJ=6')@E!0C^Z*K*6(B".6S#E
M?>X&[HG$T<"G!,05B3HJ`SUV%&*@*@+^!+B*6_XA$O^F`=\1-]-T'@VP2A[@
M*W\F(0?@?]_!>A/B`+.A1T]"1`9P*Q^#+FKF*A'@>2,@385$`8WT`!,B0E_!
M)YKF*TR41`A@(=PB%2`H`@(0`?S1'[W76'A1`#\D*)L5+&DV3A!30@IB`(/7
M/M)"`&KS@.L14G/S`,/7?+.P*\2Q*[E4*<Y4*0:@1'TT:@_`1JS575GH).5S
M6Q'F-A/B)!L&*F\1A@]$9611*:<%76J#`*PB`@Q```A@3;4G0OGT>"+P@`FP
M11+0`*3A-1T``3J2?2P#)'8E.S4V(5SC1`=`138"`04`:G0E9RU3`)@(:DWR
M;Q1@B.;31QG^Y0`QE$?#$@'F@HH*$`&I@2B9V%XMDP%H]3D:6%H>8%"B-7D/
M<"620RSGU5E)4@'M)$V;98NFDHN2@U;+(H6RL"NIL2M>11P(@%).T@&.1%<(
MP#(E]3-]I2W8V%@]!F$?!`%IF!DK=6/?R#5O"#5P&!4<`!G(,8H!-0'*EU.#
MB(Y$H8,=,&;_UD4.H!8%1E)9,3;Z-Q/\R#7&LHT=<%B:N%<T`P'M1!8!DE,\
MYE`64'T9M5]A50`DI8@3L%^OV"$067NVZ%XJY4?/6%IX42EAM0`:8"0"I5B[
M18Q,Q0`.`%6\E8`0\(P*P%0J!8G0^`JE-8WGY"&(`DH?1#X*T$7^'T*"J"5)
M2WEAU/$;2.-_?&A7$--7E!4WHXB-(A!#8TD<&2`!*U2)!C4W>,A!+B.3-:,6
M5A6(!K"'5+0`PZ=(:55"C726'5(I"71!)WA.W$0<B@$!2C%\@J5&!Q!@_U$F
MNJ(`A80K@A%G03)*).(69"(;$S"!!S`A(%%.VG5>/S58%-(95`0Q-Q5N(2,L
M&F!F%&*$W.5_?_2+T'<V&-":@5F4L,!\OCE32J%Y*,%HR($]P`E!H:8MQQ$4
MQ*D]H6=W1"%ZQC>6-V<2H<=%;)<\S9)JDB9,S>:=NZ<]W".<,Q$6I49OUTD\
M4G<2T2%II[4^R/%(LD8\-A>>[Y9[;#?^G5<&%3:W>>5IGKN'G^>)=^-!`D@'
MG;QI"S-G<<<3=S[@<$6PH##@$IH3E+Z3<2.7<BCG`A*:H*2@.S>`.KH#H2K`
M<1A'H1@W/10GHE=7<A"'.RBZ`F+'H26ZH3;:H1X*"IGC'CSG<77!$I9V`I8V
MCRYJHT10:<;A)B,0I"6G`==6'%X7`UKW`AR0`8VV<"$!<-$3'A@PHRKAI#FJ
M"E4Z'NN!;I=F:ID8`1LPCP23`>M)'W35'M&11'5!.OT'0I#S23AW:D;G=I[E
M`42:G*&6:BU1I6%1'4WA%=LT=,GI69UR`>*!;-JA;Q6@:>$Q`O]V-I!*%AI0
M&J6V4ES$GR7^P37+>:G)T:4M$8&F9G3M:6[N)31CXG4;H#\9<!?IL1Y^@P$J
MLTU!VFPE$1T68',(8&S@PW,6H%-UJG21ZJD;,%Y8&J:;`!(2=BIRUFN5@C@*
ML"#FPRV*!!HO:)X/2"</`(&/D4=T10((<"!9<B6#QS\CZ0"J4D>W@I$Y@A7@
MQ1AT\9`DQ`%%4F`$$$*H58C*B1=E(CD_5H$G=``TQHJK%"2!F``@LC6R04)C
M%BUL!&]KXUI[>`!5H;!/A1DCQD"=Z7?7Y5Y\9SX2(B=SDX>II+!6H8?<UTAA
MP1\5LD/MTYCM=7GRHQ@,X`%ZZ"?_Z#6X9"'FFF<'2['U4B;/"*W^II!,H&)=
MK4)<K=)7X`@YTIAW>.HD\I>'"QAA4TL4JI)(N]68#Z!8)X1$G5):#4!2X,6V
MK^@T''!=$.4H$P,Y&K(`Q1>)(H!+&?:4]DIC-F9+Z=@!)*58?4NXB419H'E@
MT4>1%G!>O1(:9G9*L756Q.4AMEBW#@8@=8,8GR4"T<(`3A161)2M(O!8Q*%.
MT40`8;$UF\57>`4B3]82**.X?J4J-;.WP3=:B'MCH,FTI?!!#HD`)S)"Q1M1
MV*A.R=0V=2%C5I2;HP0:)\)!9.A8F\5,#/`N@,0A#K`>;G2L(O2*$`!FK<=%
M<Z-.@F4N1L)B;J16L.BDSB118L,R4Y/^48E;OHBT4:AUO_DD/VFX46Q&,=F5
M`!%`9J#4$FH&)'$[D_525B:H4A.T4^$A`?VAI@_V3+L!$B%$N>J4(PZ`$M<(
M41#24E/3>YYJBQ652-)[62)@`/O+CD')?\!;"ME;P\]Q,C=\*^KT4M["/W=D
M`(\$(`K`2TVT@!903:GQ+W95/F7$0M[B`'?14`?4?]\AF<LQ(@>B5N_2F%UD
MD=947E"13"=AQ1OE3`X0%@IP@1DSBE.B5CV+('%C3X"D(VSF3`[&/R4$%QFP
M7Z34/\LQ8C7F+32R133C1W742(AI`$3#+5LD2]91E_+79D+S;]Z2O;WF(G95
MJ:DAQ>IS,I[^(RT(<E%L!D@9M4HPM<9U;$0SC`LSV6M>*@,\42PM$(\J(,L_
M,',#-S5*2@.O;`0XNLJPH%1V^J#1*1K/.B4;!P'#K*$Y\,M1H<I&6J0V$*,Z
MX,S`'`FG1Z&;@Z#:/'$OVCG!23L,6G#1N7P7FG33DZ$@^LW*0\T?!Z/[9J(J
M"A0N,3S>8W?6?,V0(##3M&KVJ`)S017,XS+,0SXJ\)0.R@(HF`+^U)8J,4%(
M($`M@((6)*5VI:4TNM#%45D^T0'^HP(7@(IIJ,^IL`$IPF;3.(Y.="L?7$9Y
MEU-UN2SH)1AVE,:Z\20F?4\+4+9H9%?#U3-QIR[>T43!I'TNPC?^,LL>LR1+
MY-,M8X0`:1%"301/5V.+;3,N9=N-7(1*DB1*"JA)KI5*.Z1=C?1(?I-**1-F
M=G@7"Y,>8303728!%S!<%;8L4ON0WM)+(B`L_S9:/,8>GT.W4],A<6TJ(\06
M8>1:IK(!C5P`8P%$&5,!-`)$BZ(6.^0>IM(A^4S2B>!3]N2.$A!=&C4L%L!C
MDW=$<^%$NW(RH/.3]H1/EY(4UG1%;CM:%S!"V`35/`3$'`4M^I,`(8V.@2-1
M$+!9Z/@V%;#'GG<@TY0DGA51L%@!%868%04U#_E4275YCRLF/+:RPCVN@@2Z
MAKB:I550B]13_[A3I?$N%F!??S5-O!+^`%="0)^3AA>`B<:=MRE34<PM33O5
MWBL%4>\R0C<E22C55[?=$@B@+_4T0BAU7@PP5<QT1YPM"@N.2'\4VOXD/](-
MBUM48^8B1M\438&C4?Q366A%A@Q$4OJ"OPR>TJGQ04JD/X-E)`<\6.]59FJ4
M-D?570(56T%BKR7I6N5+9:++5W46AZ(E*-E*N7&#$HM17$N>D,I%Y5"C41N"
M5`X^K"'V)&GH4INEN78%'+A$,\7"?1FE(V*T7-W%5VO[NS6VTU#F(;R2`6&.
M`6%.N9M=X8:PX-+DV-]49$$R&F2B5A#`-8CI1&UF1":^85`D);]"5S3S2YTQ
M&VZE1&TVYQS^M4J!<V`WY;!14>D-8(0AU%)I?")QDY`M,0#+T1D1T"4M5.25
M0C-&`C);&";#.NL\J"*2N=ZK>[D"%66+PD4.HGWHYR&>]Q:AI#;[(0#"`D<9
MJ#_%DJX;SG<-55[FHP`?_"$KA>C:\H"\F&2#I<A&])!=JLC8160;+D)U&6]\
MW@G5=L1XH6P)KB"*-I;0`15C\6?@,S*`*FJ`AFY2][C4A!CH)JG;AA<"DB!X
M,1;U[F!WL0'NA1=>(6BXIJC)HTI)TUD$3W76!O$4HD#A'6[0,24NEQ>?-N\F
M-'25YASAC1(48',S!6@9X&FEYO``-R7$5A)NPE2>Y?(1&/.-5J#^4Y)M:\H<
MAS>68TEIQ-9L$G].#_3NI;#G8%#HS]H$QM3+^)8Q++3,4A^M%==`ZSP[(7?.
M6#JBG+.@\IP]*T'/(=JB86]R+&KVS(S.</_UEL!R%23/3Z=[[(.J>!_X.E!V
MU0.H'B([V,,>'H(_H*<])/$;S"><<B?XE,\"G%67*J.P682.T;1%3TE]ZH*.
M9[D:9.(KW[$C4K$:CVFM_`&(E?_Z)9!3,%EA8@1B@@8Y825*@\50,&E%5$Y7
MH3B3@I8`8';`L'_\M3>.J39<(&:R>8=:+;'[<TN%CA+Q`T8B-AYBE(O\R)]3
MJ0'<!Y!A#5#<VX&5ZB,`8@7%$#``QN+^7YA6*0[`)G8U,;M%N<'$_:_/?&%1
MH*)&/`]BGB"P?5WG>=]VJFKWH:MI?B=WNC>>ZSO?^S\P*!P2B\8C,JE<,IO.
M)S0JG5*KUNO5AMURN]XO."P&:H5EU_F;'K/;[N/Z+9_3Z_9[4^8AQ64SO@K'
MS1XA#&`)&AKB7LE*R6++"$O<S-Y,I22>YB9GI^<G:.C7@\'!1T*IQ8+@J:`'
MP@#$!\+!`06"1@/%S89!@<'%0H>"!NK!A8*!PHD!QL<!0</L`4*$P\<"!G0!
MQD7`,NF!QP-U7(6`0@="1\2$A`$"I>@\?;W]/7Z^TH7IPX2!"`T&3F08^.%"
M@F<7"M3X$`'^0(0<'!!\T$"@0P(+!@05W$#`0X0`%S)0S`CP@P4&'!).=-&2
MWX<'$0!JB,/!5`8`%!A,H,@@@[Z@0H<2+6JT#0,++C`00#`!PP(7P5Q0B*J@
M0M.($P:<L4`1PX`#"<`ZU1``V$T*#B804+`@0UAW$Y!]J$`1I4^E)R@,F-##
M*TH'$!HDN'#T,.+$BA<O/K'``H4&#1B<:""A<H03"BA(:`"!\@<*\)0F@B"+
M`80+GD$W>,!@@X,!!1RT5BK9,0:>'TR[>'#M<60(&NCZ2>0;F\8'#2!'+<[X
M.?3HTJ>'6;D1P@$#$R(4*+#=@($(#0HL&%=J,@>UERI+^,!`0P3^#!#`3WB0
M(4."!!O4,G`6D[X%L;C0@%\6%)"`!]9Q<%,"@NB2@X$)=-"`!PY<AH`!&NRV
M"W4=>O@AB"'ZH(4\:3AGA#PC]F"#`Y$,0H:(,<HX(XU'45`!54II\%,.$2R@
M``8<+%#3!!Y<)L%F'##00#84L`,4#A(LZ-<%[BS0I`<85%"!D4;^Z,P99:28
M2(UE&C6FF6D&!4$`SK")P2L42'A#!P98H*4!5>TT2R^B;?!/!05A),(-&@"@
M`08*S!+!`15<8`$`%K3&P"P<%&#!!82J.9T>EWA*II@XV(#(IS&0N9Z+)'Z:
M`XF+G'@JJZ7ZX9RJ,=@PZXN5P+!"(IW^GBHFFIL*&T0'$A1`@@0?374`*Q^`
MY0`%$$2D0`00Y+:!`*ZA8`I8#(@S2`(//.#!`I%I($`#(R%0`0,1V/<:NC@.
M*QT"`=B+00%0ZO#6JJPJH*D+'1!@+VB72(#`!90B82D"(M0;@"DX\`L$!?8.
MT,$#`-BKU`0"!.#7`9D-H$$!AA6P2TX1+2"`"00,$!H``P10``/VZK2`QA<S
M$!4%`$CSSB4A`7#-O$4?L9)+"76P4T*75%6!!MEDP,!/#T"@48,.42I!`A(T
MMU<!3)ZR$05`<@`!!0=`\);5%220@89&/T>>EAL$D`$&")1G`0$30*H`!`E`
MT,M&7OTXT0;^%Q`@RPP!2%`!`!>L)*&Q*5F@*`(9D$.!5PQD^,%F(RA```8/
M*4S>!1I44![@`"C00`0KD33D`PBT]X$$`9`L60%1%V`W!15OL,$!"U`Z`<UW
MY22.O:$1<+('%PRP2C(8.$F>0)(EA&$!#A$0L.,[!2NWW.ZZ8/X#";R6R&-4
M*7"`!=@ML\`%%#SP@6>@8R!!1"=T4,`#W/(!`D1E`0=P@"HTH``',`I!WGK`
M+L9'/GL8(``#$``&!""]^8P.`A/(@$@8P!4#[`P!/<-``"R@00&T0Q`=:-,'
M^J(W`[X#>7!!'@0&(`$!+"``''@=!WSH'@/DL`*Z<T$%4\B6#P3^@`(:O!*V
M+A"YCDT``$"1```($+D&9+$OR7(!`2("`0#8``%67(H`J*8``8!.`6X$H\JR
MF$(S$H``P5!4`"(@@`QLY08-$,"E)BA('PS/!85<&L!0T((36$!#'J!`0/8`
ME"!5I`,:<-$&G&%)9XE@/Q3`@(9J\LA.5H`"^AKD4>A6`0X(0(57>L`>.\`!
M`&R``8H:``7^L421#.`"&&R(!P#@C";2@@$/J.'W%J##GCW`>-W3``)VY@+U
M8<L"`;`!S2P`D@)X0"0!V,"5SN6-#TP@`+4#BAXOX(P%(,`!UU0A"5KYC).=
M[WLGR"`Y'C``#FC1@B=8'.B:<3T&)*#^>PI@@!0%`!$*?&\&CF*3BU`I43@P
MX543_9`!8H9!#+JQ,#UD5AH5D!`'>*P=WTLA!E=V@$7:['L.0,!F=/FR*FJ`
M9%2#0$,3<,;06/`M`8A$&*D2`)QUBP%-:64`/I`!`MCR!!&P9QL_``_0V2LA
MZCN7")YZ@PQ>`!@"<.*"OAK#B#!`CAII3QZO]".'%`"+`;!B`NREJ(M*E#(W
M:D`M5)/7\>"(,CP:D@>6X<%2C:`\@^41#@H2D;11R%F4J@#\EJ(PN@XE`Q:X
M;`?@]$C#/%(0&FBD(R]@&`XXXP*9-4$%")4E3*D`,A_@0`9(.P,X560"',BL
M"PCJJ0QP*7K^-J"D5#``I\]ZP`+WZ<`%3J`!2+H$3!71$`>XY"S_2.X@@I!M
MP.!4`@S`S04U=99G+VL!V`8D=8A2`2A%J\WB:I.R$U2N3I*2H0YTI`,6.$!!
M"O(*^UK1+#5S+@Y06+,,2-$PO-`/+AJV#@^0\!43(0$)W2OA?N%`C_JZE1<D
MF.$)DR]A$RA74R9P+A,FZA0,10`";B(!!"Z`,,W"054:0`S;4<H&$]B%,!P"
M@0XXX`'"C4J&Q*47#NL#PZ`2%9*-#*LE8V('2@Y"F)Q,6!Z8*%8_B+(.5-`K
M"JN*R$4[`0,J0$2OG>`S8/8;`R009ET,(`&TX>Y<D9P-#!"HS5'^N40V4N(>
M2A6T`!'HP.J8]`O&>=D>*<B2AD>D6D(]8D%K2%"N>D`"*-?@Q4.`=!D6A&0B
M>(#1$<T"$&HRA`YL@`0B2'2AO:``)4'@`0>*S($FD(R&]4<"FU/.:\KF$`[=
M8-6B,:&V;,`=O_*0`LMER$P<X($,4*!WJ;;'.A3`$$_Y;]/4#AB96H*"NT!`
M`M9;]25<5`%%T<I_6N8-B5AP`W9E@-Q_8!6O1O!:4UB"*A&\E99Y%0-,<OM^
MN$*#EM>#;X#K:E:WBH0EC/R`%I`*$PCG2&0HT#\]%,?@\J8XDY^]!$R;8`,:
MJ$%-;WO)2LC2%;(<00N&)"H7;L`58DK^`0HX(&I/C1S;&J?'6`(@C0Q$!6TD
M_2"?!?$>"4@@`P1"US#P5[973'4W$K#`APVD`0=XIS=L%"'CEOH`C2A*S-ZA
MC`2>,H!XC,<O'W``Z<:.H`9HYP8,$(!MN\.!=R0@)`H\@,)N[*U\24\!JG&/
M@1SP/J@T8Q9--Q8P7@-.%V`E'LL(N^=$H(X!=&/L@24A.\D)'FT^4#0'5/R=
MEP,/!#FK``B`0%MC4KP+B&<":`,/A6@QUW^4K`*XW&$#Z&P!U[3\SC>_@Z6E
MG.7A8_GWHEB'?ER0C07(^A43H%2*R=GC'D.`(@J80$+2#+L'],(%'MS.Z#)+
M`%(PL@'0E*K^(&!B``?D23^P6T8$(J"`V"IN/N77@"D2T&S4GP`A"5K`EJ09
MPIR?`=B']T6`?L0?D`!:5"1`3TC5GV#>BA&/]S7`!NA?MS$.LS`0_,F??PQ&
M@FP@UY`$!B"(>!#/!M1.UU#&9F2@"UP?140?0B3*5'S&R3B`A;0+92R`-73?
M;CC`!:H9@YU"Z8A#M$B`+*":\2WA[Z58UCC+`/B8HC@@I6S$:]6=_)$$-L@:
MZ#Q?M71`Q'S?9S"`L0U`!#!`"T@*?CR#(*B"5$D&0F",_%6(_&F(])QA&O[$
M%#(4'J($N='/5(C&&BJ)PDA+!Q(#2D2%4U"*..!0_.U8&(Z+*2S^``&P@C@8
MH@?`S@(0"F^H0P=(RRHT2$)\(0R63?R]`NA,6Q="7QLVP-1,C4=<@%/T6&><
M(@]"HO<M'+5$A`$0X3\X1B4RH3`.(Q!$6[/HWRE$H:4DP$6X@`G=`OX,P#)0
M`P&L#@>`![?=V!E"4]1TS5)\Q.A(PT%$Q03@G0<@#R[A%0'<2%B0BS<ZBYT$
MW0*\8V#ID$40`'QD!U/@QP',5?R51P0\79N1#(;LR3I,A`)80)V4@@LDBP&T
MAUU<`EL80`<P``+TS2H8T@'T$E\P2X.L&H*PQ<ETE1OQSRS4Q5V`CD&VHM%-
MS?\L0)[0(NQ<R"N@6$,^3P4@831F`QG^2@,T$B-0!B6=9()294VGT<"A`9P>
MP!RI/<((W)926D(->,#,89JF^,''N40CE-H)E-H,9,"M3.7%@>4@$(JF4>5U
M[4%5)EQ7M@`''%JUC4#<R!+"G9P'I!D.>&6G.26=$(I7,IR\N8L,#(^IE`!>
M.H*\88*IO*6MV,IL(6'3"*9BI@`B&&9[**%09J:$'>:*6-OPF8'P?:84=!F*
M6%FD;=KED*82;`F5'<0R7)EH[D`Q_`OC#9F4I:9FYJ8PAHII6IM%49AI/MFO
MY`IIC@]F=F9OK@IO)EELJN:2+:=G,AET9AQUGJ9N7F>J:4%R(=EW;16:'.<^
MV,!V9MQRME?^_S7+;V:)QQF2!+@(;97F$(RG5)3(#KQG:R;G=[[6*6$G?U*6
MS+TEH8"2!S@;!HC`;4T`CH!2I7"`?';:#`@"!KBE"33+=T6/@7;G;+DE4,A2
MA"H5E!3H:VD`6'[.@&I(!FB*S"6(?VS`AXH`!)#ED]"7(WW<K4B.D%3+#)3"
MAE[CR)&`):EH66H(J8F`=K4`8:)`P$A.B3I+31#HA0+H4EQHD]HAP"0(6'::
M",06I!TIS#W7#&1*B";(\QU$W/2GF0K2"62'6_1B5821!I4C@HB%+B##`+!+
M!1Q($LY`2/I&4V##C[F`@?0.DI!.6SB;>PR`2A1`W_!%-#4;_,#^J0=00WB(
ME=WL#P%\SC,@@%?`CZ78T3\X4+F02Y@5P.C4D@%@T/F,3DK@J-U4GY&(D`68
MH/S!3P+8PDUZ1\5$!@$4!D\HAXC.50+`E%D\RNBDTZ=&JC+`I$.(1:1B2#HI
M``*0WCV%A?GET5,90+NQBP=Y`.D%J@8,ZE*1H2]8#3R4Z9F>J]$TC'Y("*Q]
MV$UXCIRP0P1(BG>\Q0+L6(5UAIQ@@]%QUYVU#T@TP#I21/MHF[0$5K4$5C'X
M!0EI1SK\(RNL0SSHY#-TP#_8$L4:`-L]GUKLWEID'_:!CH$-QCJV"^-(K)'X
MR$J`A/P5"PF%(00@;,R:POS]0V`$I/?^\<M*M:LPX%V>S-@%@B';Q>L_LL/\
M)<+EG`(7BD-`;@!7",F>(,<,D"PT9D/"E"!IH*O6SHL3/I@M\."J(4!KE"#+
M.N`">`UWB2VUP<.`@N&.7`"2*)\$B&C)F%!"T,]K90A\Y-XN.ICBN,W8RBIM
MLF'FM(L+-&);;8?B'4#@3@A%$DCVW<)-C%;=3@#LG*PZ*(G\/1C8GF-;,<YG
MM%O\?0!#((!\'("&K$PD9(!6I9@)@>U$C"U(KH30/H#_*6!-)8MV,HL)5>'4
M/(Z=[,9.G2W=RJ*N,9^[\H4C;2WSI@D:/J\'!`[\7$4&,.Y=GB-GT(+]D$2C
MY,(EM!HY#8#^3\(#XQ#/1A"4IE)*[KG`5ES#Z"Q7D?2'CA8$A=B5GCBC<;6%
M#:`AN9@NZ!#`?5@O9?P=!$F#*\8J-\P`^N[>!)B=8:5"0C**+32`(+"3?[P#
MMG(&[L0"!MBN-"1M913/+%A`!*#8Y02*`%=D16:)`&/O8Y!"5*A$Z=F"T1T$
M`=72CLP;+V2'DD"KGA%/R(C&$S8O$0M+E>&G?BX%IH*G<2;!$8](FOV.=<*F
M:?)&:$Y$!#UG<FXQF6RG&SY:)0#.M54G>!:Q&:M)&>02<V)F&<.FANV$@4D!
MWO3F/1$:<()FL&Q`UC(9!XP+$K3Q&0<R/H1)<6Z9=$YQK&!8>A[^V1@/IV(B
M<I8]6?&!2L!-F9)5'"-'YY0I)<()7R%;9\)!LB"/,OD0':HYU>T0P0^U)M'U
MR]]1PL+M@"Y,E@Y\ZQVG"+/9;FN^AR['ROI>0KJ(\@N^F.<4P`$D$@[$,J?E
MK3B2LC,;3;O]2P"E6#$\I`M$<PI":S8WS/W<R`:X4;$PCN!I`#DP*+1JB.>8
M<UQM`'806@.L0_R!X34(1(_A(^#T@OJR4PH:"0%HTSP:W8>U"(\IE2Q4`(%4
M9$8$S)5$0M1LAJ8ZQ.EA@.62AH%<AO&<``O5#L($UFOZ:=EHZOA%%9*<80)(
M`S0]P"S99B(J,.IZ%[1J#DB4-%24]#7^RX*/L9.\C)%$V]%*W,\S_W291`O<
MK<LQ;0:U4`4L]40%R$0"+/4<QM\%/$``5(#K(1'4X9UE&/6'E0W7X)_`H$U#
M8K4['-0Q*,#3?=A2J4-5*+5,D"'"W,D#$``.JEFWJ4>D=@`/NJ*K*8PM`4Y-
M==4MC&DSK2-M*,7_:(-&^`>OHDUK)(`8\ZLQ10;]"!X5VN[OB(/8K@LN?(H;
M>DW:L*]W\%S:8$">;`2SK+3^'0!IMT#95*\VB%GP`;5L=XAFK`V9_2-(,`[@
MI%EY\`]`^DCT=L;:Y-+)>FZ/!23"9@:U7(8I@)/9&<MQR]_.C)L(J&%4F`)N
MQQ^!%*(Q]=C^AP769N^&,:F&UWR&\I6T:R2%*_X$&K9??2S':_G$A^%9OQK=
M2Z&&\N4"=TF&T:F/Y?KK+(#A=(,;#KBAM#S##7B%D(SI9K#B2E\?(Z:?*RH*
MA-_Q;%\X=(AM6\$?_T##[6@XDK!L!UY)7[S..M:',](7"4%=4SP`R82'3HZ,
M&T4,:2-40)8P!;M:0L)/5.!5OLCJ6R!`6TUS:W`-[O1BP`@`HK3&/-[9/P0S
M2K`W+`*0=Q3V--5",5R"6>=>;F@$E,]??]`9:GCYU,#9,XR#V%ZC.@V9&Y+V
M^KE/O<YFGB@B1]!,/[=9T^A9*=!/<V"XGU-'>L26AA32G;!"H,/^5H*LYX(L
M30:0@"G)$J&0);/A3NXIURZT'$I0Y02XR*2_96CXA[%%C\S-@+$I5<S51'J8
MP">]Y:C;FJ=(7DU\DJ8\2KBE0*G982,!*,)10`WHRWV4VB;1NG=1Y1X,CS-<
M5D68@(GNA3,$R7H&3-SP%@Y4@(ZDQS]H0):*YWBI0H?*)0I0@%K^N;AG)SFE
M\C)/`2,="VC^,1>4\0;0@KGK`)U9^+C7>W0\,1EO,A77"JP4GR1_IG/2^YBD
M&Q5SF29K<6R&YAA/)QC3N[T_O%$T1*Y(_'J("C*[!(:9VL'[@*4-/'"]%J2-
M2`G$]@Q<?,A360U<_`](/)JX`AFX_`_^>.5I0AK)8QH:P/S*`S+$[_P3R$#T
MI0KHZ$4EMP#K-AF>";U[2)PB#UR_^+P+*8*Z&;T^:9)[<&&G\$I*M!NJW$#1
MUYM;1@RMQ#?&-)D?-%PF-`QQ.AP.G#9O:AD(?]K6%QW9V\!*3(3%Q7<BW`3!
MZ4%=!CW/_[T;:`2=LY]?O-U328L=_1Q!^AT$6(H4[P8TQ%8YD"'O;4"ZB#"T
M4N3B]5HYI!C[[4+M;"*&2(E8N,)`^D)%-A\SJL)=,EM$"*SB1"O^M-U!5,L!
MG,RGAD3U4HV(4K`QAP2=<2OEB48!DG9DH00JE"#;*H[?44H[H)[9;4"D,,4Z
M*!6EH$U20P#^&Q&^5%!*-F#(=M@%AH`$>`#%"9D>11J+3]L]-=@.`'``#C$8
MU0@YKU,#!PS`->@\X.__$&BL+9`A"!3/824>MV3,E)D(A7S*Y#03UWV<X2%9
MHTA`'!(&9#*))!H'F(8"D4`^GL_'L'E$&!3"P\"!,`B8@J2S4"@:UA27TGA(
M&I'&)J%=%#$?"T-S($,APM/7P(71('%PH9'00?"Q@)%HT]&"4G=7Y)%@84#!
M847Q,#"1L$&'2J?`H=`%4?B!T'&PX3`UBW+:,]&@,0!14'6Q\)%P81#1P16X
M@M!S\7'74?#!9?!0D*'S:+VRT#&@G2Q)41E49V'%WN[^#A\O/T_^7V]_CY^O
MO\_?[_\/,*#`@00+[C/0H(&?+A$<4#`FZ0>&#`J.36`@8\*#!A4\5.$0*,$/
M/'`F+."0X-$!!@TNM))!0!2[`QT@;&&HT$"R#1M>-!`2H8T*#!?B%(D`H8/(
M%PX85+'0((.Q!%V*Y(#:8*(Q"@<HUI*$H4+""A\<94JJ($*$'AXP&.#SX4`1
M":UL*J@IX1,$8%NJS.H`#4*N"0<B8*B8P!<PJWV,8>E9LN**!,>D47,V2(R&
M:2JOF10'H25E!902DF0@S:#JU:Q;NWX-.[;LV;3C+6*@=,."!!*.";CXP,&Z
M!,$P&)OQBT"!#58:&!B@(8.!!:DF5*S^\>&V4E$P/E"@8`6!`3`*=".8L*'`
M@@(8#AC8.YT;V`P$"&BP<=(`@0D?!FQ@X(`5;EE@#`*Z\6:%!0XX4-HB.A5P
M`66Q($3?6Q"V\EP%$DC@@0*?%`">)`KLI\!X'4PPP`&B&+!9$+U948`%%`R`
MA14>L'C,./1UB.`T!23`GGL1/&`=6!$@0,8'D$0(%@0'//#1(S%PL=P#"$#0
M4T0J:&!`*RQ145N88HY)9IEFGHFF/AJ(DH,'&53AP08>=-"!1U1L-J>2>7(@
M$Q4;U#D-<W6VR<Z:2E)!QP<7I(8`!E6T^:8.?^JPV325ZJD#FWEVP)R>@%+!
M@9V0^N61J![^&"IGFQH`RJ<.FS(G:J#LG%KG"3)-"B85D5J!PS0YS&HCGK#N
M*FD.'&PV*!4=1$"!`?*%^F@5&?QZ:`YU0KMJM8_*2F>:WGX+;KCBCDNN7_Z8
MNX]?%BB`[@=)Y0JL.^W&"\^\]-[+S[SVRAL/NOO*8^^_\#B`0&\"!W0PN0HO
MS'###BM,*CWZ\MLOOA%37'$[_FJ<<;P)U\NQC2*/_$_`'9.<L<D=7SRKN2RC
M_/'#,L],<\TV$^27!IW"@\&O,>?C*,<:7*HHRQAL`)>\2<_JZ-(V.ATRPDFW
MZ_(['J1V\LKIXIM/6_`*V*?7-X]-=MEFWXP!LM'Q^L`4<+))Q0+^%&A0Q=!*
M<A"TDAL(RUP&HAS+`4]*&EK`9D>#JD4[$.#@]^`>]F9W6\<.T]:O7-X1><\:
M#*.#L2=PTVV?2!N[:IRA7M!FSU9L[M&N)VQF=UEX.NK!`]#VO?,TW,39Z=7#
M&BL?!J)<+0K2?G$JZ)]>WSX\K,=VD*WDFU,1]`8<1+#9!7S&D(%\9W\/?OCB
MS_;0`!8@@$",$Q1`P(M]X#9,$$*VIR(#!CQI!0,%0*A!`&H1``;Q*&`!!HC+
M_2P0@`L0AC(1T(_!VC`C!=`$`>XA!0:4HP$))$`9`N``$S#2AP#09T0;T&`!
M(A``YL#!'`@8``4DL)9`Z,!^)RF``1+^$P!2K.0:.PRA!PD`#24-@`L4W,`%
ME'.+E:!A`4-C@`1NZ)<-Z&<"%,BA%2)`P@80@`$[((`%%M@)!)`&B`_(W_X2
M83X%#,`A;8O``CR@$2$B@`%B_``6E1$`#Z[$`P(X!`;H0H!B#`(!9/G9^`Z)
MR$0BD@8%L,ZRL.@!I,PJ+0MXP`,88($?."`!5\*D5-IP@42T("Z1Q*(C[L`!
M:*@E'"LQ@'4\()AVS*`B,Y@*#11"A3H0X"&0>``!N(&2#A1P`1>8PRXKTH8*
M,$`M'6)F#,H"A+2L)2UE'(<71?#+;H!$!NO8P352LI%N>@%$3MS0*>SW(ILT
M,T!6"`T!*D#^&7>Y[0#.>:$"IB6$7Y&F$IFLR`$\P`!C1*`(TDAE*K/D3EYZ
MP8LQ6(`%C/F0%DS`D(JLJ$4O2C-0+`"2:A'),JE0!2QFH"L,*,TF(Z!,2D!D
M!A1@`$6NH(%EG@0!P20I%D$2!PSXX*-^F0%&J*(2&A!A;Q`ZSUT&H`D=T+2A
MS;K`"RCS%`!\T:72Y-(5$P#//21`DDA]`'V2FDIA`J:@@=@-2A4Q-`(TQ"4]
MB`$]'Y":+5!$DDH*Y`L0,+0M\.2M%]A`!`K`@1:P(2.^R$H&:(&%-'BD`#)$
MB6,?85='JA6NE%F!3EY`G0N`"*.<[:QG95:%!R2@"0V`(P4RP-C^"[S0"A&Z
M4>VZ]P#`W.4!0QLL`PZ@HA\HB@#LPHUOE7(`RB`@D_14U`$UU!Q22,(#SE%`
M!9(RGO^,MCT;:%8N;G0!C#"(`0I`P`4.<"D#'8,,FT,`1'0ZP&\N8`*](<P4
MW&LCP**(G6B8AGGY9(`"=*!9RQ!H;[Y;6AN-Z`D/3(,M9L0&XG2ON,YAP`9P
MRY]KW*\##^!#`UQ(`23T!@)EG"$SF"&B1AVX,/5ET$](`%<#>/>S+&ZQB[TE
ML-A)C%\.Q0=-K38R&>.#:C-VQP.0.0\[*0@(&B/5S_2U+Q[C&&4V8IFY,(EC
M<[F%:/*BVL2B]N(L:WG+KJ&H/9Z2.WK^4"#)7ZN'EX/L@$H)[%$.B*T^$J:R
MK6%,'A8(,[\R/)`S<WG/?.ZSQ*H&:&#9J6H6LQ.\#,UDKA%:T'KVLZ,?#>E(
M>^LN*,O*/#00%'XUH*7O>%<[=L`&8H3:9HUF6,Q*+>E4J]K1&D!`@&A!&&G\
MM0($@``,,+"^ON[&JT'AI`?6A1%PQ);"5H`K`Y90;/_U9@O;"$J%%8`E5ULA
M`U.@@(QT8D<A:`#:$YCCJK\-[G"+>R#T9,0"*B""!+3'`B[);H49<8`*8"$Q
M;=[T!FB00ALP0`X48.<KL*`B[Q"3EELPSC$&40LFK*,'NQ`!+=SX3OVN9,SC
MKKC%+X[QE<C^C0M>X`((4Y`5@_LT(^&DPGFZX@"3=,@';;B(+A05E>/0X).O
MP(C&0U2!`S@@`^.81!.H@I$.8`?C1"^ZT1W]$SO<<R7+&,]1%'*C`PQ<!G.P
M0`&\FPT!5*<B$K"&%48><#]P8(N[[$H!]/>0;]J!'0;@T$HF4`8'@,@8`26`
M!\YP]+SK?>\8/<<'^,"!&TQCHM&9%`?&#+VR'*L/Z\C`:4W'C3A.>_&1NH2B
M++`J"UP-\XOWSM12,`V\7Z`":]K,O;.':KZK?O6L/YO`+$``:A5$`2!LO>UO
MC_NR*?EE'X-3HBU&KXV!+-&IS[WQCX_\Y"M_^<QOOO.?#_WH2W_^^M2OOO6O
MC_WL:W_[W.^^][\/_O"+?_SD+[_YH>]D,*7_98IN/TB[%OPYNS]7BSZ__>\?
M+E0WNOCX[[__#]D!'4$%X'%O5T$!%7`.,O(=</(=Z.$=5X$LWT&`Z]`!FO=W
M%)<!?&!$?2"!]A)8[8!K58`!%#>"[=`!$D`6)R@H#L@.#R4*%K`.C)<@9/%_
M-6B#J\$!`B`-L5!%`B``+0```1``##```@!`T@(`!#```P`2BZ.#?Y>$`4`D
M`P"%']```6"$UP``'"`!D1```W"$328@0P0FFC5'PM1V-Z(,8,)=RS%:4W(`
M,?`4N,4L-I2!^94!3U08-\B'?0@0WJ;^<XUT#3%P`0'@$0$``3*"A!G&A&,G
M`M,F50O0!`GT`#_X@U<P)`"0<E[X`(KX#F-@#%70+`$U`:[4=@<P`9&@)`+0
M!!X0`!8@`!9@/@(`%PS01S)P"`S`$@%E1-E09GX(C,$(#T<T(QL0`'P0`9&`
M`8;HBF!8"!@```4@`!#!``'P*]#H@T\```+PA868`PG`$K0G'LT8AASP45]7
M$9I1(G_4=J:X/AJP7@,@`3](1PDTBQ?0-@F0!B7U')>DBY21`;\AC`-)D/*2
M7\+5*`00(-!XB)TH@-#X'0"`C*KX=X9X152XC)"`2<>X`"X%`/^$B!8@@)N#
M$540!)(P1P7^8P`64!@>4ACJ%@PK28L*`AT@L@T)0'N'<!+"@!2Z:!-;4!'\
M5Y!#J7VA!0`$F`!#F`.HY1$&P(VQ]P$\-P`!,%B$P0Y,:05621]1:0"(>`T8
ML1L>((U&Z'LBHXN3%$B2D"3KL3O>00!LT$!EE(IE]!&X=2QQ2">X=2J,96=$
MZ9=_F2^O\2^$5G]!%G^`B9C!*)2S<63J5S&+R6>%Z3&)29EA,IB\)W\<4Y;T
M=Y@D4W_I]WM8UID7XR]7!IJ_""?L)X:$B9HB0YI<<R_"%YKU8F25:9NM<1(P
M!Q`;\HOMP)M^@0+W$)SL,)SO\)MFEAT/!":\R0_6QD4"@8_7,P_^$N`]GP81
M\8`"M<,:=R$!_08F%!!/X'F5/V(]Z-.7MXF>_G!CV=4"[/)=#U0!:^!!M$=%
M[L(-Z&.%*B*2S-4'(+)`+V(!`-`!FC51`541WQ5A`8HWH/`5FS2@"T!3_VF%
M8%`,"/(3G8*?3("AI)$8$<)%0/!&3B(!+D%$`PH!`@`>U.8=,L(>F.8NQE%&
M&1`4UM8%U$8&W0FACC)`+Q(!%^``:J`HX#@!`1!3EL03O;9>(E1&SL$!Q7`>
MKL!R'Q`@%5`!6#184OH!".A&GO"*$N!R9=%=8!H#N.8'9#$)Q=";Z:FF-L8<
M4$$P$[`Y7]`I<_"*VZ`'=Q%$=$`!K[#^46MA`J!@`4HP4GLS4L+T759'$?(V
M`LS!)=4P`AA@62QQ"GMZ"H=A'7NJ09:*$!!!!_')%<T1`81Q=PT0B]OP"B)P
M`5@D!C:@$0F`)S2U7M[5!%,Q"+`"#>L%;Q(P"0GA$'%@2<B$#2WP`R_`DAP`
M'9.0"!M1`>>S`;6$J>HV`XTD'ZJD!)@:'I$D`2^0C_#XI64!55E")T/P"@32
M0VMJKOL@7@1B1USD!2)A<I-:$2FP"+E@:TG03'X*&.W4:U9R&-NT`I+1+#\!
M3";PEA[B1`709LPD31[0IPS+3'H@`B!T!/;Z3$=``4&!BE0A&:CS.$C@L4F0
MFUFJ<V@Z<C7^!R:7Y``DJQ&:5!J&18U%@AKK2@T-E8$UL`ZHU+!].@M9B@K7
MNDJ1E`O4^D:KM`LEJ52\\DQ_=S7&D(=&>ZY/:P\_,0(:L@!DL`"59"T%``&[
M1!G$]`%/:$<*L#GOP14E<@P(X4Q6(`ZN@%N')0G%@+5UY0H+L!?W9`"8E(I7
M`D.=@%KOL;<B@1`1!@%,Q%B#)083,`6UYD)=VU(X.5#L94Y'4DA7P"'WDP)G
M1TY@T@&T&'7$1`()00FH@5L@-!DRD(=5^PE.984EHA!7IUF'T;=1``$=$I]M
M9P7@:`J<Q![A,0:O-%##M0)&FTI(6Q9?A),54!2,`+7+:P]_A"S^$R`-=X<G
M47E:'S@M'<`N5K`!C1<B%'`!NW,#@:.T5&`!=7(#7C,MTFLCY:N^?)`!_%$'
MEL$<[DN`\QN5$Z6]W!M%?=4WU<L-=/.^'<`GUL,G?)(V[`!Z]_84I-=YVJN]
M$_5KQT(WT/,$9ZEX_TLG<-<''PA'!PR#&\P-CB<K;V)M470.KG!:8')XPO,F
M!CPT>S,K\N$F.L`'RVH%-LR\.:P:-^(^95(%QPDN'<F9ADD/BX!79!(.K`&9
M.ER9@UEE*2.:]R!\B):9K3E\2S:9,!/%59RFFXF:5_9^%".;([-[+=-C2L;$
M:<PKW4,M<@(JZ+(!W5.=GP9G&1`=.J/^FL2I`_3P*?4R/.X`PVFZQY\"9[(7
MPY=@+MU"G&`,?QXAP&8F>XIL-;\2*FILR:N!6PA@`E0``&44H&TI#OL8+<HB
M"0M7FX9V!S32-H3B,N9"4STKAB(32X"2FHUAQL`0((!F+BH"RV5&Q>IZ,:,5
M76`RRU5P8U2\:(,6RW8B!ZH5QE1L7Z0<2XA6!;'T<H1BQOP29Y>LQC>V8F-7
M$968-"`1.#E@)=1!0<D86W$(2^]!0<A4!5ZK$'$8"_SQ"4XQ#5*ENW=XG1_"
M`IQ4!W8$'D>TA@T0(Q$@D0[P&QO@!<F`SQN@S^G#S^I"`,04(+HX`!1]3P&0
ME"#T"?N!`:/^-:06X!;]3``F((F;T2S0EDTE\B8$U&JOT%(2[19-8"/B`0VW
M!0&<)`,'L#1;$%@JXB3[M@XEQ4EL4A$68&M]A+U66`+9R\UJ?#^:'"4.)EK1
M*T2CQ2%B0`8GA`:)D`XK,%(O%\_K,$L1HJX(8=-Q40N8ID%,$")8L$SX:`HN
MU;-.U0/H-K4N!0TO$`AJ'2*T`%X#M01K[=.'9TL.%@$@D0IN=`>=8@N*0-?6
M@5.&W=C(T$Z*0`3=B1"6=0BAF@2NVE'W0:]V8""B)02<_1/O)P$#L!L$X%=H
M%Q4L@9,=IA`V``U`Y1D!%]7=C'E1M%Z\`64?D;2HE0R!0T@E]1/^#N%2G\3;
MI9P1.^=2CL$2-$@+U`J.N$1*>:"KZ+%%K%41+Z!6FQ85B.%R"*'=2X6MV1V#
MZ5H@OE`,+0!+;N185O!/W"U3M5#=]@U+@RL3$^NE5*2U4:"U2($$@UM*=V'-
M-J$4,+"GH3H(`4W,N>!<.@$&MW4?>)!I()$`V[1>M%0DO=W-?YP73$2+)<4"
M66U>)1TD;;=O7$(=)65PQ_RVT:T"+W4D#2`3!1"?V,H5.GY%S^$+(Q(4YS&&
M.Q0$WHL1+017QK`(0/X!/,XN`\45SYD=`R`2/Q(C=F<%70@&'=[A7<X^%S$B
MW8:`]"037HX2G3*Q2!!#'E(+I$$7,#3^Y2-Z`&:@O>/A"3?$&X+M4-II1VZC
M``Y-A=W!DB4%)DUQ#2?M`<%U3"*NQGV,`SD@)QY1R99B-WM#Z:!3/,CBR'O,
M#H"2+,E2%CLSZ>^7`;EC/:T3*JAD(X'S*&^2)Z="RE%IZMV2)SK3#MG"$W4"
M*W5C+9BBO=#B-R>0`[I>*-9R/*6R)Y'"P:&"ZZ:5&"H\*7@<)SH@'YWR*9W>
M)E%T*=@;O70S.*0.Z;WMQ?"'[JK!4UDCF3V&G%SLRSAC1SKW9;-Y#UL`[^6N
M[UJ<[U&VQ?$^?&36[X<VFWD,FX)<\%;\-6OV[PBS[_I.S5#,,Q\!-98',`)"
MF%-3[_B0ZE3^!@\6/RV&PL<4L#,Z,\=?<RPS#`]X@V/3,@_3TC@(GV</+^*<
MPB:ILAG-8RT^(Q_1,2?*TQ.BD(>6HBXGP28],R>&PBDW5BO2@@J_0RG:_A%)
MCRE]TGEVG!%&NS8"7'F<-@M%0?)U@RR!Y1<+,`!^LQG_2BE[_"@Y\!#&T2J(
M/&V]$<=5@#0'-PV5/#S<X`DI7GFZCC=+3/-1[1Z`A5O?Y4)$H@C&L&E40!S8
M4[424`KK<@!0B8]RYXM_A^4&0&$4=`%83A.C!94I(!B.<$.P_06E-0`#YAUL
M(#>5_T(QE.=>M"[F$[P",@82X`#C$0'T<794(`"2;T.&@5O,,![^;E/15O=+
M^"%%[7,7R!!'<H<!FX^]:Z@HP<'[8W<E)R1WBFX@Q,&3%>8`)SUV0#)2YC7X
MZ<\/_Z06K9"V:\@`\?F"H>BC.J<0+Q5V-OM)03H+&B`&H``"RJ=,RW=P7\4X
M#B,A'T,9#V$=WW)]WF(Q(A"/(A(Y?3X02(_B*$@8$T;RTC@\&I9,HX&YF'09
MQ@73<"02V6UX,2XW'E$A,=((*C0?2T,34U`4/!1T['5M,7@D,+DQL(V4)+DU
M3"3H4,0X=FTD=7I^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XI(:<$4H>$CT
MH2`X?&P(4'U<('!PL-@U7&0@=!2D5'3^86"$69@DT&`<4%!Y)WA4]R!(3.3%
M+`1&/%Q8_B19`%A,]"48:1@D13!@%FX!P"F2'D#`9J8!!0HB1F!@D.W,(B#9
MPB@8T_`,,#M^-ARPX*(>@PS=*!``YL&0%VT?I$&0V'*!!P,4$C!;@,$!I@[D
M=%1H9FEEKJ)&CR)-JG0ITZ9.GQI%<*#<@@Z*"&2(YX"'NTX-!%"H<`"!$!X,
MQA:ZL"0#ER1FQ*1)P&=$ARO3)(5-)*)!!AH1..S%T.,$IP0$,&@H@.`AD0$8
M($BE\,!)D@E2A;!MT,$`EB1!(+!UT&%Q!P>9D_#=;*`#!`H-KEH@[(#)2P16
MZ#X(5V5M!@?^-<,AA(#!PU@$'AP(J!`<`X4!FDU`6V#`=P.HUJ]CSZY]._?N
MVQ%P^K1R_`<*!X@F(>H!??I5[#N]'[4^%(2'@^][4B]JOOA2_/?'%Q]\H/Q'
M8(#HZ=<>@0IZUZ"##T(8H803TD)!(?(I$1N%\#F@AX`;6O<AB".26**))Z*8
MHHHKLMBBBR_"&&.$(D)(HXPWXIBCCCORV*.//P(9I)!#$EFDD4<BF:222S+9
MI)-/0AFEE%-26:655V*9I99;<MDED#8.Z*688Y)99HI@^F>FFFNRV68L'H0'
MYWH;K,3!!G=V8.>=Z=U)9S%U%B+G!QV$M^<'''B`J)N+,MJHE2O^&:,'2A@0
M`,!J!P`0```*5!J``(5DD"D`YPU`P0>EO@3``Q\@`,!Z`03PJ@4"".:HK;?B
MBJ0@K#*`0'4(F$`!`!IP$$`$7ZR$P3WV:$!I`F&$BH(``7PP@0$%3/`!`!<(
MP`.:N8(;KK@FHI3!`!G0^D$$!'R`0:P>P"K``"N%.@``R"@`0'@8'*/``@(H
M@D`:'P0P:ZWC(IRPPB-Z0(!4'Q1`S&+MN@KOL1<DNRP`&:C+;K("1&``!`-H
M,(``\FX0`+<67KBPRR_#C!T#`&1[@;T&<.+NJ_&"*NIY'7?"+P:V"2`!NQ^D
M-(`%]MZ+7\Q/0QUU+82JYV</X>D99Y_^%R8*'YWK,7-AGHCJV;+49Z.=]BGJ
M?4M+VR:^'0IY&,(2=YIJXXTV>PG>O6!^`]JMU-N#/Q6XX'DC7N8%^X;GB:&A
M<,`QFN]EP-YPG70@^7ZL\*W*2AWH44KF_0W*L2D8<!!ZY$Y73BSIIF1@-H)T
M'UKKZ'WW8/KKNR?>.Y,%^*,!S2_1:=4#1X2>WG`:''&G!WE6WLD&DJ?^^0;+
M)$'H-!T(=E/I1"F:@IV#KF?5!H&"7F<*&E@E?OA$[>E!!N(73X$)*VF@1YX:
M?&Y_]E]WSQ*%L`JA")4\"4C@(1DX0O628!N&*$H#C<M3>-)7NP]XXP/Y@Q0'
M"B'!P3S/3]S^\P#S!N4_2.FO>BEXGOR>%X/4]6!\A]*=53ZWGNCY+H=%2H`!
M.&`T"EQ``0-01@+P0)LD).``"K#``S)``$$,0F1N64!*GB!%J1`@4$DD``<>
M(#`'$,`'!SC"!W@R@D!@12)F>,`0VS6`Z60@`!`PV@$RL$0&3(95*[%``0JP
M`0DDH`!.=,2UD!&1*@(O`AGH(S(8<`/I3"`"!>`&!BD@``B,I0`5Z`$#'+D2
MM5B1"1X8`#P2F8$#'"`\#.@C#PSC@`TX#`(%@,`&J*A(X/%E+*'#P``.0`4'
M(``!3%QD`9!Q`536Q0#3H8ED(&``S>#$`*5J#A0X(!4-&4<!%YC^P`,88(`C
M&$Z'XD21`J!1@@GP@0"5X("P-MF>!RA@`U:`Q@48H`635.$*+M@"7T2`@CV8
M()4QL4D?!C`(2,T@"Q>P@@,F8L8]B,`;_O3`'$M&J`6L0!*;](`="&`>'7PA
M#!=P`!;NV86%8L0"&B!`;ER#SP2LXP.KD0!M2(`,D32@`G:4Q!@LL!`%%#$)
MVHS(3A%@1T9@H#<U@`8?&I"&SUA`!`C0P$"=0,\V`#4F/L6C%2H@"$T&(0)U
M&((")&"`LR0!`BZ(R02^&LYQPI5$@/`5!"(`4SS\X@YF8QYP9N":F1PD(2UA
M@!_,D0)E$(<&Q\Q'R5225GWY%1OYR&G^%::!`/_AK`$2X",/(!``TRU@`JDK
M@#*\!PB'2&(V"NE"0]J`F`'0]!HF22P5SB,$H4:")1<1*A<FXM0(9.N,XBBL
M`?)'%IFHEB'Y0$,$)!`6"Q@G'`8`QP0<P!#4RF`1*\@&`S;S&E(Z``@>V0=A
M88HMVF@@)-;EI6/CZEX<5>6R%(AD$L7A@0G,-P(5D(!GSCI211Q@-J>I5C#A
M<9JS'.!"WDR`'Q1@&W]<P51URL$&KL5.SL"#!^TB@`$F,(8]$"`/)3$!!WY6
MC&MM@`%)!,*)`UR9RS2Q-YOIS`>@4>,#5*`?(!%8!8CABPGP5P8X^"1OJB,#
MS,@86*KDC![^&#"`":C&"1`0"P(>$+#N+F9?');`:(`JF1FO2H.D,8T&JN,(
M=7V3`S1)P+D"88#8`-5;A$'(C4WUWCO?:&_ON6'R^".!7JQJSP+:<WH2U#(/
ML,!I>TO&_?X&0D0'NM`]"%!^#B2W]A1H<Z00]&#.'";^C&<E?U9`H,D#AD=7
M.M7R6?024+UJ/,,Z2?1BP!`T/8MF!*H4&]CHYG"]-MYQ!ST5:-PI3'+$^VS`
MSF&B';#=HN%80]M';',:M<$T-P81&C\(HM%_/C0[W&5:VY^6-'DZM^QK3YIO
MY>[/M><VZ+8M>MQ^HS8('1WM>Z>H*K6@5Y#?`HH%I.#7"*2W)WS^".0D#/P3
M#.`$$R==XX-UX@E3":<$=)>FAK<')0(C]B@`GH0'7$C?&`H$3<I8G94@@`H=
M0%4J!DYH",0F'36V.+YKKJ+%*"!U"Y@!?RE@`;%H6`,J1ET10`*!$HHD6PL(
MJ@0.P(->K`;ATU5SF!^P@`U`(`$^T:8%.!I$>"R@Y*Q)0`Q8%8,KA*?5]/#7
M*!E1<AW$)@@)W$!N.(%V:ZZJ$J]I@&TD<`&KFT`>A&W/!;X)=TRF?56NB2IS
M2/L!0#*A%P>("`2LG,#5;*"(%QA-F#NA5AXH@PHKN=8>:,;Y#U@=ZSCC@!HT
MJ(`#3$`1>4^`D?F07H`;!YX4@(#Q;.[^^Q$1U.\/`)D".N".&ABG79,,2340
ML(X(5(76#WA`"P)BT`1DX,U9?,F;F1\>FUB+!0B9`%EAL`''R*48I#9R`_3K
MC;)KP!>9F+X#?O"`!!3!,XL09#C6L0Z'4$`&%-'DI1P0D9(9!`(&``+S"<9X
M@)_Q)9!E()P`&$9$>$%(X`ST#1$&>M4&*(!86$`8.5\")%"OR)D.W)]@4)(D
M8%\$.)\"G,70S)<W8`#M31Y,D2`,(L#02,$G20%"F`36!1,$X!<QO-7O(2%2
MQ(`1.(#544`4--3UI44W&(1M(1`+C)07C,'Y.:$)8`\EW=5@&$=;-2%P19(/
M&`&KR``/J%G^&BK!!)`?$GA&'(Q`!BP$%Z1<F'72!`B&<1C!6"6!+P%"C:W*
MT&P`)8B`%(C`#G2"-55&<QU!#J@+$_!!0RD@!BE#)?B/34$"%5@61_7"`@QB
M)SP=)38:(+2?',`@(/C";9T``[`B1P&2*)H*'G7"`M01)E'`T,"`(F!?$@+C
M@]A6+S2``?!7``Q'`30`;?"2`FB3"?2*(,&+'<X`9R3"647`9BS``!0"!QC`
M8IP:RG'/,UE`%)@'4/UA#M!#+=E56BU`8OC28&`"#Y@56$6`>6R%),C9-"Q2
M@/4C$R7`*]T!:>$B]<74#L#BN5Q`Z"11)R%&`<0CFDF2.&#,-RK^``;,$@'T
M@P(4@#BP2O9MHP?<7T?>7P-$CH;=00+P`"6M!/;-4G/=WRMIW2()4TER`#"I
M4TD>HB>A1@%X@"5MP`0<0`,4P.,5Y1<$8U)NAV!L`#-(``9P@I_\4<`%D05T
MP.WP81)PPNA8P$(6@P2L3P#"CP0\C^Y<#@:0Y0;$AL_E3\Z\Q`IE@%IJ96Q@
M0'!E3]?5PR9E@PHHV_P$3;($5UVNQ`3P`//H007$G@0)QOQ8``UD0%8.B@1L
MP%DJ&P<`66SXY1\50F,R90!N@!YT)L<P!PD^'@\T1'I`YNVTRQXP`R>@4[L`
MYF!ZRRZF`&%J4`1X2#'$1@>X4UAP3'7^E8>R*>5P0L7D),/)S1NV+1M3F)LL
M&`Z`B=Z@Y<)*G$7QJ=JO,44(!LH1$F=WOLER\HYQVMJF$=QWVEMR)F=S,LAY
M5AMZBMMZ'MJE,5M[OF=]*DB"A)MWZB=2I(X&X)!5K*=[8H[9`.B@G(]6HD>!
M#E`&N,ZAE$Z#[F>$2F@LC,72A0<C?INBC5M=M8?1K$19B<#0$,72%$(%"$`R
M!),(S`J*3LR$NNB+IL(.,H.Z'`!66$LJ!8(Z!.!KD`$!6,(%^.@>7`M_$<4$
M!`!_G0>MI=^@Y(;Q_%,984QN!%P\E">,6NF$KL0!?*-F^.1E)=AE"<(!`(,$
M+(`$>%&9`1+^FHH8.*55`ME/"@A`I#E0P&'/3LWI2UC"E>KIGK)*P)68#E3"
M)=1`2;"`9=0@1?4"HOI"JPU&JQE&(="#)V!/GZJ`Z%%J1G$GGVIJK*$2V37#
M`9P+9&`%,!'#'9S?XW&8#Z6J6<%6&?T#$U!``$!J;*#'I(*'D'7"K=)#!W3>
MIOHJ<48.6^#/5>+7=+4+^G2-!@5<@Q++>@3952:!HA1H(S:B#5$K^5S-KVJK
MBYX%D8XGO67JMHKKE8;KN)KKN:9"N:+KNK)KN[KKN\)KO,KKO-)KO=KKO>)K
MONKKOO)KO_KKOP)LP`KLP!)LP1KLP2)LPBKLPC)LPSKLPT)LQ$K^[,12;,5:
M[,5B;,9J[,9R;,=Z[,>";,B*[,B2;,F:[,FB;,JJ[,JR;,NZ[,O";,S*[,S2
M;,W:[,WB;,[J[,[R;,_Z[,\";=`*[=`2;=$:[=$B;=(J[=(R;=,Z[=-";=1*
M[=12;=5:[=5B;=9J[=9R;==Z[=>";=B*[=B2;=F:[=FB;=JJ[=JR;=NZ[=O"
M;=S*[=S2;=W:[=WB;=[J[=[R;=_Z[=\";N`*[N`2;N$:[N$B;N(J[N(R;N,Z
M[N-";N1*[N12;N5:[N5B;N9J[N9R;N=Z[N>";NB*[NB2;NF:[NFB;NJJ[NJR
M;NNZ[NO";NS*[NS2;NW:[NWB;N[J[N[^\F[O^N[O`F_P"N_P$F_Q&N_Q(F_R
M*N_R,F_S.N_S0F_T2N_T4F_U6N_U8F_V:N_V<F_W>N_W@F_XBN_XDF_YFN_Y
MHF_ZJN_ZLF_[NN_[PF_\RN_\TF_]VN_]XF_^ZN_^\F__^N__`G``"_``$W`!
M&_`!(W`"*_`",W`#._`#0W`$2_`$4W`%6_`%8W`&:W#)QALJ<.<'-YM\AC!X
M"NAU?NLKJ*L(;W`K6%N5$(Y[,"\'^%2.M0O$\8^!UK`'=.5"><`%=*6`[,D-
M'V@'6(!5/L^@)`\1TVKRU'"TJM2@]`#__+`G](7^^+!@,'$VD%!Z]!D/PXD&
MH<>N"0:A8,[^H=A)$0=<M%8`J'1E?A2Q!R5H!?D4MD8/_I3!G\A)(31EP5T(
M!EBEXQ0Q&U8`_H!/&O_DV$1KY*QQ\@;1`"!`!=C590V&`V3+-0`23`V"((1@
M)Q&:,R)-(0A`ME2"OR0;2,GC8F1CV2E!&E``$61=7=:8SXEB&$C"`H#'!!#`
M`O">*F?=/CS$'PT&!_21!V"`/V#/2L"37+A$#_!770&5-@V&-.R<#D#28`S-
M-!]SC?F##-1'!9@*-WF"D?J8AQ$6!G1`/-U'/"I@K[2,-]E3#6)SP+FB3^Q<
M^R4!!0`$.ROO-'C`"Y7#%*E+H++>)`)4>?9*%_3P-%,`)P#"3O#^6GGDQ&A$
M:PY076Q(4#D>`95:S7VA'C[0AB,>"D4K``1TT!-Z0JLM4A"E,7\I!SXQLQ)`
M'\?-@`R$1;O8QUZ6`TYD3P/DG`4PP9TTII%):@IT<P.HY>!U@M`%"W_YR4HP
MXB4(6<ZE%6W`P^.YPU4N0;;X2<45+\HQ0]GI=`_DW`/X@0-Q%!.X2S"U&S>W
M!FLH0P>@!$SYA(D-9@&D1#]K90SX@&UT6@'H`0?PM'`&$B%,@`#XDD0?BEXO
MG=6YXL<58A3H]$H\P6%<HK/"-$=JTF#00UVMDD18,R.Q2GA<@!"H@RAUS$,[
M$"=40-8]0(4U&L*)0VPP5WLX4H=I`4S^7]U4ZS9T=5),9QT9L<_Q;D\,=``R
M(+-F271Q$S1+BL*948`&I`%81(-ML$8+>,)SCT!412MQUP</W(DS@S$&A<XO
M'"=-16N>.B*O,D"9_N)@W%8T1,"G=$+LJ5E&]0`3<#;';79C'I,G(.4,>!R:
M%4!9,0$S`%?R#76U4$,?0)^=.34"$(!F%,),4Z>%P!WJ*:`\TT:K[1Y9=$%P
M4SCR8D]9W=9\"`\/D/BJM-H%8$L3)4/`.75L6$`:"B`%V,F;Q48!L*EKF%4Q
M5YXV_-FQ,-@NF$H1^0MT)X]F+0`EP)XBB<P#`'ES1=7*'=K#)!4'<&.CJI5*
M0@%9"Y,C!.3^/79"!1B5UF5+_06-%)`6[357(HR`7:578RJ!B25#T3Q>&97S
MR@6=Z`U@+?%:I)*Y`)Y`')2CF$;`,0F@3XRV%/30!ZH`Q[&LB&0;>7XKO'D.
MI:LP=N`E!^@7*.#E!D0`7K)%9!I8C3W;BQ_*!:R06.Z!!:0`,"<!5;DX^<5#
M!W1ZNQRZ!O6`:.$SQ$E&\RP!+>U>K8LY!ZPD>7!Z-N;)'J#'WY'T6;<VJ//`
M:A/A=8.EKO^"V,!#;%`[:%0!ZCC7GU1+;OJTJ?RU.:<`<\1ZZ#PW)&M(%:3Q
M$UJ#$"QTL'?`:'.,JAM[>4B`.UD`I"ML"L\(";N"P(_(YA6\F1C^_,M^$J+(
M@36RBI;ZD#)ERQY]8X<=R\-I*9V\'FVL1,ATI`S8A,B'0Q(]$P810&?5`.HQ
M:*01AY8VEQ2%S,C_`^A)A,"`#L=<H`'0,IJ]F3!/A4U?)&#@#!]=D?,)*5]K
MAXUD*+K96@?/&ZBQ9W/.1]5+FGW"![?IQ[=9VGEVVWLR?0A3&H#8F]0[VL++
MZT*7A'DG]F"`Y69P30=,G@[PP'FH5;68"DEW`EA:4Q!@T&-"5"6MA/?X#T+J
M!"V#=.%[,YP@>(D11U0==0:@^"[2M-O#R1*%07&#SA0,&R`P=&,F%N^!>I6N
M,"B`P:JXH'.9@Q%T`*\30X+;$XL3=/S^_84G@"4^GUFPT]2J//6IM1H0`$$W
M88Z.Y\,1``%-&83;0P%>GQ''?*`CO*.65Q=&JL,*4NIZMT9);!(0V(\[E?ZO
M":4E-)US40,=`)=D?H*N0ID_N*('D'EN`I=8G1EPU4<;:$@0*0$E;L70("<U
M$*$]@X`%3<SA?2AZ<!V",A7V*91S5.D'E1]62!3+XG-"<#X/QL.PX5`^P@^G
MP<A9K]BL=LOM>K_@L'A,+IO/Z+1ZS6Z[W_"XF.)Y-"00XL;E\4Q.5P@;'PL6
M'R9V2!&**7\H#WD*&T\).(4H%`H?%$,,&)2:)QPN'Q6=GQ\-BSE&'P@=%PX9
M0PD4&AD)@!_^$ZD3&$,?N%`1#!8="Q4=)!P2'@B<@Z]R6KI$*-56@"?5NMQ8
MW2G8U^/6V>#?.>=7VN3MWNGPV^O9].%;[^+8\O#VY?S^`/GMZQ<0G3]]`/O4
M2VA0'<%V$,4M+">18D!\\P1F?.BN"[N($1&"_$<.T(5!"Q080'``UP$#$BXH
M),?@R`,9#3"\Y##*`0-Y%0!U2-#@R9,,!W3(\)"`@*$%JC;U>)""0Y43"Q@L
MHN-,`Y$3-7<I>+"A@P('%C3@I'J"SE`*!Q`4N%`C008-"1Q@P#!(P00%!R1\
MB+!@P9.*TQ(K7LRXL>/'D"-+GDRYLN6"!KD@GFCY5H;/GF]A.$+^Y/-=T*:]
MHMAPVC1JU<%0@_9,VH-LSZ!3W,+=.L,@(AIX]ZZ=6O;=%*Q=ASZ.@O?R#,2?
MAP:4O'AJW<I1C[[6NS=LUL]/PP[OFOCMZZM==Q_?^GGT\\P_[%X??WYWZ-RE
M@Z:NWCGV]N5Q!U]\X!FWVW_DO0?@7?SAYE]S"]*&`@?9M8>=?:AU@$('UBVW
MC7#%F;=<:/\9]]EO'-YW&B`4DH=?:?;QIN$'X&%XXC4.&L>B>L6IY@&(N,VH
M6`<!`&#DD486644P2#8)0`"`&.`DD@9<4^241BZ9`99&"C"CE%Q62<253BJ)
MPI9<0HD"F&4"(*8'9$ZI)9=/1DFGF$3^8FDFDVG:&::5=,[9YYIW`LJEH%AZ
M2>B41;X9IY.(,NHGEHX&>B:=:G[`YI25'GKIH)H6.J:E'S!`IZ*A<LG++D]R
M*4.>GO*IYZ2<HC`!G0!D\`*I:*JZ**6&8JEKJ9AJV"N6O&RVA@<43.#LL\]*
M(,,''4@`[;5TH%#!M=!*@`,1S7+KK+0;6BON!-E"82ZWWEX3KKCD4GNNL^E:
ML.ZU[8([;[S*S%OOOH;H>RZ_]V(+R+8#?\OLOM-6ZR\@%@#L+L,;SNLLQ`5'
MJ_"[[#:\[[\#![SPP`UG_&RZ",.[,<74FOPLQB%/3#(*&+A\,0KV#JR:!C9+
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M8&`!!UYUL($&\8,[[387Q(!"_K"PP`8VP#R>?.\$&C!$^\HRC@3^2N$(&_C1
M"09XIM_([8(8S*`&-\C!#J:A,`?8P`0(L``(8"`!`W@&!P*@*U,TH`$7&`($
M\@"(`U3A`E6J1`(4`(Q'``8"&A@``QB@`080(#`4X`D-$*``!72``*4*F`X.
M0``&7"`!4"@&`!R@@P4@@"H;0H`1+1"!!"`@+0?P8AD'8!<-"`"+%$!``B+@
M`2@6PQIQ3(#0?I*`%DPH%QQ8@0<'24C;J0YXRAJ(XC!"DHUTA'":@1S<()F/
MUGFD)'R[9$>"AQG+/>0<M<OD1+CA-M]!CI.='(,?-N$`/+!B$!)0P"(6@,`+
M:.(!JY`/`S2A@;D81@;(L,8?S$*!)6'^Q1!)-$L%^G*!9]P18D,()!2&T(H&
M#.([3[!`$VFT@/PQ@`Y\((0A!#$###RC`0IT!4H@<`!;CL(:$=B!8.!6R'K:
MLPWTO*<^]WF/-'A`,!M8P`0$8$,4M,**"7CG"7!H@3E:PUO=W(`$"D.!"^A@
M$2=P0`$4D)8`Q$5#'-V$$BE``+\4C0$)L*@UHL"!`A1S""$,1DIT)0H'9.*$
M1*!!`1+P``\HE!`X("<#T,4`!*A4G:EHP%\6X$=`)*"'_(QJVC:0@"$^@P*"
M>8`A)JH`P<RB%EK@0$H6P`$/-$`!81D,43X@`<%<P(H..`$9M1`!!,355GG8
MA`(28(A?@!7^';9<`!>GX-`L.$"E6MU%7C?PDX>FQ*T+J,06*%#5(S!`5[+`
M`!A3L90&"&D<%P"C1#'`Q;;JH(D)T$`#=/4`BTI$FPJ0@38%BXFG>@`#56#L
M8%#+$Y3F,@L/>`(2GF"M#OAVLGL=%F,A6-6B!F&'1DV%`AJ@AE5F@`&N!,0K
M.&``%%8@%!R(`@0P2@@$#.`!:HF`4V3@@&3M(@,&N.T0`'$)6R@S`T8-[P4"
M,*W_#6$/'WBK*XY`O5Q,R&<=>&<'6HO;1;P3!=T<\`<.>X']TE3"N!3K`?R8
M@AFF4JH@CLP&%#``-E8`I1\8P"(D```"\&(`71V`YK:D``)@,0#^+$D*!0(0
M`0%0(`,#""1U!\"+`P@7'A,(``0"<)4!`$!#"V!R`"8!``4$X%M8P(``!$"5
M&EM``,.Z0@.JU($!>&4``3@"!@+POENYF*U5!@"6K9"!`#R``-0%0%(&0`$*
M#,`:#JC2!$@!#_6B(`(&F,"?]_J!`A2``0O0@$=3_-L<<```.TC*FKD<##L/
MP#``2`L`-/5H!5"HRG;6P@8`4``4%"``,R`KJO-*CP4(``$!\,H#`"`8#9"8
MC11H0``:D-(/X!C&:L!N`3(P@0-,(`)'0(`'(F`4!BAUHAC0A(=U281::(`#
M3E&""1JQB90F&@*ZN@1A+(!.#FS``/W^2_%1ITDC%UC@L@$0#`%B8F`:'68&
M$HA`!-32:)F08@-51$(Q&-"!)PQ@*0J_MS$L$-\"1""QVPZQQBUS@FW.P`@"
M$,P'"+"(,C<#=2G`P*@ED.9<K[G1>4"QL+&X"02P4PL6IY%@*G"`G&_3QWX>
M#!31X7$;]F'&`O#`EZ%@@)RON1HD/S04)3!T>$26K07P@`!RY5*2A@,F!+BP
M%3C0QPP@F@("".00"/"`!&L]5P8@KSTD+3V%I`3"6-1`PP&`@)<7H*>#>+F6
M20./!YA7!@<`P$M7W8,T9V&;=X]+E;"B"4+D8A`>R)76I6@&"J"71C-\P!&D
M)Q,I_($"T(;^16P@A(D+:&A^(ZC&\W8!-0@\0%<7*"O0?*JA"E3@"+FWGFL-
MP8&]0.`)$HV`!3U@08D^X7J?4/J9(G#RBS$_P(3??03#YP?;&^(S&P]_VV90
M>5,52>11#["3*YV#-0O[)P%`LV`&D`<+)&75Y#45YZT0=4`,40)58BH$4"42
M\&=/IP6,)A]2LB190``GI@E9`8`]``#5H&)2UW@2L4W<M0$#<``UABY_9@T7
M``#SA04FIP`S9`&M4@4%8"0F<&L*D',2D60!$#`)V$0>`$01T($,D'2)QVH8
M""<09P4%0`(L>`!FQ`"KAC[\-0^,%@$%$$1`IAH):"IU`B<6U7_^]I1/XM>%
M7C@-'L=H%CAR)><56Q)F5J!R#W!R!#5E9(@$$'A$@&!H%1%U!)1B!Y!X'F!$
MG&9H%9!T1!<*SP,G\X0%144`%M6!!\!F=<8.Z>>'@`@/VU0!51(`.!1J01<.
M39@%<")Y?28`'[!#;]@'-2@EJW(%[K8+;$9^*,!#KN!L!J""H*B%3[="L&%I
M`8!"K;9OIN(`&P`EMOAXFD!L+&8JJQ"&H3`F,L!GU>5)$N$0G(%RB^-(DT02
M7-@X?*,Y_7!T7]B-C=%QE2>&&'5>-,)?&I`K!7&`1```&K``.:0))/>+5$5=
M0L>)']<!'GB.:&5FA;$EU3(`%T``-)3^!7*$`B1'B)BQ):U&8PSP<.>H=V65
M8F"T@Q=0``-I#Q#0:MO$CA2`B4EW/9G77U@P@"-8`6@W`UA$CBR0:[=RBE9@
M`6QV*T5`<QE9*L[V9RTX<GF@9C6(`%`U#BQ7&`3P1!)PC@YPCA;@DXVC`&<D
M`#KQ:&G4BN'H`KH7`"0@)A:P?]ZXE5S9E5K0`%R$!-0%5E`8=TC@:)MU!1I@
M`#/B`0?P/`;P;2K1`!X`%<&P8>7&!3%H`C6``JH0`=3%`!!0D>2H!190``90
M!12`F+2T!7FQ"V'I`!#P1`C`$M6"F%M1`(7Y#0Q@`*;F`7$)FA5&`)69"V[I
M%9KS`+P@"17^@$4.P$7N6)E(`9?_=@7NZ%)0@)A+L@1S05F;$(`K80#N5@`E
M51'MA0)\]4VA"`'<55);D)%\QA1'@%\9%989B0#P=@@#."-#]&%>^9W@&9[^
M9(]F@'+7>`;2V$_B>0_GV1#MN9[P&9_A^9Z.Y)V-I)Y@0)]N(!+EN2SJJ0[Z
M^4G3$*#R6:`&>J`(FJ`*NJ`,VJ`.^J`0&J$2.J$46J$6&E4$>J$:NJ$<VJ'B
M]R/!$:(B.J(D6J(F>J(HFJ(JNJ(LVJ(N^J(P&J,R.J,T6J,V>J,XFJ,ZNJ,\
MVJ,^^J-`&J0B:D&.T0%[L1<55F$8$#]*RJ1-BJ3QLZ1,*J53VJ3^2;JD6"JE
M6'JE4>JD4%JE6TJE72JF8:JE3CJE6SJF7!JF2:JF:]JE5?JD:?JE<WJF6:JD
M9MJF=9JG9@JE?FJG7JJG:/JD:YJG8,JF9)JFA/JG5'JG@'JG;'JEBGJHA"JG
ME=JH5@JFEVJE>UJI@PJGBAJI;\JHA9JI9:JIDGJFE!JG@ZJEH8JJ>*JJI\JJ
MD!JKFXJI?MJG;QJGKYJKGEJGH\JI69H!&0H&1KH7OC%`RKJLS-JLSOJLT!JM
MTCJMU%JMUGJMV)JMVKJMW-JMWOJMX!JNXCJNY%JNYGJNZ)JNZLH:>W&+BK$!
M>T&D'CJO]%JO%/HC>U&L7I`!&("&9)#^2.,Y-Y'TC?Z)GV$`L.39GW"`&)"4
M2ESXC`&[L+CS-IQAG_IJGP+;C`:;GP.K2M2R%Y\UH/SJKO::H)VC2>%P80PD
M!>]C#2RP(?+:$%C`$Q&4G_U*K**4#3."/C1"'=Y0?-T0LA:1#AIR/3G+L]3B
M!4C;L2FPM)T$KPU;GR4K!K>U'8S!K_XZM?"YEF9)L<&E*0*4`&ZUAP%S"59@
MMC&DE@8`$UMP%A=%5OE)`0:P%#'[%=QX`06F(0@P>WO+(C_33MPQ9TV+>?*@
MG!ZV#35+!#\S/UGD./E@%QM">!J18#D59A&IEI=P?8HKM'KP,QWP/NFIM6?B
M>HTQLJ);H&O^5K-4H#V#V4DI:`#HUG=K-D0/8&I@&6FE\A,151@,:#P`L'U4
MH'2M&V!Z]K:2VP4*Y0"0<`4C4`P7D`$$X!51I@!,(8H)((HU8$V$8%&,91@`
ML0&0<`%"$SYK%G9R&UVV1UW!Y@(`>`*+&%=Y$`%H>`(L)YP9\$(B>6C!,0%%
MM%JWP@2[<`=7\&Y%F`K+*P'=>06HYP`<@%9T67^U>;HI:[6*81L80+(2W)4G
ML"4&X'D+$`%H10#'2V=^87/C1;V)!FD0X``-4$(-``$?C%;7-40EF`(<[,%E
M9$2D,50*P#.$4;=AY0*Q0`C'FP$[,`&!9U%DIP+_E`G_-`'J.TO^AD!MS#+`
M?29+=,0+ES!>>W@,J5!$Z60+])8*%$!K5I!0I1(<]-A^`;<!1ZE:$F9.US7"
MDQ!@L$EV(_P_]Q9+_V22>)#'$IP!I'NU%YS!\+EFTGO!;'0502P("V!D$'A=
M\?.:S\O"%_Q&1=2O4'4"B$P(BEQ5UK!1>!9P<`L&[X1;3!&RQQ!'"R4#HU`$
MTP;"L=P`&C`",V`(SZ8![I4"$Y64&#!P6HP#X^4*'D"]9/5,I3`(MM0<9U00
M>SMA6<E%V`!IJ9"5U/7,2+$!GF7%/4!+N=`*](``IB#+`A>*[)?!%@S(<("L
MAKR>:Z8A[#1$5M0%"3!J!B#"+B!8"\#^K_B+6\TFS_>+A#5,,ZL(`6(T1"I5
M`0B0`7"!70L`Q%G0`:M0`7J!!1&``:M"06SU!XL@/LU081S02BA0E+8"0P-,
M;7342C*@60&4@SU0%+N`FL'P,Q#P+8*$!140`>@S0Q)!`3C0`3/4>SJ--"+G
M#\6G+14]U%C09Q$`->&#`R'5SCD@R)R[L*8KU>!9-(`P`6W'%_TD/L%`!S@@
M4<90?*/!`1;%U4;*`L>7OU+0#+;2=L$78*X5!/B3H1#+$0HK!\>'L?Q)&<V"
MU1.LSF]PU8)]V&40H!C<L\!Q$3)-N1Q!`?U5$=`X>Y?4`8(+!55-#5F6Q]N`
MUC2"+D?E-N#^!P7?HLN;+;H6G-KX9-B(O94(=`02X`2+_0_>4#T30-N(](SR
M(].=U)X8/2''81L2,`CKH[C4T@>2W1P3H"N#\#2J,0$#?0WP2AK@QWS!T0.K
MTB(;4GH]0!H3$#"E+0)=8#\:@'F,ZP':L[WM@XJ!;0OJ+1\-`Z_"2#.$5FR'
MS:^$[0:N_=K>>(Z+H`#WJY5A`.`S,.!AH'+>B]P\JWOJW0=*&`8.4'D'P,+3
MYA,@117&A01Z9V2;0`7P.@2"82V>T+A7T`$6J;X/@!:X`&EU``P5[ED+ADML
MM0,:X@`:@@%WH"L;GDDG\!?6I@/%9!LMK.,5,+PZJR&>IWQ%=''^@[&Z)\V<
M4H!%6#%O4DW5I8NW_MV59X5%^XQ.B2U=7H[@8+!F%J4*WR0!3ME,GE``3!0!
M`,#(7^`(+B!P<25`1+`JSK(*=:R$=_$+;&7:6D%OV/!.EX5>&D`6)+!,NP#+
MU'93;3>WZ+8+$S(",W(TA@F8QA`$"ST++Q!RO[T)2L`,3S`$$48/%5"[SQ=.
M$7:Q#YK.C%&UM;WE&N<!R\8$EP7F[0F:\,58]VOE7+`E"/`'`E``@>2^#V!#
M.,D)^WT%<"UMU!=<HD<$(@=N`5/'$-!6%N4)>7``]U9_/SDA22'@`==6NFP8
ML.3HTK(`.NX,.NX5=Q4#MLQ6)I''4%/^#!L0A2T!Z-O;U_9(`;_!;@)FMLS;
M`44D!:Q.X!DLR,W.!OU-ZQLG5R5U7JL%YAY[`3!V7KFN\/-P@!P@`,(Y;A6.
M55#D8I(@!C6+`\&Q>\V1`NEB/Y@`;9L@QL?3/#3B6ME@",'79U(`KS4[>X9P
M"P'6W*$=%$B`>>6S&@-Y$P%Q/UZ-`;Z78"KE>@W'!0PD5SZ#?=\0,.`C17.-
MU:M=NH4,\5\XZ#@4:8=E!F:?1AF0]O149S]0#(;1`$[I`':%\95)".&^!0G6
M\)Q-M1TK.E%K#TYP!7B>LQ0+LU:0N.1IM/7@ZO4$H`0A^?>I&?S*VFQ@P;-.
M]E&%M.C#C67^P+,/#CP>D6"4^^"ZISZT]#-^3P0U+3W"\SKD$-A0L-SN`*!'
M5OE&B@(,O(TYD.A24'F#D[#D<(=]4WB_H1!0PQ#EH,UN;5:M>`1V@]7Z+?:;
MCYY2#?GK"0BZC+'9`-<<0!94(0399$4CADYE!NJ2';.)/IG$L,T356E`W6??
M$T>Y5P!3'`!,\$^]GPZ+V'8@<"C0ES73EW[>1RT,5U$>ACE/Y#%,UC:9AZ*(
M?#:DC^4A22DZ*I7GT=!@"@;,,\4(*#R)!./#>4!8V3,ZK5ZSV^ZUI8`XT.OV
M.SY/+Q#?)8R3G^"91\9%SV"*6:+?XHJ:(U1;I.+;(N5C)6$CXQ/^9B=HJ.@H
M:9H"7XN!Q@:#QX6&PD6#T,>!!X0#Y`>&!814Q86$!D/'DB.%@X/%Q8*'TP7%
M1\<!EN_$PQDMQT''SX(%`]93Q(-11(X%^*P&Q8:"Q7<#!P('Q\?%10J$1'[+
MAN<'"1(\*&@QXTR&`_80&)$U`4*T3Z4F3F0Q`0#&C!HW<NR8,0"`,!(]9<!@
MC^*:DAHL)3"```,V2`D*D!CYZ(&X+"PB2`CTH4(!!?\R+&'#@D(/FRC1'(V8
MJ12&"DNG4JVZB9$'%"R`<L!0,(.%`QHB4`ACZ]S3,V0@-&A0@\&P@``GW(B`
M8<&C#=$^T/NP($*P,^#$'/C`8`*"L2O^*T'(H:""A!A$&5C04*'#WP5CYSW"
MD,\#,&+^SD1`D6#7YRP=$*1`X.'<XPD6K-(&Q>+NCMRZ=_/NO2,!QC"6#/FD
M70C#8C?3,LS+T*,#!D><J2&QU^&"DPX;GKOKIPA[$0,5%D'`U:5"T@[,/VA8
M?'T%@C)%L#A;O^&"(P^%[(%GOQC#/QMPT($'`CI!@Q,;4+'"!@T0@5P6_W1@
M#X`%%G%)@-)8P,(.]FR04VTABE@;3Q2,L0$V$4`@E4`07##``]%DP,,:$YQS
M3GLI,M#'$Q>HB!PV+'#0CXH><%">5D]P0%D'83R@@041-/#/$Q-$T\H"+K)C
M%RL.5"-!#L+^[2*<#`<Y4)PB4N3C'%,G&&:0!KZ`."*==&807%HIF32B2H(@
M0&`!%JCB``4YJ-!!`1,TT`$$!!3T0`6:*8"`*K,<X-T'#SCZP00!)/#/3CDD
MD`$!852!`%P,4%`!BA+\,,`5'AQ`0&4$H(H,!2@\DH$<#`@4`0<2N'"!!038
MD@`=%BAP@`$6"!09`A0@`)D$"[A*`03)U7++!"\F4%8M)]U3$#<+#%!&`03,
MP`!D=;K[KBCZL3"O(F:P<(&8*]BD'U.VS?L)OSKMBXF]F%`0"+_LI!'P&@Q#
MH12\(A9<;R;\3DPOO1C@.1P@(]:`R!M_KF888N"L)"0?X9RV`#3^#`C`2C0;
ML,;R(]OX-5M?CS16RSUX;;/3`MBJ*,W-'S3FP9^N%4C`MTK:(BL%#2C+@7ZN
MJ=C`I*XN@,`$"BBJ[&L1-,/3!`,P0"4+^\CC&F*YY,Q$U!G@98L$)%QP:3,1
MZ[VW*/98G*<9T&41'4!Y/F5O=N*JD4%RBFM"""4(&JXDJ"IH`#'?F>M]9TB3
MHU'2@;4=IVT;(A<6=`,>6.`39PC`HP'+!;ACPFQ>:'`I%`G`LE+.:9=V6J1B
ML/93#KPPP(Q?*$2-[\CL50!!`4H.#Q=SE#T`CBQE33H!`]L_F<$&";SF*C-V
M76``$69L,$`#'RB``00[>$``PA]$``#^@`IH<!I;[+6RH>8"N#<CS8MJ^F)!
M!P!(P!084`QF@$!2-M"4-$Q(7VC20C3*\P@CH2$LBI#*"AK8P"?PPEXG^4L*
M.G"@?PFPA2Y,`^?RU09#.,XJ??(#,9J4*<:1XPFK*4`N*'`N^TU@`1NP2PHH
M8(!1/4&(1Q"-"H"BF5U@8TD?E)K1"I"/"A`@'PLHP.6$8X(*@#"%PM$`70KT
M!?84`"\/D`*V'$"98*6N%11HATLL\!`*D.X`LR$5,1(@@004!P.GR=0`9%2`
M)?2B*"]\)&TP<(!9?"`9PE!``_#2O5U,,AJ*6L(G5]"^3)5&#`5!2`/.]@`%
MP"`+%Q```3+^,($E8D%*>Y%>"A90$$FZB2X\4@%N,L`HMQC-;@T@5&-*4T-)
M0+*9=8JAYW0".H]!*%Z<$`3F()<(AVES$-P46!8DX!IP;M.9YES*!0JB*FRH
M*@+L^@<*D$>9!-C``O1L!0?V`H$)B&,"^?G`%.)T/!.<X1M&R\$L6#9*7*:`
MD9JT)P:@^(A78*`!OL!6,0W3G@;@*T;G_&C$H(DY&DKLAMZ,YN-2ZHEL%HZ9
M5[G$*%BJBS-(@#[E;"E(<UI.Y"6@`JV@C`M8)1>>5H`A#[@`0_"YA'SB*P7^
M/(/4*B"E&N#%7GZ1RM&\IIE<9($S3NW9![[UJ46YT@(4>",$>I'^T:BF]0;8
M$)!.XVH5C76.8Q>LBDF-@H`Y#(D`1*#4$52P`11T0R<T'4CNE#8IB1#E<')]
M+&3UIH$EE*$"/^C*!-:3C\D:374\(9XQA*/'E7"`JZHI3U8V,-@SP.0ZLR&!
MC6YY*!YM%@5E<)8C!>L@_8!I-NF0!FK9@92?E#&RQ@6%2-UPG&5.971OF(<S
MO'"7"YS&`)B*@$*:\YPY%:$`XW&%/;817H448;-"@A)W.M8>ZY#.G#(]+GSU
M=H@L6`!D\;TO?D\*33],4T0EL>\:.H`^"W!&50>8P`&HM(($"``"B!*4!@AE
MJ$=TZD^-.F7.Z"$K`E3@J,^3@`'P`@'^:^E/508H06[SJ^(5]PNGAG5IQ1RG
MX%#\\YHP[E?D;LSB':M@OV\@3DFKV09$Q:C`TA)`+A:!O`*7#"Y9,%W1,FP_
MQR`X`06!QT$)<@ZD\;C+7OXRF,-<BN1.HB3,G8HAVIL&KWK!!+#8`/V>H*PB
MG"YJJD-37W2G/[Z<Q#66S5X`#!"].6?USR=VAI@3K>A%,UK%+/"Q&T@:(N>Z
MP8I'*<#!PN"F0TU2!SL<2TR>T$HG:B$0HOFB!KI!@278@%,H"`,#$L":#`2V
MT<ZTZGLW\4T:J]36OOXU(\ALE/Z&**^=H-<DBBTU&0*[V<Y^-K2;6X*-_;AC
MDS8$@/FV+S?^..NNT=;V`U[`@`60U38.$#>YSZS<<.^`W-[^-KP;+>R&2;K8
M0HXWODDQ`0&D`Q@*.#$H*,!O"U3`*X4!Q;[[G4Z`Y[OABX;T#/LC.F/'-]<.
M1PD+%%`0,V`@`+G.^"EOXW&LN&_C*>BXQ2^N\KC.&Q)FYM.]5R[SA96\$AU_
M=\-JSO&1=T+C^MH%SV<N=/RV?'%[$M''AJ[T,U@Y$R@'1=,Y#@!D<\+GP`SZ
MTK,N5[HRV^42-P[%M:YRD#L=ZU4_Y<D#@',V^%SJ5!<[W)U9=!A>0-TH"3O&
MW97RN/NA[;>9.BC\3@.S6T+G(E\[WQ,?L4=3N\S6#E$-U#Q3Q3/^.N.'3'O*
M%W":G:>\[9BG/.@%"'$V$!OL,6<#/K@=`:E@8,)Y@FL*A`DXG`:A=HJPR[RX
MFP;=A[['7%C`"P30=>66(`#`#_[PDYV!WR._]\[?V]P)4>_:X/US`TAQ&IZ:
M1%")BT`&22$00JB("ZHPB=I/@5XR(!4%61"!"#L0!*A4?OT8T/N*E]874+7W
M%B`@_ZT0!?[)VO\]'P'2">/5U8]]G550FE%PRA"@E/V\0@H(%08,E[-4@P/8
M0P8\@!.8U1((A&QUP*I5PP,H3CYQ2A"PFJI($!FIT`1,P(0$C304"N.H"@?(
M$J84H`[NH+SA"<0L%\QE&\UID$3LQ'#^M<"`'%7\10.%Y(2)B*`_S,#YM8-<
MU,!3Z$5`Z`<*8&$+O.`R/`<*CL8$<"$&"`/H655,]9IMJ.&QR8L;RLL!'9`;
MQN$;6HP=OB$=UF$>XB$<UN&__.$<]J$>"B(?WF$@&B(ARF$B[MK*'6#R?<[C
MF9[DI<'.M,$4#D@$;`"!10,67(!-F<@)'H(4T@L5+D'J/0$6^E-6%,%>4``^
MQ`#5]`!B42$?140AN!X/WA>'``!(]"(O:@1(?,0O"J,P!B-&&.,O(J,R#N,Q
M`B,S/J,O$F,S+F,Q.F,U2F,R6N,T:F,V2B-("*',19\TU1V?2*`?H$4EO9L$
M6(D3")5988'^6<W&!JSC5MA#F:SB03#0'>6#%2H)I/C-%H)0!UC)@-S12EQ@
M$"#%"8H!9"!>+LK5!"2`+NF2`DPD15JDQF%D15;D17)D1GKD1@+?1XID2'8D
M26HD2H)D2IZD2K8D2[ZD2<;D2,ID2<ZDQLW8T(V>GC@D*3"@<IF!NG5`>R";
M!RQ&40K625C,Y6Q05RD8)6R`3Z"A&`1"/2A"JHF!4:K`"#TD5W;EBHDC21R=
MO4WB`K80YNR?5[H0"U6,)N`:&KIE6U9"P+SES['E!M'E7<9E7MKE6M+E7,;E
M7[)E8,*E8(K=!NB2KBA7Z2U@]8$"H[3`R;A4!!1'C>E86EXF9NK^X,OYESE2
MA`<``+[,1OT@$'ZL@/=Q$(/,BP1E)FNVILPQXN(HH`V=7DP%0%MD@,"ES@$`
M7P;\6]4@6+`(2T!(P.JLR`.@I6LFIW("&Q!>&VWV30)H"MBHBL;A#I0=QJ7$
MPJ6,B@A,YG)^)WB&(SGZUW.&@CM4``#,&75N33YPPS3XA0MTQ?YTQ75`@`"`
M8WCFIW[ZVG'P)"DD'4IPP&F`T;X%4JSE@\B<1CA<@*(@`5TT21*0Y7Y.*(5Z
M67\&F81VP@HYD#0((M'PRVH6P8%<9866J(F"V6:.Y:01WXFVJ(N&V6)6A4^^
M*(W6J.(UIXK:J([NJ-85@FSB56?RJ)#^#NG%I:AQ1!Z1)JF2?MN%DF>&+BF4
M1FF731-RSE!Y#E`D5*E:OHN69DZ7+L67BLX+A6F=D*F-L=QX3MR52BF;4H69
MMBF]12)MI%DC],=61DB+-2!NKLE>%)SX-6`S70<+0(E$0*5.R!]SC40%2!X'
MX>0@&"K24<D%.*I@74@:5$Y+W:DB4&KLX2?-#8B[W(=62H0G]F201@@%S$8^
MA0X#X9IECH@K!`(T>)N$V-W"9`A3D-&V02`JOND*Q"A>K:F<E1!`^8UAG1_!
MN)@P'$ADE``18.';Y=BKZIT%>,9`@H4:*,'A%(5GN!@S;<4\RI9N>9IC7<53
M+"7D104-7,#^93#%$E`A3*VB2YD!'S%%8KK2JM!'O-IE"I2JKW95M=*'/.P>
M+Z1&2DDE);BB!'"J*P*D.-#KD[I+M4H%6-@?3>V"33V.5`I6-"#6&00+M,+4
MB[&A"E`AKW:"D2X@DKK!:E4K!P"+&F@?@]J#$KP6/ZC./2A.9/`+O*)`:8TA
M$LC(`P#MJFT1Q0XMI]8)+[0`$,@K(;P@>T`$#;P#%<W`0/J3$<P`(+Q'R4H0
MI3:)J]S#!-C#/LR&5/R1!/0`4?0`_/@GC2T!.S@##+IK5G3%#(Q!9E523=W#
MW0XM$#"`@SUM&@P$!US."Q:(U/:"/PUD/H@@3M1)O9HB!]JKOG#^0-Y.5L>2
M11'8R(3D+11LH;@^`E)P'#R:B`X$[@4.IZ?2!A;6%_R<663TV]&.K08,;>$>
M)"KZ$RYR;!82G#0H$[?4PP2L!)B$KB0<3&Q1!9`YZ1M@8>J9+!H\58%$6$!X
MWV0Z`0R>G]'PP_:MP!:^ZZJLRD!.X(>DPZI<QA*XK;1U*Q56*PR9%0UX1CX4
MA2=ZX@R`A?PZAR>"2!"T4B0,EAYI!_7VA$4$P6H)R!*LIE")#NC>P^ZJP"Q`
M!#\00?J\QD_D2NO9#]$LL$[H2B1HGS_AKV<X1^T(2+;,P#)`[DH,KUFI659T
M0`306IRL%GJ@QPHL`;!`$`2(RRI":S;^K,B]5`.$4&&W3F9/_%*=."_C5*"C
MILT>9<7J&,-J&4D[.(48.$`%F%97-4!DW%$+CN'!5'$,'^>BHM3!+"ILVD;*
MSN;J"A8*N"_TGH'T4@#\A*$=$X7M.=4B]"PK=B$9"4@K3@BQW!$@!U"WCFU7
M]$N4.(!S+#&G]&LCST`0.,>"'.X3D-:]\BX,%AQLF<%`\)%4<``6KF8<RRC<
M5@#5<&$'!VVWY(,'OW&NI%Z2E'(].&T6^-,-2C)24'))G%PPX";&GFP:UFNJ
M2L!AN"LKV@7R%L$R@,J['E$%7@+<ANY1*)@5!@L6$'$^U.(CPTO+[DFW4@(*
MX*#X[H4JY\K^C*4B)NA%4[0#!ZS.95Q&H6``"G`P(:S$P5A`TH["],VIL`)3
M.E2S&@"&,-$Q"H#P(BR`XP!&Q_#Q!C@`N[ZS/D,A>T3)#+@B5%KQ`*5#=/P`
MI]9$3>EO0*!R(V.`(;BN2']6)7!T/N1@*N93&=HQ<7(@'5\T-'1OL9%1"51`
M92`S*)>J(T%T&)=JDIA5/PB)*^;##0Z.L%`!L?Q7(_=#M8YA#2"1`?(T(I1R
MCZ7#A[`K$C"Q/J?`,BP*/@!0%*T:A43"'>U)J1(+$;RC".*F"-JRNQ"+;T$#
M<RU!!B@S<YBS4\@"JLJ%:@6V&"Q#/<!S!UQ&M=XTO):`6E?@3UC^LY8VJ9I&
M[,D%CD1`R89`AQ.(BV=G<D67IOWYS5"R1U*<A'I`-IL@6@#1P`JD@PLOAC#I
M1V=_%QQ:H;Q@KZ/B-DXBFG7(GN*`CS2(=FEVZ(AHP$FPR9H1S9`PD&`1CJBR
M-B1'R,/6T&#';X?F-C"MIDG_*QJHQR-8+$(D!7BXPG.8P2J,+1)<$'*CW\<2
MBW4<2$[4%S-WMACL#>'L0M):1U%*$&M+M_MZ0GA)`YI(]VH3"((C&GB,D/:N
M`#F.T#YO$[!2Q<J>:4R9",TQ0F+GXR.%*29T*YPNWN?PDZU5J<*XBV4OQ1H'
MJV7'ZFLGJED=C(@")H&CW\:VJH6T5.K^%:5WBT("E<`=,5<%%7>>1D)5]DL^
ML4"(4MU(]'C%L9A-B#?)A?@?J*\:S]<;3"P-Z(7DT=IJDB@:E*H=HT$$+(,Q
ML!8O](1LB2R_"G-,+78]Q%\:'(*_RJ7&LI;!JH:)V%&RDBR5_WF9KKCR_G,?
M0T.WA!_E[D(9O$:J[@)Q9LK93!E^S$::GI5'48(G%LC/2M"J_.[8O@;1+NPM
M:'7>R3+5&.^C<:_E;K/4!L%FD47]].-WQTS8\..CXS&0ISB@[SK&+6]E-R\G
M%HI>).HL8Z*5*$Q/]*,1<\I`TDN,S\:<PT4^L;/EK@X8#^0&`$.J@?%JU0;[
MQO7B]`5RQQ_^MD9@!&B`(9RB+^O80Q-!3RRL)]UT9$Q`&?.ZO3^36%(?H:\6
M@U(Z[SGM$\H&-Q]"+Z/@.#]ZR4Z(\;*'14!)`N433R=V`DD\5T/FZF@TA<\&
M#,KXG-^T9PB#(>@#@](`NH,(;G\W/L?MH@:[OW-*<=T[S,OHA$\%@+J!77.*
M'A&[Z`X(O6\R;A:E;#SR4RET)8!B-*Q"%N"F9VAB`D$)';^S"$X\*M.Q/E_\
MI'$T7;N2<_`T/:M'/YPT#8BT&?SR4%!F9H5Q$,1U%<MU2=1:S+^]BG>,=\\H
MZ7$<SG5?"%50`E')-3-WBGE??",$?D27!OIW@B-X"0P^XD^:.*C^&Z(!`?C0
MM@I,:G;G!SZ05B3L_7U;!X%I"*CD-]R'/D7T\VSJ^J1AN.BG?I)2MK<3.ICF
M'*QVV:Y.GNK7/C_+J<R[ONWO/N\S!>FS>.\'O_`GH)4?6V,./_+S/H[JN^DG
MO_/#O*"#Z7]9.*"Z:=9)J]XX^?,_I(\6/\J>ZO:'O]#MG\4U.>WS5YI*HA\@
M!R`8J^%00?W,7JOBE*!"`8"D4')LK!W"F/F7:V&F!0AXWR>.7]>1IEF.7KNZ
M:^FE:NQE&'9BKPZ3"6\M&&VTP=AN*TXF-LL$C<WI!HK-:K?<KO<+#HO'Y++Y
MC/8>R<7/AN-:>SFO(4FD2=6Q.64:G''^H?'EL2"0@)&0)=)!@'`0Q/>Q8,&T
M0BDC04!0\:$QT27B</''-O,!`:$52?@Q$6&I@C&@L#`Y$*$Q@,!0>DHA(*&E
M89!0B:50(!PZ2=HR4>`K/4U=;7V-G>:18-!@5@&9=7',TC-L,(@`M^)G,C'(
MI;.4_:$#_X6`<D"AFB%Q98(#@@\*,&Q04,F"!"D6)GC+,"$!*1,9%'2B$(`!
M'!$0)&!`4)'4!@L.*'R@0$%$!@@9="'@$8&!!PX6&J3$$`&@B)$V.^0B02%"
MC07")*#D,.&HST%)'W1`RD`H!5`KA%VX4&C"!I,26GSZ(-2"`@T>#!0PV7#>
M!5L?UA*DT*O^P#HW,35HJ,#@20-O%B`\$.6M@P6A'")8@)/J`TT)\S1<P&!K
MBM:!*Q1FZ"!A0K\)""::(!"-GNC1I$N;IN<A0`41$A9PP&`T%I8#`'A@8`"A
M0X6"&5K&Q-K@@0(!3W!\8`!`&((',M="&+!@PP)5%R`Z>+`HT-QL'G;<\Z*N
M0P$/""I(U&BBPX`#O10\2("Y`H$,"18\2"30,\$'"#QH4-9"*N1YT(`M&@@`
M001P50!!!0YH`$%9#>200'`<(!B!!`@TM,*!$41@D0.WP88!!`PDD,$"!Q0P
M`0,KPD6!B`ALP(`$>34@00(9%C?"6`\P6"!S'ZBC0D7;<)"`<)/^*,"!!B^Q
M)0(&`APP`60?)$#!``1@)PL!)LH'`4H+4,+`F!54,&9-#%!078NV)+;`FN28
M@(!)K-@8@P05&`!.!^4QV=D*%!1HQVF&'HIHHJ9U$(`!$>PYP0$0!*"?%FNU
M^$$!$<RW00,*0)"4`!,HH.$&$!@P3WK&#$0``PPTD``$&TCJ`30:V!1,H)$$
MDBHV]H21CY_'42"15@$=,*PB"USPJ@&=5B)0,RI$BPF1*G34@0%MV;*!(F`M
M@,%@JER!28+D=>#M<0-X$Y"W=5)`'QWD@15!@0DXI,"]"J!DY(<+>/`A!P40
MP(,*#F'77Z0(;\?``Q%4]`$D$5`'T@3^+5R0`!UN+4#!`@C`8H(%MBB`Z20Z
M-"`B!GOM8`L"G%!02R^)"40`*"TPX$!VTKJP0`/[*)"LM")X0,`"`VRG:-)*
M+\WT&*F9E.`'T"'+!4=%#T#?)#4U$%52$2:P`2\6]!*)!0(P$$`&!V``#04%
MC(T!7`AH4!+0#,S)@@Y(^XH!C^#ITTQ.$>AQ@@$3$,!!F6#+A>+=(_0\0,&/
M,]#?D-N!V/,'(BM&608/4]#M`HHPP.2LT\VK>007:!L091&P71@#!5P`XMP+
M*(!`B[A/Q;8&"0`L@8T&2,!25$0$@)UPI"(R@`TB3```'`B,"=8!>3RP`<@B
MN$4"+Z\ST`C^X1?8CM<(Q';&P`02J(Z`,1-44&\#CP*=F&$@WH!!S:38%4,"
M#*"3'@)T@&2**,BK"*:"[DA@/!]83=,>",$(+BTU/-@3!):C"B]0Z2,0((`#
M.'$`X41@`J\@#P<>4(`]`20&[DF1SV[W``T<8"\.<)7U&C`JK65!'J3Y%1A2
MX@&T;*!6^@%8`WC0*1Y\@@(=N,`Z-O``"FR'1@5SH`IN91+%5"*()M!`!."0
M`:<HI@%/B-$+LAA$)LX`C17(8FPZ$$7-68`"CIGC(-IXDGI(`50:X(!'@H`(
M$I3$%2B!00>RJ+(K>"".?O3;2%1P@0@]\ATFP!CH:&*"#QVG02+^T"1F+'!&
M-GU@!XJ1`%;8`0&;N`(618"`,[J8%`TDA`,<"!/2N.@*5DAPE[SLI2\`M@ZX
MV$5R6\",""Q0@0M(X``Z8$`%6J(!AF3`<:^#@@<D`$932N`O$W!*+:'X%T%T
MP@(KC((31].'[_ARG7^X'1-TF0UFR48$RZH&!M3)SGSJ<Y_\O`%G%`!/,`24
M##P<C7>T84TBR(`5D6B#<<HAFR$X]!15@V@"6>#0-<C!!$.D*$,M.M%%4-0%
MO9K!'MXYTD)95!(/M<30$MK/F,I4GU,(`PR:I-&'#G2A0I!#0/NPMVOX<*9$
M+:HU=FK4I"IUJ4S5#CJ'RM2H2G6J5*W^JE6)VH>26B,0^+RJ5[\*UK"*=:QL
MT%L/[TG6M*IUK6QM:U(+BAJHNG6N=*VK7>_JJPMHM1IRK:@:(EH&I!95L'@M
M[%():]B8`I4T._!;8A\+V<A*E@\UJ*PV7H`"Q*X"!1W0;#W.*9IT@J$#JJQ:
M4":P5RQL0)'UL`%$M"J%$PP"J0/M3@PZP*.`XG85;OC'"CPWIYVP-J7ER,,J
MB`G8&52`!Y[5PFJ1`)#"I(2X:+@,%GS0TH=V8+98B*T8;+N"W?[5NO&P@:F>
M.%Q3)-2X(\!N%SI0I1,X5@OP9>X6<@!=9C0-`05`@'\+D$$S\->__`UP&59$
M8`#;%*[TZ*O^)*:S@/E"P8]#NZ5E9S*",[F`+"=X@+QB(2O%4.4$O4)!>M+#
M"!LTB:3UZ,H=2D"'$72VQ5B(,2J\*P+0R?($0V.O\S:"T77$E\1WT(/%6`R%
M'VON*IVP\8Q)H.*AF1C*Y2#E*"=RE4/.8"Y/9D&723H%[SH/OB^82QVF7`,7
M9,`D:-9#3G"09B+S>`0KIK(_`B)E&-,`='`NQS-+8`'F^G@*7#XQE=]I`X_(
MN#AQ/JD))`!*-RC2Q"]PM"LB/6/,QJ"6*0@7GHU381=LQ+*A/<D`7JJ!`)13
M#%E"=0"ZRHQ67U'5R8U".^**UB^DH)X_I<H%2!@#!TR@$A>`%RK^&@!&,6)`
M`;WQ@9V0P#'%"%L*9YH'!RBPF@Y,6]OP"J*BU:>8![P#+X-X0&;\(\K3!I$!
MW&VO^F82;4%Q8"2:,<D)!T$!"0QBCJ]!I@8P4.PA1N684NS`FG@@[$KD6^%Y
M1,F^I6BQ&ES[BT@9G`:B^`8**#R*'=C`L&$`\/86K&_77$&QG]!&Q_X:%"9)
M"8[P%L849,@DO_Y+W)ZPOL-8P`(H$+<4^'$14,+Q'1W@&,C7-,0*\#R(#7*%
M,.!;@4.RNQZB_)!)UDR*N"%;!@Q*"<]!&10U/L8-#W@"1(+;1CA,!=^47'C#
M/R!N4D0E!7T9@;@K48'US0!'+X#`QE/^\@IL[KTK6QF<@]1H`LAD7=RTU'@1
M3%(!)QB[V(/`(=ZRL:D9!,"^-@4+`32/W#!DG@6;#X-91^-@+<"JUB0`A<=/
M\AW&E%EEH[0OGVNE&'CA[<@;B/S.D_+L$_@1\*[XRE2N(`S<;X4#4;=34K3B
MRK](,?):GH$P/'UD0<61CI!LR19+U!`-2*`!%>@C@TYR!?##(OFU"F(@7+$5
MW!NE.WZ?_PBZ<FV+C20#8(=T+MY/%^[57E@V$2HS72Z0!-Z`$N6T%>@'>.UG
M''S6%71D$EIQ']C1%=,T%<U'$^0T$@WQ/H=T;;D4`PT81"0T#JOE?">@.C-A
M)Q<81+-U'[+^(@Q\I@*@\X&ZH1OS1G,C!Q-SAH#YQG\DX&G=00H3<&WR5W(V
MF$OM1P$`5W*"`A`->!7F,Q6YA7X?0'@6\'Y&X&LZX`^#04P4"$4EX@$)J(7-
M=0:CQPBE5P::`'JLEP6C)V-N^`6\TD."``860!FAX'HTIQ]'5BM>5'LWJ$C+
M$!1(PWM1MW,6H(<4D4S-!WL7P6<1)PPCH8/.UQ`;H&\M)QB-]TY_F(;E8(-,
M*`CO%TWP@@$<8!,.L!5WQF<WQP-4$41!%'(4B'O7)@@3H`-,Y!A`5$CNQP-"
MN!I6=H9?9'(^*'(X\`ZLQ"$<17-KAGO9%P,2&(,5R(F]YPJ>P`#^`/<&.G<8
M-#$.%_`&DNAB*]"`)^&(O<<!6@9?=*9O(P@P#5@!`)$3Q,>$)T%+.\=\GSB"
M5=@6/"`,Y.4&\***GD!*_T8*N`@*%L-R*W1D%@,O1TB*4]B#5LB+U8A\9Q1R
M7C@"U=$;\!)U,K`26)$+H-2,)(A.GC<#M6$*F4<#=MAY,.D"+DD(IX<:!_4%
MW``V?C@"R#1=)2"(<^1ZY]9`BN1KV`$#>;>*/-<)[\.`%<"+I+5<VK9<UR9*
MRL=S7*$5&H=::Z9P@C%$ZJ,61Z&2)E"*K-4W)_&$;#D(@N,!;=0)L-%R=(1[
MK9=+*%$))$0=*.&6V>.+#J<!"QA&Y8?^%'-9,()!2;+0(!NP$O6H`^\T1U>G
M$,J%1RB1,]0HA=MH,7.4,W-$"J`2>2CQ%$YY2+&1%*6I97FG']IX`DK1=7CI
M`:!9*QFH<4?97K<Y#EMW@PK2`6PS(6&7?LI8;`?XFH['+VGT<TKG"J_`F:,4
M&R?Q`BPWFYK!!/6(!"9A91IG;%QW!6L&.@!8C5_4&]%TF$$`/IKSA+,IE6<Y
M&A(P`.&5-F9`AR1@DV0`G_(9>EO@5*B7:Z$P;QRF7SE04Z)6`L^%4G$Y7_[Q
M4B(P;Q.6`LM7D#'VH`OU4@]::2/`84/CH/C41RH54F<&$-O%4YFEH7#0<1*5
M0!MJ8^N0HG+^AJ#/A0$CZ0EZT`)/`05V`0?11#@X8&,=-0/LU5&Z=`1#,Z0<
M1G2*,6IU,&\.NJ0]-@\G14MN$$U;1`/KL&(,^DX"REXFD$PJ9EXT(*9($`0F
M^J)G&EMGV*`GVE-09A`C)E$<&@>6U@+/96DR1A9RN@&I\A4D``\S\5*DT4F?
M1WJ<)U`LF1[SJ5F#&H>TQ6#9D'H(=5\L95)N0`XA1:DJ\)LRMI^+4`*9%EYJ
M^$"(M1/MEE2GA!I^F5UGL(H3Q`6_)JK90*.Q*@T5<&I%0FME4`$"\%(9D*MD
M8*N]^JNA\*C7(%HK.5VW)E+KTZD)]4A(E1:EM`KG!E_'$&@B5BG^B$)8GD6K
MDR52KNJMUI```"```1```)`S9S"NYGJN7&(&XUJN[2H&.-E@_RD-S+<3/*=%
ML#"82*"OKZ%.%E-^D8F0R^@$@U`8>E6(&S`.-V40%0@R6*`!&:>=6"$B;1%$
MJQ:N&\NQ9]"MU3";C8BJ9A"R.Y>M3F.RCC@&Q7I4@2!A:.!^H.!*@T-'.3./
MJ$`[ML@N[E`/K\.%@TF.LF0!LN0`$*`$,?1,.Y<!G3*Q./`@)V`SEE)L!1F0
M'^FN'8NU6:NU?T6R]`JI]EH*)Q04VTB!)%B)U^B>PJ`!:_(PY&0^S!HW;*)E
M4Q$\2I!%<+:"6I"$HCAV+[!C6PNX@9O^3X%:"H0+LW)H37@86I%*LDS4"1/8
M@!&2A36X%7!4#A9S<DL[M$D`ADF`$GHE%%72-WL:?#+&%=,9![=U9%)4'55[
M&`T85((KN[-+NR/@M7P#:V@`&U=`"J3@#\D*![U;#X,!`T%Q!4F18UF4%/7@
M'0`C181D#E#@.1N!988:1FU7,/S#EA_YL;7KO=_;5EG%6&NI-+,YA$G3&^"K
MONO+OK_E!]U[7XQK&C0!O]10O^V+O_D[5OTI&O*KO_\+P`$L4^)K4&`KP`>,
MP`GL2_S+'?ZKP`\,P1&,:ZDU#0XLP1>,P1E<5JVZN`:LP1\,PB$<#\KZM2_[
MK5R[M9@ZJ2O^/%7WF[4N?%<%ZK$J%5@8-:\*V\&Y*\(S!<,[[,/E>[M"]8A>
M0&:A<`%GLE$P-0VU]:T8QEM.O&74E:GLP`--Q`B>,66)9VP3!9!L,+0DH+'A
M56)LLE-9#`C<EP%6Q`5F++$JZE==H!.Q.V$_M:J=5S4:>[ZU)J!V#,<R5E([
M5:=>`*3TX"()T#X;@@8^DP"+C,AGH,B,?'GQ`%JXIL,Q<`!)X@5AM,=*/%(R
M'%&`S,GH6+J18(*B_,9<`+0`=Q6S.0XC8+0SD!-[54LJC*E#JR=:N%)1\DI:
MG,>QH,L7Y<95D<9#A(PH%0-=W%`F7,?!_&@[<;>?G(4TO*T@Q<G^10"GI33(
M_$G-R[RJ=XG,4XP%@KA2(Z"9UW`!Q+$!$PL,<CRIYVP0?;3.9N#.Z;P5`D#!
MMG;/OF#!.1`M/@F=>`,[)S%L)P%IJ%#0L"$(9$$*.^>%G>`32+A&G:!,?,:<
M/O&\%/``7&@4[;@0;?$HKA!A,3`!(<V)QME;--<=\*4@FU8#>=%`$W"$\]8`
MWW%-.Z$@3T!"Q7%DM',9/`!*;!,EB&<^=,"P"`&UJ%4KB"F>A4A'JS42H#*=
M<\EQ`0T1@_`)BM@6"PD'`9UOE<(<8&08UL=F(Z1V5R=N5\"<0;1%<W1,D<91
MI")M?(9,)=B6_%`)XC<(P6-OE+05R+7^/GO]!'WM!D3G<YOZT],U&!%+S@NP
M;PLQ=(Z5;Q_YO,6V7:M%%C#M"0H2U4!1*1A3"1@016=$"@P2<:*TM.D\&+Z[
M39X`T1V!-Q^"%9_-SB_Y>3'9K)-:GQ1$G[7M`C+9!2P+LBX;!B53-:+H6QMV
M<6#!`;NXW*\U$PV9@CN';<_<>#RG%5&KI,,&&QXQ1TH'7W<1M(X8/(.Q$ADK
M1?)HRB6W7"S`<OS7C^5WIW/DTW7-?]?:`@Z@;YZSO-('!P-9"8R!6O#B$<V(
M$T30(IU%%1;#?Y?D'V3$!`;XF[W1&UN$A'0`<.'B!!A(3K64W"N0()'&9W:!
M'8-SCLO8@,?^[0)_V'N/\11(83YME!);L1IEET9XM`*\!SK2/4<R<(7HIQ5O
M('U2X`$L\1?A=P3<-^3E;>00`"&<>`<![@]L$P@`0]>C]-\^<0)0<&2N=`5&
M^QK-1DO_=Q5Q\P;7I$S$Y,UC7B7YW0E@`1O1).&H]0\FD1-,/N)?!A8>(`A,
M5,ZE4)^,\@3-!8>:>I]C\.>%7C4,_+65S`(F@0G%3;5CYP+)I`J@L`/:.:/.
M')`*D4;=F:_8)AC5YZ\:%[=I['`TT8'[&+=]P3;2R7,C6.7*]VS*-PXT(9;=
ME01XA]D:)P'7,0-4`9;XB'Q7IH_*%$VJTS>&H1^#\'H)'DJ5%4;^6!@NVU.>
M!-L5G=4WCG$5JD!$)Q0WEVMC?/:$E5Z+["`2%\G>G@".0_046802=$03?NE%
MG6ZJBR@8D^E8[<E$Y`1PN>&V0P[4+ZV1)'`?5-%&`(]:(Z80C@EI?3.+55Z%
M91L)1U883U`821!-]V09$O[M=`!ISYONHR3AD*;@!6,8%M,WO7$1_4I'1EN!
M$]\62UO0]<NH+(#HK1`!\5FHB'L*N3V?@(##E`P&+G(`]UQRUVAF3R@,KL1$
MJL/G0X.+%^`-(S'$5_:$F8@_<]2+<LLFY2B6#6&03PAPGDA]PV9M9O],S[0"
MSY3C&!V7&DLW?62R2U:`:&ZTGHM'#B#^C;A\;6NF&)&Q7,-H93_Y&$=X&%=1
M^)2=\L]L91#Q,([QD91=GL@$&\RK"LNU>RT@1;8H#`UY!!"A5Q2X'<K'B!^8
M`;`NCDX@WZ-42(ZH3MAF?CJ83-\131%2^LLE#-BYZ9XPO6L/$(_1";7?1`T;
MM0<!%#MP2)'$!+!+@>\8SKH,"U>A;^JS`[`CX3I0;$W"C[_.<RFON3]=,/6=
M`Z\0-[5R2!F0,YCOGAS1$'#@&M;PY[XM>H1:A[?-!3D?7B[IJ!S<OQZL!6X+
M`I\XDB,G=M56<M@Y62N\GJCZ=9V89>67:3R>SO#C&0&''(X.TQMZ3AF,DOFQ
MZ#C0CZ9R)'7^C98>R3,6:7I$'\>"]5"-F%&NE+%<.DRB)"_2?FQ4Z&A0B&Q<
M'":68"QR4.A<+%YHX.AD?%F.;%`5B5#B".EAZ,`==5AD_F6N<62<P/HTXMRP
M&!%)/97^D`%E]9*556@17<XQPD+!G:R)Z7RXL'R9/4=3?]08U2`>6F2+>`IF
M^:S*'7E<''$>86R(%EVL?,2S4;Q'5M9]RJ^/HZZ@.O+-A!\.$\@A3$CN2`0"
M1LX%.*8P84,CX").1,C0X32,JA1.&9AQ9$(,3DBBG/CQ@ST1+2VFC)EQI<R:
M-E%Z,$03QX2=)7S>_!ET*-&B1H\B-0HTZ=&<\IA^F#"`!(<`E9;^^C@BE6J`
M8#*WFNB*,X,?J%FG5(+J#4<$&1(BE.@P00*?2APDI!V1"J:/"VWG]806F`2&
MP!<,#S:K4656QC$S8:6)56G-R>!P-EYX67/0E9;YIORL.#-EH8]'?R@PP`!K
M`0J&JF9](,!KT65B&YC].B59D8K10MW0X`2DP(5&L$N4TT.%XQ1.G')`9L-3
M<(8H7"!5H5'.RR93F&3.W1#J\N;/HT^O?CW[]NX1;G#PX$$#",]NQI<OW[:/
M#0_TVQ?:%/>59U)>2'5`@3P52.`2@2PQD,$&AF!`@07SS'$*`Q<*,L$BR.6D
M($L3R'`.2RM0(&**);[7HHLOPABCC#/^TECC40.>YP%P4(F(S3`>'!07-!8*
M=F%V)`0FH@0?6:!!#"R)F)B*4[)HHY578IFEEENB9B)_FIE(E)>/]8;>CDR)
M6,$\$EZHRH485&`('H8TAZ0.%%2R)&%S9,=<GT%^0@5V@EZ`R4%"<)FHHHLR
MVJBCC9+UH&(Z8G`@91><L($$ADQAW2$2J*EI#Z(B!PT$B5`@@5<?-`##%1/H
M8`&LT)`A:R2SVLJ%I8_RVJNOOP(;[$B4^F;6%*M"U0QR@#:#Z$,_/>-)&6LX
MZ^R1SV+KK+#;<MNMM]_6B*-YE.Z:XWK:@INNNNNRVVY2.F)J)BCNTENOO??B
MJZZXY9&;K[_^_P(<L,`O$FMFI0,CG+#""S,\[+Y=GMFPQ!-37#&[(<E;KL4;
M<]RQQU=&:K#&'Y-<LLF/5EO4F&*&*6`TXT9\LLPSTUPS;_&>%[-*Q9:A01HM
M8U;J39&I])&R90B]$&3D')V0LP0N)5G2$]WG2<J<Z5@=#N`LY0Y)4<NT$[H*
M`?6T9XO)40HIH6QF&MID?\$S%T]%_9&T3'.-7-6D@3DC!0PT$'@#6G\%>`.`
M$Q[3WX<C[K*DBIF$K$(4%#"2!0U@X>N$%AVA0>(D]9C0!B.3("*0YS(K^407
MA&Y$D":!=AD%,"S-MT:'#J4.>4,-1IU,%A*WUNBQ-_6Z3Q@\8!G^[*RH[KH(
MR^/PQ*\:!!!!BA4T,,"7:`2P*0S9;\]%]7%BK_U8:\-\,$H$5#Y3D!M,8*D&
MLU:8")R"4C"'!A)0)\45%R;$`O;(R5Y(4($V6>@C!_S$IFBPA`A`ITYRF4.<
M+M0##LCC"!6(P(4,L@+F5$(#$2A%G1;"``@<`0+/^<%+1E`(=L#J$>V81YTR
MT!(!GD`21LC?/!1PH0[@98<=Q,Y/B.0!!NAI!!CPH:GF`#\"/8(E'8"?._+7
M@_MQ@7XDTA$7[H2"%2*'`E[XP`+O$`TW?,)Z?$'C=]2$QGG\,`@:X(`"#K(!
M"/X`&^X@45PFX,0%J(D#"S#$'4N!)Y[^H,B()51B2R;T$0Q(H$$I.D1+7BB"
MP!0F4RVID!`J``&)X$!5V/"0*I;XID^&,BW7,H$`!6.(^05!3L/;@-RZ](&*
M(,<CI\'E13)4$UX:`2,HP5C.U#<2"C1@-RIIT",\,$+D``$N$+B#IC#0I`C,
M,4$>Z(,WMG/`-OE@##:\2V%(0)T*Y$$"Y=S$A"+'.BS4"0]1H8"A@#BA>#UG
MD2PI%"7N""5,7"$1$Z#G3B;P!&SRSZ`-<B&)?.8-/T)`C0X0!.O*.4V#1B`#
M'?!<_)SY!1NRI`U.2-$QCO`<-!HT+A$XP@4.F"(1FI,\<MEF!B(J3;)4"J;8
MA,`'&I1$$9S^RBO5A$0[+P"!3UH3#TY8IPC<@,;9=>`";BA4DV@Y"$/@D8P"
M30'\1$B@GJ0TJUFUP!SP0@7^K=1#Q"&H":9@B`?P``PQX.DVCP!7ZI"(#`=Q
M$@=6"E>.5F@8?K2#(5I*1#JL=!YB3`1(_3)'PO"/K#UYX0@ST(>>`NEQYHK`
M5"S2`;%\20(.\:Q8PG;+T9X"`*#,R,-&TZ^1=*``"Q@`=,AFQ\+Z$AH6X.E!
M3$*A#(QQ<Y*0%0<J,('!"D5%3DH03%`!JA0P]PO.=<,2'DJ>Y4W`"W9T@SP*
ML3N3+D%!GGR!FJ"1H>QJQG0'H:?UU/2%Y<U"@!6(TS:OD"HB@77^1(&P0$9[
M:@)#+"DG/.C4"'I27],MZQ,2HD`$C!M3;("T0A9P<&\IX4F6G"ZP?.E`?S>!
M!7M80`)C(&F(\>(-YEID=H.EP`-&9.(/;N##F'V>_E+D@0?P%S*WC<H7!@.[
M!A$!`AN\0@;1BQS6P44#$,B@>:-R274\H`.P>T:%0\J!Y&'`>JQK<B:$Z[/<
MGHY6&DB$($3@8!(<B9YDQNT'%G`"";L(F!U0;65.6P8Z?TG.NIP),<VC,XU<
M0+21.<A,#XD"_C4(`EW0U*);4N@V,(`+A5+#@R21H!BCN*E*+2Z*CX`'/$QA
MRPL`H`X]!X%'1)6:(\`<7SPT)TU-T3_^*YB%YQX0BQ+D;X^9C<&'N-"D&-C#
M0F)\:X*<-&8GPVI_UK1AGAZ[.04Y:<#*,3-UKJ,U(`7!"62)`0!'T!:\@%B^
M!\&F9#7%8P,OP%(22MXF!D'6J58(.XAHATFVC(1"Q9*L\^:$24@1@7+B9077
MVM")"GC)J"8BB8,Y$JSLH0(U]<C43RG$_'Z``9ZZ<*Y/MGA;5$">!G4ALU-8
M:7.L:9!>!Z*P/.CU-K.]\I1C8W^+8"F)QI"(0L?X,$9(]WLV4@9A[K*SX*"S
M38#I`:#SN2Q^GM?7=C>1Z8@RICV00$HCV8,@'"*E&Z@5`&%7@L,008Y?SX,'
MW&$I29Q`@)7^*,L2FJH&5VE@%W0I02'FD""`GB$0-3C#YE0!I`M5XHHM?%Y+
M+,L$":U`A96HD!$"#PWE;(<0>-SH#@VQA+:'L9(K\:H>EO!$%D`B$*KR@.>F
M/EA!].#J1H!+$:LS1=+/(P^C\]S_FFKH$91Q#G0"X!N9C8W^TO(3.I"+UN0"
MP&!@78\\L0L?XZZ755F3!J$G3$JY<(K0<Q(-,)1^$W22H@?!GI:8=^$(]P"0
MM,R",!R,PC9$*2<ML+Y%%4'49W,;D_FC`.F8F?\I]/_TE_&+@80&4PQ&8J"$
MSUB)/!5%"PR-2@`*L!A@$36/S6C)+$0-/;6(S^72:GU-3XU6+]7^F=$1G<.@
MCY\94P>FA.]P3B`P6=OXW1$`5-MP!MDXA@RZS4HTC>V8E@ZZ3=[L(`\B#0WV
M8-+X7;;@S0\&H0WVS=0PX1`JH1"^S0`B859\B6V,S6:P`HQT@&L(S@$80%!L
MH0(<3@-X(1BZA@,P@`.4(6^L3?BP(>F`H:>11Q0T57G1X4.<PWT\PZE18!_Z
M(<)@0&X<P`$@P.<,RSP((B$:(DE<0"(68DR42?K`H4T(4`]`@`/DT"%!P'`,
M2=P]P*8,R=0UF"`YW1^:XBFB(GI0BF9!!5E,8DV\%)=M70,TF7]<'/RLR`,@
M#V8U2`2FXB\"H["L3.Y@BY@TH4JTUFC^_!E1H,)!'`FVP<4L]-5R99>"M(4A
M'$0VNF$P<F,WIF*?=8D`,L4=-(BF],2$[175V9<+P,!!3)A`G4Z()0(">F,]
MVJ,]ADPQO6)->,W<X``@L&#CX>$YD(&7:%0QWF-"*N0?%DPQ3>!"0F1$2B1J
M1*()[J-K!<U$:N1&<LPJYL@R<F1(BN1(:D0R0LX)DF1*JB1)@B-%HN1*PF1,
M0J1)0@6\/*1,XF1.FF)#6J1.^N1/HB*\L.*[@"10&N51>DQ+*N-+S@1,A,G5
M3(M/B(W0U$T-1F%G8.4,-N44GL83&N,33L-GB&72U(%H2$T#WD*=>:55'N-5
M$L^DM&4P>N3^>40.273``7A``Q2"`#C`!R0``1Q`!AQ``40:0F#``A@B@0T>
M.*!<?[1)8V;$2Z##6YK+6@30!Y6BT^B$0J0#$,;(1V1``PSE(;(2.9R<6[J$
M0(#347"`=-2@:EH$`F[CT!B"E%$F6WH*2[8AOQ3EG4E``U#``G3``O3``3`!
M`J"9W;R/THE`!`2(B*FFIXT*=Q`6G9`!`P:"$U$G['```Y17!9#!E.&,:4)!
M!\25&<#">"H1#6Q!-,3)@XR9$#B`GOQ;Y_R0R95!'V0*-AA!9^H0%\1!DZ!!
M6M`C"0BHKI3`Z'P0*'S0-VP4%32"762.*]C%&$6H2]"`)AQ9%J3^0M;`@L']
M7F=Z700\$^P@PEYXG0D0W#32V$\,`S;$2U0E@Q8P1PVD*!KX#GJ*P0E@C_1U
M3F>F03:HPWVJIZ2AP<UE@2H<6R`8EU-\0C[D`.GI$#I4@H(^*0X<3`8P``>"
MPIA!)C=69'GT)AT0``,P``6\QJA]``)H09FRWD^!PT)!0(Z5CI[,Z0C1$X7`
M108X`.U9!%E,$B1A@RZ.CH50AUZZ@AO,`5SM0#2R#NLPF$B8%'2ERAB,`0JE
M2%:9%`]!PL--&)1D%3;D3X-PD`C@6,-9TP=$B*5(1W&<CBZ."EV=JF^99WUF
M&0#^0"'4*JXZYP/XC`VEVAW`!/(T`H[^80)[?8`*-0EX&H(#%`J&WE)/58V'
MI`,]\8\#0`!=Y*DY^2IX*E54-`A9'!`'(*J3D%49,"H'*&N,G>L(4,)Z,5B(
M8.H_`$%+/",X')5]@&=/["L<!`B0+*JMQ`G&_<&HYF5<F4`C7,@#!%I]Q1\V
M-`*FY`]/Q<D50%(:2%M&P0'59<`$S,>\00(D&50'8&()2):38%,MG>)<FH<X
M9@0=14``5$`"M%DB($`.',!A+420:..>7-*)"!E<G,[FE,IS1->A,,B)%*Q+
M1-*%#,;IJ`BL/`DY0`(6>(-!O))4<1551`"J1-5Q3.J3)(<4B6U/T),*86-6
MK-<+]=8S\1C^AMW7DLV3ZY0B!QC5'`Q4"<P701F51J7(-\#.0.D.AG`*@S'8
MVYK4"KC!',)<V5&(A<2)!CS`D%G$LQW79>F0<I57JEQ6)@1&C+5!B75;(%R`
M`S!'@J`"=%DM+5F`K6&(4UH(B:B0?<QN%&QFX.;$+`0)2Z'*<?R$#<%%?EG(
MZ/[`<9&%DVV.@='3@"UII83:[,S/!)S:@.&M#R@O@=TCRT(,4YIF`F0``&3`
M(#'`$=SL76)0YRBG"/3B-,2>5@`)JKG70421*JC`<<B%$4P('GA.'ER7\T9%
M638(>$+)UA8AB9BMYTS2MK5!==!2\N")@JQ7C4ZM;O&8"@C!>A7^E]WZE]^E
MU1.!7)8]&9`0$"(00365G3I=1OS@R0F7%$L8%\4)L'.6BE2%B$"XX_Z@`^ND
MP(Q1&S9L*55<1Q1!ZO=5K3F!U:3U@`X),(E<UX"5`*R4G3<TB?]ZVUWD!'0-
MPE45@J;<Q9N!$I`8%ZJE`JR$BGN][MK&@]#N@-,2+1A`L'\U"`8P0&T5[X3$
M9Y)A(Q'DCR2\W)I,@0#%#Z_!P<OUQ%?E@)HMI%+^!O?Z0`>TV'!@P`$L0I1]
M@`(DP"-2,IH-SA7,@]]-`%P8"33\Q61B)Z[]6W\2WEIA*3@([@^@TF2R!%U0
MP2N\+1##A2=9'BA"Z#<0D*BN5%]=T3+^H!GPJ5$B7`B#$`%D'M?B@2(L?8(0
M)$(ZE*I]Q<K@A4@UJT)VQ$.(O,"'L,,#V$-G_D"IDJC]\$\G*U$IL!L)9,!?
MM#,IV-PX5\<V3<`+5%):I`H3E)2-T9TNPH%MMO(FB!$TF`*$'O(OTPZ"'MD=
MZ($HD0H9!0@"AC+K+)2[8A,G]T5*&7,@$*R[IA1_$5)M'I<01.KPS,WHA)H6
MB-A)K]T#S/-Q(>ALFDP^\B8C,\QBRLXB)LS\/)+]/?%DF,&7HJ6O6`8JI%]G
M8&!&I`#Q(B4RXJI+7N13LJ^&@D;MO.72Z,-MR@A`9B5<QLCXT<%0TLU$)%_)
MQ*>8Z'3&R33^3H:I:QV+RCP>,7X=!S9U7=NU>V@O13)=9'K(#ZRT,S\``Z"(
MJ[3SA:2*_M#%-A'1_!`'"@>VRMYU9'>E9#L-33+%:XU$6\`)@`&1@(YH"\R7
MM,(*_RA:6T3`<6V`HO$4742C3U/V:\,V4BBRL>SU1!R$#1E)6>7VSW:LD=B0
M4YS*,`A;:F]9?D%/;"-W<@>%98^C39=`<%,<)&C`+MI0(IQ*DSRP-O%K;V37
M=COMZ51W0"KW>),WV<SV9;ML1H`*0-2".$M53TE0G<1""@C!Y>'`7B1#7.M!
M>?-W?X,#38NI<Y=.R^P$3OOW@2.X39QW<]\D:CJX5B9A@DOX:^?^]5)>Y(1C
M>(8G!8ZLM7D+N(:#>(@/15N/1GJ+^(FC^-`P]X9_>(J[^(M#4PEN[X7#>(V+
M^()O>&W;^([7.(!#-8\#>8WSY(P'>9&[.(DO,HT;^9(G=X6?9(,S>90W^8HW
MQ9A*^97'-H[+=HMC>9??-94KA95[^9@CY9#_.)FC.87[N#+J>)J[.5)JN5*8
M^)O3^4\ZN;%P>9WKN4AR>$_N^9_G))+7I)@#>J%#Y)VW8IX;^J+CHXR[];,R
M>J1O)+Q`ME$0NJ1C^B^NN5E@=J9[NCV:N85_^J@W>J4715V2>JH#HU!^I**K
M^JM_C*`GNI+#>JU7#*(SQ9S;^J[/M*/^3\JE\WJP+PREBXRP&SO);/J@N_JQ
M,WN^A/HB0WFS2[N_@+G*`/NT8WN[$'O.M'FV>WN^5+N87/NWDSNW/#N>TWJY
MJSNPR#I10OJZPSN[X#J+IWN\V[NBG/MEC_N]\SN7A#M1['N_"SS(,"=JH/K`
M(SROY#M1+GO".WR,M#N]/_S$X_N_#X6N4WS&T\B\5WG#:_S'%Y.I`[S'@WS)
M_T;!_SK)F_S*=[S(C_A)L'S,NT?$=WR]R_S-VP3'WTBWXWS/,_QHUKS/"_U2
MNOQRJ_S0(STY6+R*'WW2.[T1Q+FE\_S34WW2`?V--'W5#WW4BWO6:WW/Z[RE
M>_W7XWR?%PC^S)-]VH-$D::\S:L]V"_]303\V_L\S8?YV--]R8=]4<Q]WLO\
MPN>XV_M]S,=]96#\X&M]LL\ZXM,]X&^YX#-^R=N]M>-]Y#_\WN=.WUL^R!?^
M2#P6$E3^YB/\MC?%/#Q``C!`_-`8Y(L^Q2M^4+@M$$%]Z+=^OSL^+%(!$#5(
MI]>^TW-]:%@/D>P`VO=^TK,Z4T!'`^@)[Q?_UK-]4?1BA0BMYC?_Z'?^Y!@$
M6\P^ZU>_P%^_0CP``BP``Z0%641[]VL\Z0<X]Z/_O;_^35B`?-"'3E!_^]_[
M[0]@`R0`YRK'6]M_W8,`UGUD:9YH6GKCF6&:*L]T;=]XKN]\[__^P*!P2"P:
MC\BD<LE,>C(73I/TA$VOV*QVR^UZO^"P>#Q\M8R>C68M_;QBY+A\3J_;[_B\
M7E=M$ST?#`,*"0<2'QX85GN,C8Z/D)&2DUA59T50B"MOE)V>GZ"AHJ-8+WY-
MG*2JJZRMKJ]Y4)=$&1\;$A6`57"PO;Z_P,'",GU($Q\0&AB'N\/.S]#1TGM0
MIT02&1$>'L=5M=/@X>+CY$&62!D4%R1M4+SE\/'R\]#G2RR(J?3[_/W^GJ:0
M`&)7J]F_@P@3*A1C1J`&!Q/\Z%M(L:+%BSZ*'9$08<($"A1(N,-(LJ1)DT\N
MS!HR86"'"/D6G9Q)L^:^@$<P/+A0@8'^!9$R;0H=2G28O2,:&B)2]*ZHTZ=0
M134<B*3#-Z91LVK=ZJ@:DS0QFW(=2[8LEZ-%.EA0X.";FZ!FX\J=6P2M$$`1
M*+RXT&TBW;^``]O`::0E.PAA!2M>S-B-2B0;&E"8T``.UL:8,Y/5>*0#!PY4
M_6H>37JHUR4<UADLS;HU2J53%+EU3;MV0KM#TFA0(V6U[=_`Z1'.'6A0(9AO
MQ09?SEP:["(8UIGPW;RZ=6"<CU!-?+V[=U<I5PK9`"%#!X\D+G]?SQ[4<"+)
M%C3`H$M]^_OX&^$6(H'#A%SMP)7?@`3.,941Z5A0@5Y`*5?@@Q!R<5H3U$5H
MX85?/5>7)E3^B(;AAR"6$44I%\P6XHDH[K!?$AZFZ.*+*&1W3XLPUOBBADO0
M:...(<J"A6P\!NFBC$I4*.21%DZ(BH!(-DG@BN@PZ>24[4&)QDA49IG?>SE>
MX*"68%;GXQ$.%(```@;`9&28;`9'I!`42,!"!_5)V>:=M2G)A(YX]CF:E1F9
M8%5R?A9*&Z#CA62?H8QJQN6&&X3$9Z.4TH7C$1S\M&BEG/[U9A!J*?!`!G5^
MV>FI8X6'Q@=Y*<)7@ZC&.M>C01CV`0=J3BKKKD,ARD-DDS'PC:Z\%DO3@6AX
M-M":QC9;DYXL,8"!"QB8.$,'&HS`P08T;)<"5=O\X"V':8C7P[C^XW(XG0KA
M3I?N"B>\JRXBWK:[;HS?VH`/O=O)>P*=\,:[;&X#XVOP#>G*:R^X.:!;,+T"
M4_$MNC4PS.ZR[Z:K06_@*DPQ4;[N,,$M#TC0PJ8R=$1!&@Y8PVX-(A0V$`7(
MU=%!2"9P@+,1%C3E9;S'2`SJ`B1$8,&T.Y@W0\S0(6TK&!Q4(.X'%'!KPFXH
MK'&"!5:K4'6102N"`P84Q,#!M("('3`)':"M%;1"&.8!!3\QB\(QT5'-;:0C
M\(U(!=I2,(L'%4A!-B`;'.T&!=9<\%,&I/YD@709_+3!`BLC<LP&(S0U.0D:
M2%<"YQ]D6[8M:7AP@3HG1!K#>=R66,O^S59?H!K7)#R='LZ5QX`![AE(_0'9
M']S\]0>&18WXSE08/4(ZBUL`"(-S3WLSTBFT=',V!54P.P78ER`V!H9IH'@Z
M4F10/N.E6V"B!H+_/0O\(T#@@&>8`\*3+2"-8('T'W"<+3HG`P%"S@.2H]PZ
M-I`Z"C#@=0RR`.M40+OB52`"9X.<+4S&OQAL8`+:RH4'&*"-N7V->!YH@#:&
MMS+C=0T%Z6`!2%Y8O>$M8!T8*`\)&$0V`*Z@`2WA1@P0&`%2<<`S`;3>!#RX
M,@3JQ0,>-)=%0J8#T,#03NN*0`4`1S70+%%.,#@$!$IT'@T<P@1C_$9_YI:!
M!K`J&[H(X/_^+C"WD:GA:.G(0`PB8#4/'$(#@`L:Z``I@E$-$72Y^`BNHG:S
M\W!M8.KH3P8^^)((0$!G9I0"")'WQ`_T3%`O"$EE&/<`\Y'M<-4*B0,VL+>0
M>&!4!6$>"2"P#)W][@)KU,O(N*:7=(!O7CO$Y07(!KZC58V82$M;$:602PVX
ML8@0V,;(D(&!"-S,F=/!P"V0,<QL;G-!B(!`[*+#N$M^QF@5,-_1^-:-=45G
M<G7<P._P"#Y&%LZ,@(@(!O_#0!5HTV3EW$`$+"D%UDW@`GRDVK3:4@L)H&V5
MG%-$2"2P#O/=XI6L5`$@!8K1%U8@4G2$P`A6IY>C10271SR!0TG^L#J]80-R
MD)M<S%H:Q@^,BELPD1--/@6$O4D`@'93J05:P+@./"!.PZL`8C@@3J,B-6<Z
MI)IG)HH\Y%%E,BNMP`.*A]#)<6L$MN(&(D!R2$3@,B0(]19(H+<!QV5*+2_<
M80<^FKA24F!!`J59/G7QT_2HA@ID.\0QRA82"TQ``B`)(%(%N0'A:>"2N>O7
M8#,``;J]H&@TT]DV>IF)%%```@^H0+4@YQ%KZK&S)9C,#C\3DF.X%A`?K2IA
MK6J"=&P55R:R[?"<-CUNE4UXB5.+!22P4K)ZC;CKT"K5B&M1N5J`M9JSA5=G
M8#YQ'B.==)NFV`2'.[$]MJ#<$JM9::;^M^&M8[8RR!MZ31#$E@3-2Z3-[&77
M=;S&?N`0,(!I#,-E7PPH-W.*E9J_*'*I6B$#"LQX@;5D(+?R,DYZ_?FC!AXP
MMZBY8`,4[N+-..``JSX-IAHP8>AL)YO0W7<#O0F:!=QH`IG^!)"N+$$%&L"-
M1/@W`R;#';RX^\$>WS4BA0,@^S8FSB36MFK'H'`YV<@U;2Z1JH#0&>AR&-GI
MM$1P'ZV6=+BF$L8U=K3KL*+$(+"@(L(4!G0$<\YN<5[0D-+#O;WOW"+%@0RS
M+<*EPS!5.H#GWVF2@<.<,\X2EZFVZO$#,Z;"+!0<`[(J8Y*RRV-_=-:!\]CX
MD^Q`080U&P'^^%5@FK:3:FR["3G$Z,6+H"O;9*TBM8@(<E\E")[>!)E:5K86
M-*-E2II%9X+ZMG9[Z1#M<]UGBUQ@4+`N>2`BI$C@QVRHB&H*&K'<$)K.]:=T
MOYQ;#,PXN-.YX7D('9X;3I#8%\S-D^Q+K"UHF0^6QK@$$DP?@$O04O](;:XM
MR18,H5AI\#U!&2R0@&70)MK<68-L,8#`$I&Q<+ZD[73A,PR=;='.#HG[51E%
M!$7'NKG/<$MI5T,QBCU^WP62G"J.`X32H("8:9'JV^*N1>A6J`GX?0\.`X$?
MVI!*GFE5P&1/8!NI:@&2A[/4;:F5%'U"<E<2;'&LF;.`-OC\N#/^A)4=K-.9
MX/08LXR22M\9G3B?I>8VA!</%\-+J-LB-:]J<BM\5"CZ\,SI<6XL,*XB:<&@
MZB@%OF@2:=C"=BWHTSPJT!HC//V!^;X17BR%`8$"A,PF<T!)U,CR/,0(FE@'
MK`E,TQON>(`\K]DUN=%CH?*E6S`2?$B'LW6BAHCXR4G@!JHGVVK:'%)?'(6F
MKHR50-^)L-@*_C<=UMD]:[H85.D&<E!BG*)>Q!@@[^=%1Z%EP`^(T[NBUY:Q
M,P`"8"<XY+CX?,C/'(SWYH<^VWCAK;;M7@96<1B\=#^\IR7,%N$UOO'UCO>Y
M_16*P`0QW`=_>*<N&==[`3,0PW4RLC3^?0$8,6O3>[P0>.?7+1%H`^"W4P4&
M!+1D`(B%'+@7+MS`,=LG-/9R+\LW+RNQ.K.P31LT+QR$"'!@323@@B=(!1@3
M(_+G;2_S-52!8CA(-=8B@O$2A`+X@+K03C>H6/3V5T;8+N$2:CK(#GUT@2;8
M`MM0+Q8#A=/$#>%%`PXD@V?D@J.S,^VR38``/Q"S>PDC?QIP>$8(A`@H`SA6
M@Q@$@46XAKVG"W&4@WPV$-ORA/+W?HI!>T!P"!$P+0F&12=P6++W->H3.U^S
M.H/'@RS%$6Z0887%`>D05P_0`)ZA$G6C>8>W`0I@&!*P.:>8A'_#>L73=&\(
M=V^X#D.E$K?^\!.?-6^>M2VI:`NEY$EYT0$,$$TG\'-H!E_$-2TLV`%`Y',^
M*&-?4S+3,EPPL`:UP'8ZXP#A<S,+U'SGH2A'=0HZ(ST>,$:W\EGP8S1"XXB+
MPRTELPY\,7B(A3SJN#I6<SR%@VB>Y#([%!'1%5U4P6%+-#?8`)`4$%J()BD0
MP4K-9P(=<0QTI!*QB#P+T!3PLT"_J#[1=`&5]2YLASS*M@(+,@O#Q2T71!_-
MR"H3X',.E4+8X!_PJ``_T0'F^$%R\EB3QPZ'13A'Q6QF044Y`!JZ4#>Z@A>J
MTV9&E0$4M@%MA#P?56>490)L1XQ?$Q%5,RIVYE?%=C/%0XIWLRS^01-6@@42
MS/,9_T$^(=9B$T!T:O&&'E!0.E.`,O:&GO03H<8X/'8">7-0$^`3;[@]8P03
M:L(J(^*0%\!``%4Y3ID4"T154CA+""4"Y($^AN,JM55$RR-GWK,R.E4"UD0V
MY;%50,=)9HD\'^1'::"4<59>KI8NXU@07BF5#]8S?J1Q>I,X$D0WF.=)`@<N
MB&4RA5,X\<@_\V)8+R<VB%AAS]@Z@W9YF8(8`^%?Q9,W>+8-,+$@BL@!S(!B
M[-9.;'>3[F.9`P&>BLEYFT$K0`!KXL.([&5>&E8>T@,^)40WN(4SF6D8D!@!
M*E$>PJ,)H19<KA2;[`6656:;=X5I:;C^185U1BN`2U+5,R'1:'#U+;6`7<1Y
MEW,U5UV3-K2H5!0`BBNC%PZU#H+$9Z/'9],2HIE@6$S9F/>U6QR2B"L3'6NY
M,D>D9J%!@]\Y/#$$8/FT.-C06LM"-VQ7(B%Z/2MT//E9-S`T4-T@H#4X;#_3
M7EV4*1+$-5)F5K3&#89%.!/JH!\Y';BD/XKXH!.:`A_)=@$)/F>4-M,B3^>E
MAM%EG%0CI[:SDE55@T):/9`3<9NE-HRQ@>?"*@P0@T"A>BE`9OGX-15@._YW
M#%``$W.T-8E67A^P`"-0`9\C,6*CG;TH7N+5:W@J7B"!-L<PCE58.?6$4*?0
M5MH@00^0&A+^)&JQXRV:NC*V`W'GE:'D(WMLHPXKDPR(X5I40VP,^CO,0&^&
M5557YC@:^:9H=0$/D$RELT6),%R<*$&)`#F\U@&X!*UN8`%ML3*Z4UDK,ZFW
MEU;`*E8@I`Y!HZ16LP!2H#42<X<B!:JE"#B%HPZCV#Z(-3?/E:4SAWW_`4*K
M<S^I84W<H(L#:V2.0V.`@SO59P+*19PY<U?,<S.-ZG^!5`(.\#\ZLSKB93L2
MP"T?P43#HR"/9F+B\S^,B1EC(C,68#^-QYXEL))M`#")P#:D0VU+T2\8H)U\
MN&R`I87KYQ(EL!*),`+[HCHY6X-B@6)IN!+ZAG\_6SP0(QZ$EPC^??1]63@\
M&WHKU3<"9(NUG'B$01<OWU"VJ1%E_;0OD^0MUP<Z`#.W6>@M<H@/:Z`X6,M>
M07NU&9B6B2`%98LM6)B#_E&"HX,XWY>T$=,YV-,"3)F&0T0559NT+(`X_52U
M\N0M51LND\0X=WLK6;.UX[(MWG*V8MNX&J<T9\.ZI0,PWCJT;E`07UM;MML8
MB><#MX<T**,"N5"!-[`,<LD'^>*`QGN\U](O.3B'R*LPO.<OYIF'%E@$_N&K
M*."*^/(Q-<`^U!N`]W<O2XB"2S"19X&]POL=AO@#6+@)-ELQM9N^%$L5?XL#
M?I2LZ8F^,J`UZD<^+\1AU^@`IJ(B)E#^F%,S?833,/'[?4C'`_(2O#J@08@F
MO:.7NDYX`M=[*\VG.L3!!],[!1]LA?(;&$`)!-.&+5]%CLK`+1(@4K=">+/[
M%HV73]5G/M^'-=_"B:P8OSRL?!(,2BSU#;O1.4WQ5DLQ"\QH/5^K-GGC`KWQ
M&$DQ.QMC"]:C#)"+"$>%.*`G3\6C(=@B!6UE"Y>E`<KV!.&E36*,-%I#/DR;
MCV]I(F:<'MRR,80[L=DS(H1["3$L!<Q$@RW)5;=B;IYTC;:3/D*LJ2Z@1BO$
M$8!`;+<"!QH4Q<XR(TSS!Q]0)@F`)KEBLX!065GV.Q_0`(I#7'@1)]4C2J/\
M.7D!$S0I!>;^RH\<T``"5)OJM#&.DRVTQ$K_,QM,907A5CEY\4I-MP*)B#P3
M<(=)ZP"[^DG=9&2]]C\(5$T>T!$HJ2"-U:4,X"7>&FJ5]8J1AW4.)RVSD4+_
MTU8E,K,B$,LQ@%!+!`4KHU3T@6/T44UK235HI<R\QLYK\#M*"0%R`C[]N2X0
M$&^'8*BJ(YV"18^=?$'^APT-,$D!!!/1D8BXN1N&57'FTW3'G$\K%&YO>$_E
MG(J$-\DL4K]&H%>?H0O3AE]14`$=!F!J,U@8=D&TY0:=!F?EA5^@1YPZ-5C$
MI2EYL5S+U5<K,!FLR#AO!3BRI%YG>K/3,Z%,'#Z;)U8C%E['0*?^ZY4.IO9V
ME:5Y[EDU[V9X>O.&:YE,[Q7%B"5.\^5'4@-?+MI-M`9?\YP7&$L>GR4#^`4%
M+265+LVL,"I;:MBKFB!>7!DGB1BPS!-;.IT>9FVIAOT[Q4O20A"S3?"[*0!&
MAJ6=-=W,<F*5<U73:C"LM/4UVM!->'L,<B)6PP1IY\P_X?G#B*`S`G8(QZ2O
M7(ERNQI;$K-)(S.)ONN$M?E<D.JRB'"=K(-DJ;9-7P-(J6$"H+Q>Q%RL8-W$
MXE4MU<)E-L8VN!+%F:"&*5=QN>8]N1EO+2%[XZ(-WB.,VWAL]_42[FE58*U8
MOBI>F[3:B6-K''(Z+*V5T54UG*A@B</^?I)=%^C)OFLQ*NLYP`ZICNHC.2YQ
MS)X4X=44`SX4LA$.0",R4/T:D!`Q1*/81)^VSM/T$=YBC[$7>[BPM**3AK4@
M/29-`@#T030HP4G1.L5\"VC5&P^`IU)7H?2&IW:]7-;0XQ&.`M(80-A0XS`>
MJ[NQ!M/\8M^`0/G&2K70W!C@`-XK$E1N0I4#RLLP1'`8)])!8RXP`9IR6%TI
MJ9[T!/K9W%3P.)+1:DU$,[Q&D#%`XU%>-T:]L`'D!W8\X$&PO@[,*N#C.'WQ
MOLCCDTO8A@Q&H++Y,O,B?.1;.HJPTX.N+RL@69E^?I(NPF)=O9-N@4T<?083
MJNN"0/KKO.'^2PSOYWL(@[R`3N"57`2VXMY!)96=?NEHJC!?V,%-*`<*'L(9
M$]G)JP(II00O!^H;$NMW4,(W\!"K(RS<,0XAS.S67N`_D%>A42W6WNT+(:@^
M<)`-L.-H@WO>?N[3L+L$7.MG9.[H_N[.H"I'($&>L>-+@>CPGN_#@.V\*Q^B
MX^YSV"\(;((H*/`!GX<&3RX#K_`,/^D/X[P+'[W/2[["]_`6GX`1F/#Q</$$
M'^D%/_'B^_$4+_+<Z_$F;_`H'_(8O_(2W_$NW_`P3XC@X.PV0#,.4%E(`_#Z
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M%"`J3`,%0H\"R=_R)X_]V>_RZM?P#Z/QWZ_]!\_](S_^)M][%:?]')_R9/J`
MT"!EG;Z%&:_RWD^]X0_Q*4_^`\CRDG[^_]N/_R#P?=XXC2(IGBN;HB_LD1?&
MJC>>ZSO?^S^PY\E@.L&C"%+D9"0CH@:YH2"KUBLVJ]WB/"8ND`8>D\F;2CFM
M7K-]WC8.4X/3VT,,9STQ?C(0$90451UAH:'05YW8(>/65"-D)-L;X<6%)"80
M$5\:AP-%Q$->'T;4T6-FJBH2)1P)QN6JK`KJK.UM*QWL[6K&!:>:C(J'7(:@
M#6]RY)M+VZ(RYF,S-'4AL^N'7#7DW2AAX"G:]CAA+IPV.6-M.GN:N?/E=/N:
MKS?=G6G0^CR_UGMPMGC]X'`8-/"@E7]KT"%TM\F0G'Q`]C6LR$.AFET6TU#<
MZ!&%"7EJGGW^W%+/&CA]:$26;'B-#LF66<X@D^DRD:X:+&VZ>5@HY40J.WG.
MPTAFADZB5SHJ[6>TC,:F1[JA+'5,ZLU"#+$&*<@5X5,P2+\&\?G-:CBR`\..
MV:J6!\VW17&>2RI7AR]@KH@8.V7P+CFV6UX)!)Q#FN%Q@KE$38R"B#TZOB3^
M0.R8VN(MC2]_8,IYE@<GA-PZ/ED.Z`^OGZ%EUA+SLN?5JEI?F1&+\QV]<"9?
ME<V+=L)L<U9;]@V:KK/AEW,;0NTCMG%)P*^(&?HV;O3C6NU>AFPMHI25V65-
MM[(9MM#QJ\I/#2@[;W.T^M*3J(\BA7UA)_37QX]__W_\C1#@@"_^Y!>@?P86
M"*"!!/)GWX+]W3<AA!(R&.&`3@B3X'X1<GC@A*\Y9AF('5IXHH,(-JC@@RL(
MV**)*E[XHH<3QF@CC3#FF%]()M:((8H4?E`=;M[]A$%?*JE''G(`G3?B7TMB
MPAX23QIFVEF4^<`!`Q-(\*678(H9YIAE?BF!EV&F>2::;;9)YIMBGJEFG'"2
M.<&:<[J99YEX[@EGG'K2R>>>;IJ9IY<+^"DGH7P.RB:B%#3`W65<4E`HG74:
M&FBCF$**)J"%FGGHIHB6ZJF@>@8ZZJ.I,GHJF8JJRNJHJV8ZP:2K,7>:?$!X
M(```P0H[++'%&GLLLLDJNRRSS3K[++3^T4J[+`,U&>9!`--JNRVWW7K[+;C+
M9ENM=5_M.EJO/WB@00;M:O!N!O#*^^Z\\,9++[OSWHNON^W&ZZZ]]^X+L+_Y
MVAOPP?_R*V^__@K\K\#L#DQPQ!#K6^_%!D,<,<8<:XROP?Q&QIG$(9M,K\(H
MJWRRQ_N"[#+(#"_L,LP<>YSQRA^S'//-(=O\,M`E^YQQS3RKG,'(B1F9Y4;E
M2ODTU%&K9=8]S@F130.#D.CB?QULX&(7,7R@003&3.``!.OV%=H#HGQ`@1$;
M-""!!QV$DO8)%C1P"0<00)#'!0]8P,$E%:2`)"`:4/"`)0Y(X$`&%M0M>000
M9.`!&H.?(*G^.(NO6X,&2-(=]C`N-"-,!P^,_H+77`_S.NS3.`T8`P8PD$<%
MZ<%@@P<16,N["IZDP"7L#QC13`3V>`"!`0]T"#LR+ESPQ7_05[\[@;N#?</I
ML9^@@0$)B'/"!;H#+[;IT!>)1W,7:.E#!PQ0L(`3&MR6OHU^U\2A"A$T(`(#
M)*"`!E1.!!TH@`0BL"X`7*(!N'I`!@K@I11H0'X(J`$"$/`!"R#``@>00`$^
M@(!1)%`$%-C`!`0@AP80``(:2$`'.J!!!A"``[_R``-NXT`%6$`""WA``SIP
M`!QJP`,'2%J5&/"``XR`#_J#D-2"<`'?32`#'3CA!SI@B3QHP`+^7\.`%]]F
M`)W(8`,<L%\-SI`D$E!`(!S0H"5$`$82="`O&3``!>Q3@05\(("=&1L3+B`#
M2]0M=(+L@`6BX($@I@.,'##`!KJX@?@QP`B1>U\4AP&?(V'R(@M0I"=\AP$@
M+@"'$%"`!RX5@1,F(`&1-`8#<,B`N6G@A\X[001\]P8-J.X/'W@C+AW@O`98
M0`07X*,+,A#+NGU`?PJ(!P8.,+^O=28"[*JD#$7`@02(``%$@",?.Y``_Q5S
M!$X0G`+RH`!V!4`T"4#B$7;1ME5"L)4:Z(`"(E"M3*KKAU'HP`)\)S@&,`!\
M%#@`!B3P0@Y88(QOXP`^+R``"CA@`P;^:*AR(L")#2P`%!/@XQWS\,,&,&`#
M!3"<"O1W@0!8=(H,<``#(/``!S2@`;\ZVP828`$(?F`!Y1Q''".@``J\<`,$
M)<8!&JH;?@*"?>4`3Q5X>0!C6("/MWMC-I^Y`0Q`@(\JO<00<YE%!3`N`2YX
MH@/?*8$_U&T`!YAJEPR010@D50,!.``"I,>`=WZ@;3W%``44(`$+,&"$VDS`
M#Q70`6#^4H,?.`">F%@!!72&H@>X30(,8("B]O07`3"%8;4`Q@_X+W1R+>`#
M/HF`3C)5!1E``!H@H$`FZDT#3D#`%")P@!AR\Z'BY,`MA8J!"!23!(P]K"L_
MT(`H&-9X&.#^8VA%4,`,"$"H@DW>:Q%``5!XX`$IF,`X7Z$<UKA'IA:@*VG_
ML("]/8"U4CM7':S6@PT44P,:K.IC(?I.*BR@`FOM:E__$,>\AE&$7K3`\=);
M@A/HK[%R1$`#3EK<H>Y3!=J@0+7TUU_EOG,"`$A!!P@0BFHQEK$(B"$XQY9(
M`*S-!!A(@`*^5JT&I+:;\%27>QBP``@<M'?.$RSAOC8[J&'X;5[U'6XQ;+\/
M*"`!QMNM$$DP@0N\435[_,"4AQ'+/B)2`O+KJ1$,ZP3\'L`4)+AREW2Z6BI<
M0`&?W`#=>N1%!9A``H6I!@8J8%\$0"#*$7!`@#^@T-;FX"%#S@+^/JH08O_]
M`;\42``$]MO3@V(`O&_K8%4Q0`#,4?.C%,@K@W79(PD0@`$*B*";$;K!5C+`
M?Q@8P%YC\>K`&HX`FWXA825P.0(D6`&`I6P#`F`"$R]6@PD(@!6I8`"!+&`!
M!E@E`A(X@6I].;I8B.8`9[F!(U;@LAQL*#4)G0,/_'`!>9@`%3`\2R;T59\7
MR-4LX^7`(`I$B<D]@4^'](`$O(NL7ZCD!]"0`>=!X,LJF"7=8JS88@ZWJGXT
MB.H64`,&C)<:&CA``O+,@-J^T)J)/?22L%0'J"*!<!BHS]<J8(%'9_&7'F`H
M!S8@WK%EX&L=<`$8@>&_)JI`BY:HHP7^JC,$#Q"2&!?0G`@V<`%C=$`.1F!H
M$4D@\^"5L0_N&P$UIRYS.>0A;LFTP!QV@;0LROR(O_/5TD>P=`[D01N2%/?5
MN&>YN9TO!B*11Z6U5RYY0%$'=T_Z+?FA'['!O>=.C\_EP'!>!B2)#!8@@&B^
MHEN0%YX0<(Z2XRG/!G95WB8<X+HAMHJD!#\O1?E!7W]`)(,2P:CT'CK0@U9?
MH`UM"$`MDGWM:S^@W-]^1=V3D(-8U"#=)ZA"+/K0Z5V/>M?-O@4*`AOQBP]]
MNT/?^,1O_HU:8/WM,]_X0KJ^[GV_HA^5J/K=3_[TIZ^CY'N_0M'_OO>J!WP<
ML7][X.>^BJ3^7R,HYI_^SX/^YR&)YF'!'10#7S@,DB#)`2*@ORB@PS1@`SK@
M`S*@`;:+`DI@`EJ@!D[@`C+@`TH@!X8@7S@@"';@"'X@$5Q@"6H@"%;@"4(@
M!&8@!7)@"6(@"F;@"J[@#+:@"6Z@!_H@"]Z@$,[@#OJ@'-@@#XH@#;K@#]9@
M#^H@#<*@`>:@$IX@#U(A"L)@#&9A!"HA#@XA%VJA"<K@%A)A&9XA%`8A%HK@
M%T8@!H2;(83.$<H!#=#`$=KA'.(A'<XA+/"A'_8A(/[A'>ZA(/ZA'A9B'OKA
M(2(B(BZB(3(B(3XB)$YB'QZB(T+B)0YB(S)B'?)A)FXB)8:B*([^(AWJH2EB
MHB2FHB9:PBI.XB<&HB!V8B*2HB.^XBP6HBQJXBC:(BGN(B?^8B/BX8W!00S%
MC#'FS,(<HS(FXS(V(\P@8S.>C#0&33128S4:S34^XS4>XS-JHS8J8S=N(SAB
MHS4:HS>:(SJ*HSJ68SJNHSN*8SB^(S1.XS=RHSPN8SRRHSZ>(SG:XS;FXS::
MT0!V'D$6I$$>)$):Q$`&QS8L9#M8AT,.!C<$AE0X9$0F)$9FI$9N)$=VI$=^
M)$B&I$B.)$F6I$F>)$JFI$JN)$NVI$N^)$S&I$S.)$W6I$W>)$[FI$[N)$_V
MI$_^)%`&I5`.)5$6I5$>)5(FI5(N)5,:-J53/B541J543B555J557B569J56
';J4LA```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g18202cai002.gif
<DESCRIPTION>G18202CAI002.GIF
<TEXT>
begin 644 g18202cai002.gif
M1TE&.#EAJ`)P`_4```$!`0L+"Q(2$AP<'",C(RPL+#0T-#HZ.D-#0TQ,3%-3
M4UQ<7&1D9&QL;'-S<WQ\?!45_QP<_R0D_RPL_S0T_SHZ_T-#_TQ,_U-3_UM;
M_V-C_VMK_W-S_WQ\_X2$A(R,C).3DYN;FZ.CHZNKJ[2TM+N[NX2$_XJ*_Y24
M_YN;_Z.C_ZNK_[.S_[N[_\3$Q,S,S-/3T]S<W,/#_\S,_]+2_]S<_^/CX^WM
M[>3D_^SL__/S\_3T__[^_@```````````"'Y!```````+`````"H`G`#``;^
M0)YP2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>$PNF\_HM'K-;KO?\+A\
M3J_;[_B\?L_O^_^`@8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"A
MHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.
MS]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[
M_/W^_P`#"AQ(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)
MLJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?^SY]`@PH=2K2HT:-(DRI=
MRK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-HTZI=R[:MV[=PX\J=
M2[>NW;MX\^K=R[>OW[^``PL>3+BPX<.($RM>S+BQX\>0(TN>3+FRY<N8,VO>
MS+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX<^O>S;NW[]_`@PL?
M3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@PXL?3[Z\^?/HTZM?
MS[Z]^_?PX\N?3[^^_?OX\^O?S[^___\`!BC@@`06:."!"":HX((,-NC@@Q!&
M*.&$%%9HX8489JCAAAS^=NCAAR"&*.*())9HXHDHIJCBBBRVZ.*+,,8HXXPT
MUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGDDU!&*>645%9IY958
M9JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGGG'36:>>=>.:IYYY\
M]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKII9AFJNFFG';JZ:>@
MABKJJ*26:NJIJ*:JZJJLMNKJJ[#&*NNLM-9JZZVXYJKKKKSVZNNOP`8K[+#$
M%FOLL<@FJ^RRS#;K[+/01BOMM-16:^VUV&:K[;;<=NOMM^"&*^ZXY)9K[KG^
MZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_``<L\,`$%VSPP0@GK/#"
M##?L\,,01RSQQ!17;/'%&&>L\<8<=^SQQR"'+/+())=L\LD4ZM"*REFPS(7+
M?<#LALQGT%R'S5?@O(G.QO&<60P,^.R$#204@?,(1)30@,HZ,!`##S*/8`,/
M((!P!,TQ**!``@D4G475/#C@M1,PE$"UU4;0'`("+C@A-@].$Z$RV%"?';;9
M"SQ-PM1.Z.!``D_S($(""B#0P-52>*#`TTT'7?<0,+3]>!$D.)!VW$/`;,,"
MCB\1.0]`"\V##0EXL`4#?//@`@(B"!%"`I(K43;^#Q^@'<4#"2RP@`(>Z/"!
MT6D_P#(,:+MLP],C("V$SQX<T#H1K^^.>14V.*!`W#:DSG(,J4_N_?))<)]V
M$BJ3,+80=#-!LPXLFS^$"`I('SCP](.??1PN`*#R#3SP?P/+[&,?$;IG`_XQ
M0`%#N!_4^,<W$!#@<2$`P`-&!P#)"5!U`7B:"RS8O?\1(7_Q0T`%E\<_$O8O
M@7RS00!'QX.M\6`$3YO:!1=XPB$88(*$8V$"CY```%BN?R74@?]BT+ZGC5`'
MXFLA`DNX01X,X'<BT($+!%!`EGEP@$-H``*2N``!Z&X`"%2A`(6X/+[I0($Z
M%((!)"@X``B`:3$H80'^3$?#Y;$/!EX['M,"T+8S=H\'!F@`$?OGLA6J<8+Y
M^Y_+K@@]`!3`C(8,("3KF+W]C=!U`""`R@@`@!!`;8:$/*3JVJ;(17[RE$/8
M(`,8L$$;($!]`#@<#TJP`".0H)9H)!\/U@:#`KS@<0QXP`87<``KW$`!("B!
M"`80`Q#0D0@>>.85HIDXTUD1`0DHH16HJ;(%"+,$?ZL"->'@@@#L,@`&&(`'
M'#DU!@Q@C9YTP1H'4+1R<A(``"CF`=)IN1`$X```^,`+\"F`$D9P`%,+P"\;
M@$\'V&``^(R!`QCP0H@6X&D,%<#8REG"`%AMG0$=70%B.0"5[7,`ECL`1$7^
M4`(`I+.6!O#D``#Z2`P.8`$&&`(#\/F`!A@`H*U[P4@3T+T8#.`!FA3<`\,&
MNYD.H&TQY0$`8&"#`JC4DPL8P$A;MTH>$,!J!'`!1`,0`#H2`&DJDR<`!E`"
M>UI-95H30OYX@("5BM615`6`V0K@``,@S:@PL&$"BKF`!`R`!R0@@$HEVE`;
M<)*H-QC```*@1=H1P``%X%\%;W``!!2@ED(0@4M+$(.1#@!IY9QL.QL:@P#L
M%(%P6ZORAF"X`BC/G5N%VSL!T#K=T:X`M)MI9G7`Q[I]H``&*$$)#E"`WX'T
M=Z[,I`T8*L$'P+0`DVV;:#M;RP\LE0@?H*,-%"#^`K8)`7>=&YT"&M"Z6_(`
M!H5MG6$_X`*S>2`!2]LE`A8'O07HH`"QX\$"S"8$!-@`!`RP&@,2,$$/(,U\
M!T;?+V>9@"&\8`0&((`(;+#@#U15PW!#P`0/7%X7D(!U4&.`B/L'@O*^X`8%
M`+%<%X#B%XC@`T1-\0,>\+OW[?AY(!A!C4,`@AR'X)?N@U\"[&M-`1.8KE-[
M@.'F-H($/"]Z3Q/!1#/\/#?,-8(N,&Q+K;:``!"OI(M-@#EA```0N/(`4NPG
M`'99P0?HSP$#"*P0/%``!A1SJB/@;:!%0`*]*I$'`O@`#)*[S!LLDV7YD^QE
M52>`%[Q``#%HP`&B^U[^RXF6!U:%@5%!`(,`U'(`5HME_JP62*,"5P@/I6@7
M8^!90%H.`11E&0-R&@!/ZL#0`PB!"%IG``2B6JIE^QT#'ECF,[>PPL>N8*!A
M\('#EB``+DLS%1%P`#T+^*L?V">H#Q"#&`@`<._DP0,*T`!F5]@#WW7B?6.0
M`']2#6F?=6+0#'!KBL;2!D@-VR_;+%6)'M8&GH2U`%"7YC6W&08J>^CA\B>"
M0,>@T8VNVT"K]^HNP@`!S!;`QQ_(-<L*7*JI[B/M;EBU!Q@`!*U]`0PP7=F^
MZF``%'6A8HUZ:A#DCZ(VF##XQJD#`3@8N"%00/5@.SJB)D`'M`2U!UQP5A#^
M&$`''@!!N&'`NQB0.P0&T*8.",#6(BP@!#>PP0=R:@`/C'<!,#B`!TH;`P(\
M#0$WN`$"7);5TCV-<YN36KT=X%\'-&"\$S3Z"`C0`*H#O`''3+P'1%"`IBT@
MA0IPP:)CP&81>."5N"[!L6F[P5<",O-V+[7G"5NT!\!\<20`;GCK=L#:(:"6
MKULZJ%%OOK`>5\"+8\#ER3EG$!PVKD_D00YO$``2/+5_4V4S_^*J.@4<P)S&
M5UWQ#VO<!PY`!!D\H!"N%P,`\"\!3M/?$+)*^$NNF@$9I!IE&2J"`_PND=4W
M@#F;J_WI&SOE7@6`WO4X!/`[+C2``8!?F$4$.&?^`P9@>L(G>BJ#8Z[E1``X
M.`0`7'%U`P"P.?^';&PF1!7D0DQS1```-!6F:XXT4U.3?-?&/^6D,B(46"WU
M4+_#,L&V8`?04OQ#@11U;`&@``Z`7%+5-@/H-SWD25/54OGT9$[T.R8(`R%(
M!`1@.OG#/B?8``/0`#L5.P\@<B!P@L\67&,X@"X$;U#S-YU4A$.P=B-P``>`
M82$0:`W`4&L32&KF509H;+^#?N7G?X@S3C903%!&.%R(4+#V2B#P`$KS`K!%
M`@W@B#S@`1^0-SK%;UH8.PTP`@XP`A5'>P0P6`9&5VEG>H,H.'DF!(VWB)-#
M;0Z@2;-G`R[@0",0`J;^0P`,8#UP1HA;!#<B8``+T`"#Q5D%1CM--CHEX`$#
M\`(N$$9$97H/T&0\EU5/0VX"MD%A]$H,@#24^%Z5\T"SUTUGMX5"<`!"Z$XZ
M`#@OY`"=.'XO\#;<]`9SE7W(9X#`90-\=&SYPWD!,#5Q%4',6'P/-(_Q-H`?
M$``=V`"OQFY_J'RH8WZJ`S<&$`.:!VG8!FH5!@(B]SES1#5S)EH!"6KWUX^@
MUG-L"(1X$V\%>&A\Q@,!\`$4.3\M)0``$`"(2'6W!TBOA'RI9G"^<U@+<(\=
M*'Y?!8+JEP!U-3;$%4\=N#M$0'U#L)+YTS8@8$YU%U(8R4Q46'%E57X\`(?^
MAP:$,.D"*A0`9O-[`6`Y13E"%S>#=;.2'J5]_*A->HA!6"A1$^D"0O>5-8F0
M!EAA9@B8#W2&#Y26`<B&$UAYR#5V%2=RS`A(E^<"3[.2<;62Z&<#$)EO2/`!
M/>9*!>9*(\",3^:9/%"'#R")B!6)"$2)EA@Y#>`!D5,")>1>'Z9-#."$4*9W
ML%9,RR0Y(\"%WL:(=>,!(6"+I3E@Y!4"OP-@&T26IM>+#+`VS>F<Q3A[L,8`
MC7<`S%A+]*:;ZG:#5--X+M``5M.+"["=H/-*"]!Z;J8`C"A[3;:>B!5V7QF:
M]457R/,`[=A"+[")D]AC;9!6VZ=\?!A;"Z!880/^``J03]K736T6:.,YH%\&
M`)TS@'0U5>5G`&O$>0"P=X7UE06PH"306@>D`)`&D6Q6-`.`?IL6:$$Y9Q#*
M4'5)5P2P`!1J@2?Y.PU@:@*04S:D41]:;6&#4@=@.R7'/\EWH8'U@#-W:E`(
M`P^09P?`;!2*H"47;5((`$25/X0X!`Z@H`Q*?7"%0"ZSDA>ZH);#5RGJD13%
M@&X6?7.&``AP:;54``(P`E':5P+X0`+@`&.&;"5@`"\0AMZVDE^ZH,5TA41@
M`'<:@K\F:J:F-2>J0I-X?(!IJ61XJ.B$:'ZZAI=$AL6&HROJ9S8P`I1E.*`&
MI-!F.CFD4C9:2R/0IM#^)%[/B74)``-X.@2TMCPW.D<E0``D\`(&8`-99W4N
MP`"$9@#UY0``=$,N<%5U(Y]$,(JY(ZRPF5ST672@)5>H5@(A0``(IP"]1`)B
M)0*O<TR"!`)H]YQ3,V#8V4PBX)W%!`)*)U<%``,B('(N@$NOU``#)@"VHP`3
MUHSX>8W[FIZEJ0#7ECSD]@$"8(SKYS6[IFZW*@(35&R_&@.)E8S`Q0!%<U]_
MM`9`,TO]9#5O4SCTRC=K\P'\DVDJXXB6@V,A\``4.4$CRV'^)00E,$'5-S7P
M!7=0@SLV(`)6<P.?EW".J+"ZFE_?"3H+ICQ:9JH3R#H/``,>D$>\\P&>Y`#^
M;1,WPHEUG!EO0C9L5K.S/+`#:_,`J<.U[]-C9CLZG&.QZF8V@I2PG*@#Q?D!
M]:JN<PLW3X,[3R,`/$L$Y<6R=C,$?$L$P@DU'X!B,3!\60<Z`'`^?7MXTP6W
MR#I!)^9)('``:EN:>H-(#$9D?DLUZ+>7B[NR*I-I1?"&&W8X3:-!\?-D(P"@
MTX6W5D,"$P0VNIN&#3"SJC.Z"C8_E4,UGO0`19-I"3`"Y8-^@25DGFBR9L.W
MTS4"+O2;MD1@-]!C(,`_]\6T_0.@)6`UCTM>JN@!)?"Q5A9:\3,_<`MWXSL$
M(>!M0F"X.M``O#.)1=-B0K``739CP1A#Y`4#">#^`#:F`PK@2<)H.A%&.U,S
MOZ59.N%;OV>4P.^#`#Y'6IX484W3B=H+H+1S`]V[2^7F2=L+-0W@P9.(`"-`
M`I%3-"H#P:K8-M^K,LN[OH+3OKL46..5<'H`E8Z`OWC6I5:@`[K#4+(D"($*
M`'L)!BP3`I(E.LM`;US(6WL@Q4^P7'0Y"Z.H"&`C.C##,SA32'*3.69L!5F#
M7]JC!``$/DG#-;V#!&U\QDRP`V6L2W?LQL!3`@B`FW0\!>M#->(Z/GG\/7TC
MQTN`Q6:@R'],R$CP.O7&R(U<!3)C,Y*<!`[@P_53R&)PR45L!2,<QHG@R6S,
M#7:L)Z2,R*G\!J=L$*O^'!263`2/JSOUIL>/0\9&``,)=[\2#%X&]4S$<P3V
M6\B!C,?$NL-N?,)#X#YCG$#N:P2MW,I+<,IVO`/1+,W2+`39/#DY4`-#8,U%
M4,W:G,T[H#+@S"`G9F(C0+]1('IMZJ]QI\F]Z$#S<P//7'UB$%C2FD"FMV?2
MA,CCU`<LD`%G"P7;+""#8XDA0`+YN\S;ZCJYDV4-0%]:)D@/P%]"$'<3-3JF
M^$HL@W<C4%.ZVCK"Z`!/8WBTHS42/4'H!3-*]@+-A#Y4M6"F(\).QF$23#I"
M9E^_T])$,`*%Y0(P)F,H0`,\0`,K(`0<P`(\D`,I8,<H<`)"@`(YP`,KD-3^
M/-`"*\`!&@#5&X`"/)`"%Y`!.8`"2<T"+%`#8,T#*)`!=DP#8%T#&7`!*L`#
M%Q`!)L`#)G`!7:W-/"`#&(`!,L`#*C#6WJP"`WT"-:`!&W#0]R$"8=62N_:L
M/NP"S>4!#G`#B^<"DJUTQJ<T9]4\E,.='?V4ZX2;G'C1"&<V`ON;:J>>2I=T
MNC=C>#2L>Z=W32,UK*,#A*4T&X9B@CL""%4[)$!4UI-*L%=YPL<W*;`!/,`!
M$K`#-0`!%T#8$&#4$S`!1PT!=5T!6(T"$-`"&E#=%-`!.;`"$B`#)D`!+5`!
M-2`!-;`#%K`#.8`!&@#6&Y`"/#`!)B`#$K`"*%#^`4Y]`3C``1@P!#0@`2J@
M`A60`A.@WMJM`0]^`170`AG@W*],'M(JL.SUGW53`@7@3*;CL>,WGA^KN:0]
MVAP-:T0U`GO%;OTL!)`8J-NXXMY(3`)6-.;(A02@33$`3@_4`,IU.+(8`B'^
ME4ZF.B!PY(3X`.:JMP7L3CX.Y!`K!#B``3B0`1G0`BB``AI0`QR0`2C0`AW0
M`5R>`1Q0`P=NQR?0`4)@`3EP`=Z\Y4*0`3+``A%@U#RP`3+0Y31`T-5MX4+`
M`ALP`P=>`1C`U1%0U7J=UW:<`4S-`Q@P`QR0U":0UP/M'QO>GQ_[3.X5L27N
MG]3D7KN:-/PJ!%D39A3^-:>E&>,D0%$Q@&,+<+#6^P&_F./U*9J0)H0@K@,_
MNU#KN0!6PWJ*<TO#OF=/3EZB:6&\#I]$<`(88`*&;@$XP`+V?>47D-:!C0,:
M$.T%;0)NO@,7$.=SCM6"S0(0,`-"L-4:H.X;H`&8?N`\0.@S0-#>/0,RT`*G
M?.E"`-B1/NF5WNCSK@'\H3*0S=G`)9_QZ%X"=/"2W>DO=.I$\.G^^@('(,\R
MM)+E,]&75XFN!S>HPP`)7S1_@ZN#"P(&5FU34W+_1:ZHQMMP\X;D6I1E!=F3
M6#45.T%SD_(/F[(%/0,1,-@5P`%-+0%@K0$6\.8$CP+1G0/J#MX6[MP6<-C^
M$M`")E#A%3X!5;T#$$#0UJWN.\#?+2`!+#`#%%`#'7`!2.WF@YW@*N#E*E#U
M)J#=&6#I>;T"7A]T^P$_"AU8[I/1FBPXN?/`?E\TNCPZMB,$+^##^/M,$YA"
MJ`/X5"-BOL,WPN@"\2H">G9?Z;7"+=PVRB57".``^.H[)/QQ7!M%+69>[E/#
MT,3"(^`""*S))V#4*M`"0H#86:W??ZW?-9#7<,T#;7X"SLW6IXSW&U#63&W6
M=5[79^O\/,#M=7^V92[\B<[F56WH'6#'R._-*6#4+<#4-.#\AY\H?;X"*6#6
M;Z_^9@W@*+#@[P_@"ZX"@:W578[^Z7_5Z`__5^W^Y1)P`D"@0J%6J)21M1*F
M5L6FDGA4-8=3*%2U%*IV/.\7'!:/R67S&9U6K]EM]QL>E\_I=?L=GS_KW/RY
MO\X/<*]L<'#LD"?1;&='IQ$R4G*RJXF'$K-K(^62,B<3-%12C[34]!0U5765
MM=7U%396KTNVUO86-U=WE[?7]Q<8F!9L.-CX&#E9>9FYV?FYK!AZFKK:^AH[
M6WN;N]O[&SQ<?)R\W/P</5U]G;W=_1UML3`>3'[-/E`.G\Q>.E%:T3P]^P+2
M693HT$$V!,,P5..PGL"!<2`V1&2*8$56&M-PO`@/9$B1(TF65.,"94J5)6)X
MT:$2)LHO+V*J?/&EILK^EHIRIIS9T\5-+T!9>KD!U,7/G"5@X.Q9E"=0I3F;
M#@6Z\Z54+S1["N6!%"M2/S"`5OUZU272+V27F@6;5BL/KCF]OHW:<VK-NB5Z
MAHT[MZ;;ISMC\,7KA6U.&UYL&,YYP^I2OX=YP'`<4Z@-HGX*2X;;<['<IW6!
M<E9[5_&J&P(`M`80P#7L!D-;PWY=&X``/P=<W_9]P.6`WK9O,]@:&W=KW5YX
M]ZX-&[@BULE[S_[J&SF``9!Y-"?^V^5TZJVMNW!^&_9R'@:R$S=@5#SZV^63
MVT[OA[U]Y-%7.]=/WS?]U&.O/M?>D\X_W.C[CKCMF,L./`0A)(^VX7`;L#W^
M`\-+<+X*L;--O>8*!"`Z'82SL,/K(+S/"P(#U%#"#*UC`#OL'.QN0MA"\`*$
M%[%+JK_O%/2PP`'PJQ&WZ$*H\;ND>*"1N/\\C/*V'=?C$+H-483-R0:0O$T`
MR,P;K\J-=#@3S30!T>$&-<]L\PLTVW1S33?G/#-.-M6<,T\Z^73I33H!N5//
M-/OTL\XT"1U44#Q=(G310Q7]4Y%%`XUS3DL3+53-0RW%5-%.`0W434GE=%21
M/4\U-=)1-07U5$-'Y5365#5-]%987YV55%3M%#756&L5E-)?V^3.J%Z';=17
M9?4TM=<O;FU66#0E;3782:U]]-<Z%[WSVC1#,XG^W'+-/1?==-5=E]UVW7T7
MWGCEG9?>>NV]%]]\]=V7WW[]_1?@@`4>F.""#3X8X8057ICAAAU^&.*()9Z8
MXHHMOACCC#7>F.../?X8Y)!%'IGDDDT^&>6455Z9Y99=_B,BB0KB9^:/^(%(
M'GQTKMF,G'ON>9^=X_QY:)EW%OKF>VB660Q4Z;$9ZJ9YMLAHHEVR>NJ(D$8$
MYZ6]OL@AGYEN*&BLMS[[YZU?7IOME%U`P(`#Y)Z;[KKMOAOOO/7>N^ZX^?X;
M\+O]#ISPP@T_'/'$`Q]<<<49;QSRR"6?'/#'*:_\\LPUW[QO!CRBB`<1SAN=
M]-)-/QWUU%5?G?7677_^'?;899^=]MIMOQWWW'7?G??>??\]]@&\4H4$UPAH
M@('DE5^>^>:=?Q[ZZ*6?GOKJK;\>^^RUWY[[[KW_'OSPQ1^?_/+-/Q_]]-6W
M#8%6%&A-@<_;GI]^7FP@L`356"O@:D<%*?I_:[I:0?XW-$,,,(`Q$V!`%GA`
M!/8/@`\D(`0E:$`%/M"!#IP@`R.XP05Z<&8%%*'6(CA"$';0A"'$H`4W",(&
M6N2%+N2@"B7(AQ$6L&8QM"$**SC#&E*P@@GLH0YI:,(;=I"%/_1A"XL(1",.
ML(D^?&(.3QB0)0'`2JGHSX'JUT4O*H,/8\HB*G3`&BY^$8UI]$49L9BU/&S^
M48UQE",N^@,"_0'@C'/4XQZUR)HQG@*.?!3D(`?BQU6P,8^$5.0BV\#&'<EO
M#8%DY"0I>88ZJ@8VB:SD)BO9GS^:0I*<%"4E'7E(,XX2E9.\)"35$,I4OG*/
MI52%*V%92S7*LH]XM.4NX^A)4^J2E\'T(BY1T1_^"1.9\_,E*]-`RV3&@UK^
MH]JLM(8G_VT*A];4)@,-@:Q4A5!6#=R6-Q$B$&0UZYEP6&8J$)G.-3A`.784
M'6Q@8P,&+``,"\!G0."9R:9<T34Q\``!SD0`!WR!-P(PY`"<I$\>(*`W"1A!
M;SSP!7B*@)_HB0$,Y#."$1RSC#:`IT(!X(`8.`C^!+9Q`!]$A\?A!:0`.PI`
M19^$3QN\3SLD<.="6&/'69YRIV>`9PA@X"4;A&``9*$)#Q2@@&\VM2`*.(!E
M#C``'H!@`#%X`4WX,(`'/,"J3AE``URP&``X":K'LP%-;(#5C8JN*3HH@`':
MQP>ITJ0!!#!/4);Z@;#J```OT`P"#E#6%P"`!Q/U``QZ1`(;8-&>80T#`3[`
M`RXQ-0$/)0`)8(``(P6U(X9413M!6P8"9#$I?K7!1EL"U2^XUJY.500`1B`"
M`:PV!J%QP0`&D+_)5E81`2!J#!#@U`$XX`8P:(IJ;3#1II!@LUGU@FM+((`2
M!.`%,=@H#SY``*,$`*W^LG5!`)BZSZ_H@*,)<('3OD``.PZ@`)E-`#[!:Q0G
ME=8,OOPI,/';D/I>#:"Z3(!L8QM5IW95!!.%$0\(<,PP#`"X;'2-<0K0&X^Z
M9@`C8(Y3#>H%&A6```!8['"NZET>W."LTQ4O8BE;,Q((1P`^?;`=`0!=$MPS
M!@"`##.#J5]V`K6_]:BQ2W:$55LQ]<`JOIIK>3``$8C`JL_BP0,,4`":@J'%
ML_7M@!E<T1M`QL@IA8P-`F"`!L#7"PLX[0-V9!X;O(F[)M;!?UUK'AX4X`%?
M$(%V%P.#!P#`MUBN+`!@((*X,2#'H;&!"'A<RU(VNF=`#O(7$D"`EBQ)!R'^
MD+-=,\LF)#]5MJ+3`0B\"PB.HH30O_UN>)M<63R1FCG`0>H"YLM0'G`9)P'@
M#A]*0-LI`V`G=4:L!U*\UQ[%-0!V]*9[>9#B]\UF``F`#`/^.NDP^!@5-I"T
MM6W@'8SVB)X`$.EK8!,#+P6@W.=&][?)W1H7&""SMS9Q>R.<8LS>N=T),+)<
MSIH`X_#!``?ELA_,$^X=O0\V%2WP=?BP@-ODN=NN<2H(',Q@&B?EL,;9;6ML
MS61K(TC&9-RVM5]2`D4;I@0ET$%C^*)REJ=\Y2T_N0M27H(;V-PE*@=#67$R
MEI:\H.5,T0Q.R+)C'@Q=N?6@.<U-OA6^@`$&89G^"0EV,I02",4%T1G*8ERP
M8Q>$!>>5,<O'B0G(D7^<7>4D0:#1+@=LGZ*=D!:F!L<&!X9\;H=M#P8;[2AW
M,CA3[X%/V-M-H6W^MMUI">E(T0"5)T)\X<V,ESPB(N_XAT`1\U'SU=?03OA2
MD!;QO/6FW7D0`O[Y`:+YBX$`/FN&$N3Y!@L8>QMLD``#Z)0/Q`9``A;S>C=^
MP0!]_\J-R!#\@AA?\/$0;2XU&601$(``&*T,"5X`@CY3W_I>",%B1G"3&'S@
M`XOI+AC88YP/!&``BR$!"`0!`IW&H``%T"FC45*"$(SE`S$0P;B.#@(-\\`#
M6B]T`.U^$D`'&DSU/N#^_[Q`!+(/PJX*!EX@`!C++$K@`ZJBQ6S@`@O`U9X,
M,6H+HUZ/T?2.[W[O#N;L\#XN`1R@`>)M22KL/5Z01&8K*0:`_40L`?AG_+Z@
M`!B`?PZ`VGB@`0(`^FS`!@:```+``8H'`)R*T+RD_(YN``0`HNZKUX3C`$XJ
M`.*'`0&@`6*`I5IC`<Q#.`[D`%A/QTY+=-9J]P+@MGC`X83CO2K+``*@PG;$
M`'A+UEYC`;I+!`Y`MCIO^8KI[/J+HUZ`HY9+`'B@>*YJ$1MQSI*"V9KBSZZJ
MVMQ+`40``49``"0P*0S@`3R`?\PC]C(+Q>P).!S`NQH`.(KG)OB`L*[#!9#^
M*@S.#P`VZ][DYCI*X,44X0-N(&Z2ZCJ,D-`>:T?.K,E"H`3"2KBNJTT"@`1L
MRPOBKZS\3I0\CQ0`#[\^``#T"0`JRZ^NPQ+%$;!JL+(6P``8@+QVT`L&(`0>
M``'&T+IVS_9`P`$$0`%LSP86P*E0+`9HC;NL"JI0[+ZRS,F@#.K$Q.'@D,-\
M*OH0$OA:H[+,XTP(#09T31RC;P3"RLDF*A\+8!;#"@8J[!M)<!#-+@4GC;#R
M\0#:9_SLS,@H$K`8C;9$@+Q@<MZ:3`2*AZ@F4`"2(BE$\<1N(A]/#-@8(+/&
M[P'X9TGBBJFLJGA@@!8I[;,XZA_E"RK/R@7"Q)[^;(`#>X0-*Q(&`"O/*HW!
M0F`KT8NVMI+KXHPQ6L)+K'&3L+&04K*_8F`"$0,`1LVJ8+(O]Y*I`*#"]F\+
M$R``,DVR+*[9E`NQN#$W\H=`@.//VN<HD]*J@+$)_ZLR3L2IPG$M3@0`\FPR
M3TH,TXSCY*JR"D`!.*HB@[(V-.P!$T`PV\CA;O$&]NT#!.`!#L"\R,Z0Y/+:
M"K&TM*H@RNHH>.+HDN(E<LX&8&`Q]&^MC/"^OH+KSF2]IB\TLB+G@%('B!/I
M.L/><JXJAJX>4JXJ=.#IT'-X:"Z,^JSKG.0ZL7,K%D,'',LYK8X/8N"^"FTZ
M?;.-]JOYDF^-$@O]FE#^0+%AG0C1+@_T\4YP\L1@Z:)F(4@!.-.)+M](.!D4
M&"!);304(W[SQQ;40QLT9J3&1#-OFGC&$!2B:>BN'NK$\D:TF4X2E#)41B/"
MH>3``PY$P0(1ZLIP,8C-'=O+IW3ORDZLPJ;J1[LQ2'/CCTSD1D3'.)X$`*3O
M1B/M/T/T/2JTM*"J^WC@Z;K/HR#O`UYJHMZ#HSY@MPZJ'@*``6"@)9LM!)8$
M,MYG1W(LP5(-%K,0JD*`*+,PV>243L'@^0I`^GJ$`&[`!D),^*[T[VBT%+31
M49?,N"J+RRJLPNSHNI)0QKRRRG@@!GP*U^(D^W;T^=HQP0C`!A7AS48@+[W^
M@``JZKJZ8T<`#0`/X%05,R!6L`6]X`/HZLG@!K@F%1%`--MLE%C3JJ+2ZJ``
ML3N,`ZO\`,QR\L]>Z@LFJ@3VC=D8;%AIQ`"_X`71;=?JRP,.8"I;+#\#Z["6
M*_@<P`%`X`".E%C!($'A#EEE%+TXK=5NK5(_+?X2(`$.8!#&+_<"BPPF:D=V
MT"`KJSD!KC==P`-"`"-ID+O,U<30E;L`X)Y*\@-`4FY>@`/GM5BS5$$#U%'W
M:CWPB0`HS+@JBLOFZ^BJSE=-C!N5T\7^L]>T*P!VHL56[Q/-2P&6M:[:<38,
MP`/,0V?-8B4#%C@ZMLF`(\M$EEY[ZI`R26K#X,_^!',Q_BS$C",VG>H%3F1*
M`V+\\%([2FKU`*'"L!`.6R/>N-4+LK8`Z+/T6H,`%B-D.?$U;J(V`Q$OJX(U
MC:RX]O5JXP12L_%>\=4%'.L+6&*[>"[I%($$^C,YDY/FJ$ZNLA,EU@X^=6[K
M<()QP2`&0I?GCFX$JHX]OT`_=TXZQ8XZ"]=P218E319V\^`%K+1VF<'P/NGS
M$G=>&XU+33!WZV"5F&]XP2%X1[3L:E1$XRB<PJ#RPB8.QD5LQF#'J!?R3K1$
M*4@A\@Z:A)=$*>]%!R$[E09\%6EY(]5WZ\=+IA!MB4\(=6JT%D!FV6"W&-$Z
MZD$!X)+_AF:W`&$!QM;^#!I@,>[)!"_2-A:@?T]"`,7@!>BJ*OJ)1.)J-=?`
M!O(7EBX4#T"/C\B"L`QK`HG*"SCKZ,"OZG1@ST"@<Y4QL;(OTQ;C=D>@*K[4
M"T:`ZSP`!+SI-CU`*%#X_L01!OX/!M14$43@!OXL_$+'2DM@)S$RMES`I[9/
M^T+CSY9U`5[@A^4BB0/"/*ZNU_IN_13-`Y(8!DB@ML!4!'K-FX;820#V:M"1
MJL**_NPO?UY@BQ,KB15``$;@3$)@!!DQ6S>*S48OE@Y7#R0UCH0-HM*OR=C/
MJQQ`&(,+"6T52AQ`-H7C$XV+!3.+S)P$Q<C"'17````A'?V*!,H(W8SDL,;^
M$5%+$M#6]@42@/6`PSQ4=6*I-`ICE1$9^0!?([)X`UJ)4#/-PSEA8(^O!),?
MZP%L[ZI>0P%J>0!NN4>$PP',0P!F8^'FK%9C`)Y$;**2,'\.()5=53"U$/WP
M5CL6H`!`0`$*('E!IEY!R6H'B0]PS<T>2Q+S=/^H-P`PR@&`0ZH2*\7B!E21
MD'](8!$U+4Z`;0A-;EP.ZP%6BP?ND4UF*L=*3"=++W\L$K$X\1E)(`%F0]1>
M"S@NT@9V]$G:AS;LZCU4L9&?1.L.JS=LH'@^$0'0Z]=*C[RZ0Z0!LQV-`]/X
M$0R@JJL&+088(#J&E-9Z40<JRL@HVD0.ZGC@,`#^'%J1XEE]FS>15XP/4NP!
M:U-@72+%PK$H=Q#6`'#(YNQ7L7FV7D`'(,H+P<`#8,-(A)JI$*TQO2L\`8LQ
MZS8?;\\`)A(P]?4&)C#'.!&CPDC'/DTH`P`!`M:\W&S:$$"AKXI_&,``%H"\
MM'4B#],H4@RPCKK3%DXQ*_/H!.```K8!SMI7!5*VH.H!;0"N,9B/2G"TUI=^
M%DXFZVM5Q](\?`JP9H,!VL=+AVP`P'8`#H"@`!#ZJJZPDV(LE^2^P!`O&V!)
M<@L`0."B88W9/`"C.'J7V^0F_$T(?9I*OT(`6FNN=BX`%J.LO6L2QV6\_*`!
M#,`\=&H`&,`FQ?&LR3O^+MLKL_Y,!^Q:R0BT)4Q;,<>RNE;.<XR,V+1+Q/95
MHJ6;D-(7<;5:C82-8FWP!@8@@`E`*`H[FK&+7TU3.YIB9=?#J7),I3^;)JY9
MJK)3;B!9PTCR/?R20'6DV02K-5Z`1FZQ.5/9L]-L`-@CSQ@Q-`N"H\0-(`,P
M=-"M)!4;3)("IY)J]?)1U\[Z!00`_88\QY-\5*ET.AX)V`#RRRNKRG7@FV.@
M.0P`,EJ,!`*@!=V<D#3X#N#HG3\F<I<33-M3$6KKG,#+!0#7+%Z`!'9,YQKC
MQ`)UY_)S)\4@&N7;MVZN<H^.A,%43'!N<;G#,HYS)K0KT`ZK/PW==<ES=&7^
M%CWYXM+EXI018\\$:ZW6PN3ZDZ9W(G(1(^5"M\^WBS%D&"<\E^9X(M!*5__D
MM\X-&4,Q')7*\0V6A,Z3@0^\Q$<=]'COP5CM5=E1J>O>@*;Q3A8L8^\H]$%1
MR<[M`)&KW17R'-WY@6H!=-W?G1W*G7AQ&][K_1HLO"YIU][W/1N*MV3Y'>"1
M%]DWF-X#WN"1`=^3?4L/GN&M0=[IX-P;_F34'5\2GN"S/?`H7N)]`:LO7-_O
MX`-26^0?X(SES@/?:8&_Q@\NF%!Q=WLM0@1X5T)3=`P<8(%'+1X08/;B@(C3
MS$J/MFF0>@5WK1[LR`7R[.3#=PS\6`P68`$C8@3^DH*`:7X--!$!$(!RO<`#
MS`L&#&#G=33KV8#I^^`KY+4,'$#^KC4I;)[J808,V&^B4Q[JK944II[CKYUY
M/]X.5JO;ODX'/L#L]0$`%:Z5YD"VK\8#"+\-$E\UQN#PSP!>:?L-^&`$IC3K
M]NGQP>!^$.VD[U8,#K\$\(F])G_PPX`$`%$>%D"G$$#NE09>M>OY9H\/:"0T
MN)'NXP!.=#3PU2#TTX#-;0!95/^A6I\4'I_UTT#X4^'XUZC=C=<5EO\#_.T`
M@*L$`E9>V7ZB$\L#D!JX0KX!5OM6$R!_;@`I;1X=I_X!("/DDX>/'>!7$0U,
M`_8#PB@!$.`#?#3Z61'^N,I5_$\,*8T#"#R'1(GW:30.'][#QC.ZGCS7`7&(
MNAZ.@X/W>CP,#F>,P=7QNB./><D`+&P.PP(FE5X/-EWWZ7GI)-5Y+2@8C#RY
M>$B]*#PUC#1@+=P],33<?9#8)"`8B/"\,8Q0BB`Z?!@PQ-R)5"4X/8`@)$3Q
M@!P@+3VA*9"2\,BEQKD$%+@D-"0HV'X<,/.(?+2E.4'QH"V$2(T@5J8A@&`O
M(!2Y(B`XD98W/3G<&`TYB5A%?;Q\1QO0PLLB0.MPINM."'3;;I@QL(A'C`4*
M>93(=>:."P4(EC0(P``-#Q("")10H`R@$"+1CA08$>*9M4KGTO$84064%`;^
M`1PA<$`K"HP%N>`]*?'11<@#)3Q8>Q=#0:Z6/!`>>)@ES#N&;6#ERZIU*U>N
M.@0`V-9U;-<;8`V033L6YJT`,&PL*&'C`*L&"Y^P/:`CQ(`7-Q*(`)'@QHL!
M(D)@BJ%'1X`1.@X@\O"`A]X/@U\$V!8`Q-YT='DTX$S`A8T&!>Z`"."7&0A,
M<_<TYN$AL5Z^?A.`^+!$!]M0B&1."4""#P,8PG4\<%1`!!]'M0?`T)$@1(S3
M"Q:1JD2%QX(E"1#!.,!=7`D$P6,@>R+KS@$[!F*$F.S@KA0$K#BJ7P*C@([P
M.DA0\L`2F^TEWA,V0/,``SP4P(`-+ISF`2PP#+#^RX%H@4")#146R,-T#"YP
M0WFR):"#"P3H``)TG(R@&S:]N0!`+D5DQ4"&$"%1@@X*X/,`)1\0L`=;"*2H
M@`Y"D*#'"`/HP``PE2`8A8(,.@@AB3=0*`X:))0HG0LD-*##8U$<8H,!'\0`
M@&,/W!7#:'^A^=X='Q80XHA',/0<#"\(0(D#"^(73((.P&"`#G_A\\0+<A(0
M(C*\%0$"H$]\"*20UJ1CDJ2MA'F#`3`8-]R?#(9P`P@"`*66JJM*8598K++J
M*EJPTLJ6!PMY$`(]*J5R1UY&X/H!-+()F^L(N/%@'@],B<!*LC<@8(L'2R@+
MEV`J>:!`:P<JZT>P"AC^BZR!2H0P`@*'+80,#(Z`,-D=1QT@7@F4O"C"@O4F
MP(L!?P'KQQ)H>4!`"(GRDL8V)>3KBFQ=%!!"N0:\X`*]/$K'$1JAQ8!61#P8
M8(NOSFIG&8HVF`<@L<ER>X<.(SS08++6P(*`';(MA(8(B95(<LH+`*,'7B3;
MTH##N(+`R2WN2@%#`P@,P%\^"Y"R5VO`K.R`R[?^_#-6@CYIAY/Y5.WRD-!*
MNT@V#8AP,R4P9`B=Q`?:,&]0E*"!IQ?I=/L$SR]K_4&YY\:7M=S?K-QRF`,X
M,-P=,2C+E@*NC`"""`4XD0TPTV:]+.224[YXVS"\W5$#+W3;&ZVG;^6J6*C^
MC_45`+.RKA9;'^"JJQ(.//!DYN;1[N\"SDXKDA9(Z?P$"`1H]/+6F!O8$"X>
M.."`"[T'DS?UTR[0P/`V0(N7]O,%M)#.L##@,6@+Y%XRW<N&,*D"[6.C?+\G
M&RB"`0(8B$<5"'3^J0+<%P!ZJ(`(O?Q6@GM)05*2P8O)OO$UCHS`!2%(@`/*
MPSWQD,`16#-0\9X@$K]1PF?*LP;6:E(`=`S`!;PYD'CV-B0$D1!=WO*0#<HG
M!1M8B#N[D4(VOD""XC0`&!\,`25*^$*L9(-&3HA+_.XPQ!!:0P_+,ULHP(4[
MT.4$0"YXFY@(^`23H0%S@NJ@WH!A'[Q`ZWL>"%_^UL!8B2<28@`"H%'U,O<X
MA42/)GJ+S$(<9S\!ZA$B65S`%NE%`NFMSW2Q6R0VP+*-0#&R$K**)%EL53L7
M*,M$'PL&`>;G`4F)@WT,$,M;C!:**-R`/R72EM[$42U?Y`L;,0!.1V85QEU\
MD@$T*:6R`/.$Z(#`$;?(UP<6$,N4041CLSJ@"Y89A\Y9B4C76X)X/.`-H\1O
M@E)P`"8>D!-L?"H17N1!3\H!I4XDZ@%<R,<("`"4#<$`*S;@C\[D)B#*(+,C
M!:3$D'2P@%`J8(>%@F")JF4>%V)J1Z&\0@@6TCL/&+,2`MMF(*7`C!<<@!*$
MK,@3A$4SO+#"!BCZ6D/^!OBR('ZC@1[M)RN7M4,MP.UK'"--+'43.KFA@9;!
M7.$=$(J7'>V2C7QKX!U4ZJ![W0B9;"&"7A*!G[T9,:0=:^H4T&"Y)T`L=#],
MI1-$FBI*LDYU8,W*),>Z%4O.,`$%:``!=!<-!#1@`9V<)F60(+`-*:`3=>S(
M`!J@@,DL!@$,>$,('I,R!30H)6D020+R]U%BX56OQ2M,7LT#@K4FH$3D?!5^
M.L$`IDR!`(/]WXE&RPH'4/``H!`/70O@@!<T:@$(Y([NC*:#%#Z!+V98$%&C
MD@_$,@(`11B!6V^1BP4,8!MS8(!#6%&`!V0'<P:]H0$4P``$\!-3W!,L`PK^
M8"$Q>A!A*9O#"[:&`"P9P*_Y*B'68/"JQ1U@M(ZX00YIRX,!+$(!1:CN=8NX
M$'K$M9/-=,!$TYM>^WX`/V:R+G;Y]BQH7:(`H7S*"1=`.1&(MKNG2("%QTG4
M98D$8H8MV!SBB2DL#:"R\SOC#VT0R`7WESOIC18/U^K@\WJ@K]Z]@]5L`(*%
M%"3`R-%Q#B<WV`*40*N4"+*%G6)66+ENPD_FQ5FFG!6/Q<!9-K!&"40P,XHT
MRPY;?D(,NBH"TK#B!MW@B,=@$`(:X4,N)(A![PAF"PE^N<LV(%@PM)SF;L!#
M!P2S`:`9$C?F2&%KK1H!<^QP0/BPHL4@`-D+J"/^3AOXV0N(B($(BJM"BJ#!
M*9Q^$J:E`-X[O(#/<F'(EZ7`Z1%8XS\AV#(K7@!K.Y39"U(PWZNGH.M?AOK,
MI5:44UX0@R_C0P=AYDAT@G'F`SDKUS0D'*-II,D[O&4*K(`!/'H=A3$G@CK-
MOH$(K$U<-&0;38OKM*\!`>RG"!MDV"!!LX(B`K_,S`7UQM(3^/TN$5C#?-A8
MMJ*L6N@LO_L&9:8/0TQ1U8[4&]N@:#8YT?""9]^!W+1FA+C17>YOX!E+_AYV
MI6U`<2O'RI$H[W>55QY)2'8%YOD8;-P,X&279\6C7/GPX'`^EHS)V^="7Z3.
MAYZ661L]Z0>2LM*;[G/^UZW.RJZ#G=,7*7.RE(;#K7;ZCN@(-G)J*1%A3SK,
M/]`'UEV]ZJM*>]>WDO:FO[U@:O_ZW.ON=+&NO*QVY^'>^^[RN,?<[X(?O-P)
M;_C#"Q[J39RR#5J.^+\_/O*2GSSE*V_YRV=%\2N?^N*M#()4O;TT8:H$I^D>
M-X8(7&6J3PO@Z=Z557ME+)PA7.;)FL-`75W!2.`(>L@)BM9_'3\V^[+,N_B4
MVU<"][2?_5A(`(Q-_Q[DX%)]"2+E>M9#,OL\S):\TUYZY1^H",[OB,Q[#X)$
M`7_UZF^5E#]/^]H;[ZMLK[T+'%T$[5>"N$VTV/4%+];TTXK>K9PB?5TQG=S^
M%ZU//I@,U@!@U1$@K#S@JO#9JDR#NWW4ART2$Y%%?[!.!'[#ELV%/F7%=6P=
M_1A=>;S`S64%!E:"R919]^1#>WW56)&1!W*%#:8%5#&<5H`;YF6<RFV>XPV@
M$T!4'91>-,!#ET6%"QPA#$00O1R(`\B6$R@``<R!8KW`8.&:I`#<8;Q/(EQ"
M%(1`O@%#"`34#$;A`L1!;FG+&!("`^`##'CA-HB``/Q/2(Q!)1"1+_B>&8I%
M0"@`EX#,")1``Q1'3$`4*XA`0'G!0G":LK'A&K%A@JE,MH""F1P`J1D`DE7$
M!-&$"PR6^9A*OXD#(1KBS"RBO0!#%MH0G>E2(##^$21&0QMFF4I\H1<,%OH)
M"Y<XF1O.4D>9R`M\@`!X0`:982`51@+((5"(@W2]"PED"XW,2QX6S12@TA+(
MP=ZDR'Q@FQ8N"P$@8R[ZWB^1@,2(@"_AXB$J0')MD0<$0!>X'P]0QR:20`G8
M`0QXHSQ.HPH>B1I&00E`HWY%X2@($Z6TCP/<1[:(10D44Q0HI`>1@@/T!TWL
M!7[,"R-&P\S0&P'016L(BS0N0!Z:"BK47T5<@@T!2![JDTH.GN(U8,J]CL\1
MB82X@+FDQPW@EM`H0]P8DB1`H8<T``Q("!-<02&87$J,0`$<6UB@1P!\0$4T
M@0$`I!Z(0!\P`QO``&K^Y4,R"&6^.(!^>0``P$#&U"-=&,<'A$03$$#D(,`+
M@("A2($K))E28@9:*D`7Y$0).,``I(J&M5,-%0`P?*4+*$.R(`(X&M:?="5H
M%,<#').'2,]=@MB7*<#_O```>$!%`)Q41L2@58MX^"7E)`=#ND7&`.1[N->9
M0085.(9X#&98'IM3IJ695-\!X`,%Z>4`M`0:.(`XO&4=V11(Q(@'A,0C!0,7
M<$(4&0$UH89AE(`!.)]47A9W%(%L081SG!D"($(`/(#'O`!2%@`,I(+'-!-`
M4HY6-4":V.4#F"8)*&4JQ,"TG(@9:9<Q^1,3@B<^&$`"D$`JP)QCUN1I\,7^
MFQT"@X!`!E%=`1B%1R6`!^`C/`H`K/W5@S)((+YE#`Q&1Q1D,]T;`FS#WH3"
M.6)""(0%"<C,"$BGH>@``+#GM.P%"81``!!:M"@,/;@E7`X>WJ&<`*)<.NC`
MGCT`BOR/3'A`*O5+`QW2"R3@#3R(&8@@UG2''[R6,(7$%VD/\;"!=)!3OC``
M+!B?)#4ID73.LKS`?&S9;,03`E*&LH7G#/XHVQ``Z`C3#V6,%-A<_$"-'V@!
M(G#5$US!4G`C)^@`Q+Q%>SAF#'SI=@3#:5#/#&70%^%.$]@`1,5/\>A,GG*'
MN<!,5F+IZ#B"2,U:J)7(G2[+%L72(8'!F08E[)#^ZJXY`CFPS8*XJ+Q0*;TD
MT8TMYXC531\@#']ZD"E,1F;Y4S?$00R8Z`TX5BC@TFO]Y(GH"!H,#IBDZ7&6
M`$C<P)84$7/BZ@=,A@)PJA\LR!DY6,:97)`:@;L8BS"%!WLXRW<DP+%]Y[E.
M03KLB:'(C-Z(`'11)P\I7%(N@082$B3(!KH&TY/\$SXM)QZXTIS!1;F$YY<F
M'A#NJ!"BG%Y$1(.*!PCT9HO<")N(H.B$CO$,@3=I*!-,!HB"22/,S1.,`.Y4
M5V9M@P+$P(]9`EA@PC<X0P(XILYD@PML0665XYSR$RM\P```@&;]$CIX4\3T
MI)+&#TQ<54=$#R+8EGW^+0``=-5@%$!>+8,3,(``!``F0&LB]0M'+%`#M6P8
M<*T>6>I!/<DH.4(O^.S+\B='3<$!!,``E,!?\"QW%!++NBS0<M&XUH<TI$T@
MFB"2)J!/X9,SFIHC9A;P4%/D@`!P7%9E?0`9V9?HJ.P=).7K\*25.BT:G!<)
M$```G*<&)5CC*">WDBE*B>!G$.X7#8$'H`7U/,#0D%G>.$X[&5,R]$NU_BXF
M+`\(Z"5/\8)%Q-42(*[?"BQ[%9/DHLQ';<@NT,(RF$2.`8"1$)Z.6AF/6ADL
MO"M6;5EEWL#2%$'O-!!B]$2E*LNZ+N`B,("[:('3?BRJUHP3A,!7LD((V$+^
MQT#)^YJ'4E+*MSZ%AX60B7@#(T8MCZ#G/.E+2VB#.U0EU1`PQX#*`<"4H)+J
M/"2*5";"K%3'_#CJO>`O+[3$9+40C8R"[,J,QV*##L@-?=%NQ5QP+=CO"<?P
MHO"""!%$.##.1IC@X!Q03]$G-C`JM=S!;#Q!57Z'!XF#3C@?`DQ&4CU%!UT,
M_79G`KJ9>GAJ;@6ELF2,!/G!%S-/U@QJO_`(&'CQC=V<N-YN[7#)+SE6[W8+
MT2Z"HC($923*A]PE%<EK&N07C;0E2HG1)_&AAS"'LC"/'B$`J4'$DV!DQ'(6
MRG'>2\**7A1"^PP`*S#7+<P*UG""W[A6R`ZJ`TS^$%I`B`O@PEAZUV6%[OUN
M1%^E0A'<P-&R[`"`0##9@%N=\@2=QK'<C%AN2&A`3+12@@%T)P%`ES)*@3KM
MKP!L$94Z@H_8BVZ:4&Y0@DQYDPBH(644@5$@JVP0@*0X`@E4B&"DBG69RV24
M$!K@0@Q$ZRPW0"WWE`.<HW48[)><RP-(<S&_)=/J#638Q3B;RS"CQYS2\UL6
M@34S@&[JB,K@E@&(!>8LA^(6S-XX]`#DJF.IB-_\#PE\0AB@@0LPR6U%P:!.
MAVJ-,[9)V/$\R$]R3"#RX46$@&O%0`!,"PC3P0@$(@R,1N](F&PLP#4;%US(
MQ4N'IQM'M$5IPT-[TB+^A.0$U7%".<0$84()&<($=<%^GF,?O(&\)65#X5<T
M`,8#!$`,?*50?1*$Y*MX%,\GM4R+($4)X)<Z;=D`/,`YII[=_=_$QB3..<8-
MS,86Q:&8W9DMV`";$$4O+T[TP,"J?4`44VVJ,@2I/8FQ,@3TT!&F3H'V[,'9
MD5GTR#.B$B8H`L.D-D`1:/9E?S:31H_`M<8(H(=CN[:RK38)]*4TY.&<24$A
M;D,73P$=0FH[3`'N!!UB/,D6J4SNV+9FQX`6>-WQ20\B^'9'1-HHE$!(S09K
MZTYK/!*?GC8#[&UF`T-TKW9<E@\PL&<E1#1I)$(4K$%KM_8764/[?(D7R/?^
M$GO`S<Q,F5(B-MR9Q1S![WG#'2QV.]3W@<P&J3&VG$6"M<V&-_A-Q,2$N]@+
M0(I)XC`A0UAV3'`$*+3W#15V_5FX-6*#V>5W7$*0S=1S?,=E:.24SUI(E0;*
MS13-D_P0(6Y94((.C+]`/5O5)]J:%FA!%)0IH8QV=QJ>Y@$VU?D@)84:D10>
M,&H%;V`!5;4.6($HZT5YY\$<EM\M)D_:T(71#GXYK92YU'DY:$1=FN<=6##=
MDW&>T34@VUG5^ZE%H&0/#[J>2`^!^0!?\05>)4C/^E7YE6^YHB<?6*4?H->"
MVS7Z@>RYGO>?'AHGWRVZI'.ZW.5>I\==VO%CH</^'ZFW8`&@8:*KNJ7W'_XU
MN<1^+\7"^:S3>N+5^JWC>JXO4N.]UY/K>M7QWZ\+^[`3>[&GN9-+G:Q/&:+Z
M&JN[7="9NK,C.O[I`+1/.LR!RN)HNJJTVMLU8%/CGVV'.NG-7U-O>^=A6S"D
M]`:N^K1CLMQE.WQGQ=[2ROP=R`=4%/B!C?!->JF35?=-NKQ;NE#>WZ[E1K(5
M7KS'FKK'#[\;^^FXRMA-&?A.&2QH;J>_BTQ#6205\=I]U-B>3A&_^PVJX.(4
M%]8]9E;@8#X8#0N>N]HM4//F@P_''JO$U8'7G8M(>I=O!06Y58[-QSI]`Y2Z
ME<L_/.H@^\0KNUE5JX/^>BMQ[AK4:]LNDU-FWH%I/(DT!-V7:,DNP\.>*4*B
M<#TV[#)'F$JID.+L[=E1X$,#0&?&A<`'>`,3XCN),^1=6$W6(\6[6,.#!$/9
MI\';GT3)(^(?2L/-'<6Z.`';IWVH.<M1,#>H].?CZX;^"LR6_($40*.)H9K4
M@WWF2P%?$!<<@GY'E+ZBE$`U:CTYS8P,-W'F"GC:F#[!,/Z\5_Y':>`7@7XM
M2,YO3S89,*0=0"/M6[U+P'YU&+>B%/]).`L3AH`X$#PYS=(',*G<]]OSA]H+
MU#X/'7ZR1/H-8/]O.^B^[L5703Y$E#-^V,\=?`)#U#WNVW+ECL""F,KL$<7^
M@?3UT:<.K"M]8*_<D@!!(Q9`?!(?WJ>H8/`6!H^BD/`02CPL@R#B(1@>PQ7+
M*QQ`L,/C8;BY!@W/`5D&Q=*/@\V&\#@*>@,U`QTW.`00AX&0,9X#!9"BQH0'
MA@2>DL"'`9"QA:VN+P,2'AT>#P\LCP^=@@<'`QLM+@2X,,9.,R:>!`>/@M%2
MGDJ/A0&=!@6E$)T#CX<_%P6G(X0`GA`"A[47$`*/!H2D`51D)20&!6*"F[$/
MN82F0H](K(_-$H`OA%%T<ZQ23QYB)&CPP8"+$@NPC&A""\R5``I$.&#@#E6_
M0Z1N^?H`SA2J!<!X-*C8C$P!8@U,>7-P@`>(``[^8#AX%*G!`G=(@GGQY<(&
M@00O-()H]HFG*"=0I*0C`$/$`$H%^!185L#!JS9OYG$*Q@N,B`1A;%A]%4.8
M`DTQ&(Q"(&U,)7<@W#"P,>:`F%+L,'U@$.X4#P4E=!C05J#!8$$WT.A@->K6
M8\B1)4^F7-GR9<HZ!`!8A-GS8\T`#'PF?0O!#5:E]NA`4+=++$XVV'P<0T)A
MB'`\1.3&<L`%#P=(DGA`@P7&:`2_@]=[`*-`*1@\'@C_T-PE#Q(-7B@<8\/L
MC9L\#F)!H",!%V&H2MF^9DDW[QC/R=QPA07."VDAFEQRSTB'4!V48.4W[\9P
M3K6[W(M!`1)F,RN[L4K^&2R)_3[PP(;U"KC!!I=><,^&!%P8A)0__BD@.E9L
M<.$Z]A"\)#<(<]N#'2P66$0_+$J0Q@"A$"B!A/UT'*P4`[C8$(8/3WL,A@R'
M`\RQ1HPTRS?RO%N/@)=4<N'#`Y@Q,CHL=@O3I9#&8(T=%SP8(3<Q%X@-%E-"
M$($[*K/[QC[B6.2.A[&$,JNZD1S`0AL;W!HAA`:`W).'`QDMX#5&6GLLL"Q(
M".$!P%YX0*4L/Q`.!)74<*8T4DLU]50S-^,*U<INV&PT5B_+8P\L!M*!``0,
M0."/M7B((3=5-")!FF!]Y:T1LQB0ZH`"/G!!H5):2R#9,@X(1+H``FBB@3+^
M=I6+N^RBT0@+$`S0M2'7I#6+-BR&99?63D1XU@G'PI6F&P2L7;0V:Q,(YZD`
M$@`3NR9*46`$7`]0&%MML=,.VD:<-`6$/0P(2P<.>7`CUP/.*QA2/BT!R(5Y
M+]DS8_8<CF$`CI6L<11\K96FHQLLB=D`NG*#88``#MK8`(5I9,3#`J1(`M,R
ML7B!@)[92E>Q7(T&M`1<=75IYY[%>#<<!KO+K91B?Z77V%1""`$52$>XJMX&
M2DXY3`$"M@'0!<0(%]I2&,CVMS$2TDA=1@3^A\\;\E6X@!)`P%2!%QQ@^X&$
M6\&B@$=CM?QRRUWE#'/);@A`-,XG.PU>$%FA,>_^4>"UL#:%^,)"Q$CK<I,1
M';$`L0NS9M=(18W3<8"3OL%]F!%QL5-(TM>2PV(ZUBE\_;HPF?C-1G(;@('8
M_<9EI&9V2K\"AGGZAOX\WC#^;;L'7+`>>I=6GY@!OD</9T7:>4->-M<.@,%M
MB&E-.;OB#*X3HW#=X&!`"RX4T':Y^9X(#D""\D$F*.1Q4M(NH8,8B.`Y"4B7
M#A00/R>5`'JE:*!\G*>QT=3-:[93Q7[H5R9X><!L:),4":X"/%"5S&\2^@T,
M'N`FD.!0.VYQ@7Y$4((!T.XZ-]`0!QFAP"Z,($2#6QWC&@`\M2UG<)B@5.B\
M^,7,;*8S8,2"YF!%QC'^[&,@MG,).&`0`FG`$%CJN<2L"C""7PFG2AK;0C1*
M`(,`B"`&5VQ$7=PP@FB00`>;T($#0K`S>07&;>NK2RE$]`(1*20/Y+F!CF"`
MQ%65H#5CP6-&`N<>%Q2`9"=:D1X(\`$8%(11V_L%#!;P*`,TX`8@R%YZ8N`!
M`;"&`>!S@`TV<0-'XL>7#@"`Q%2!DQ@\()@W&`\MP*>2+T1S`$)C`%W<8;P<
MG<P`,4B9WPXPS#X,#H:OC*5P_%"7G\"2`2`H7(U:4P)+>.&7*M%#I#X036O0
M#4H+N&<^GW8(@$K,"]=T0D&[<\<#(L&"PA!")"`:"3FF0@27VB,`59G*_8'^
M:U&YW.4#0*"05*[R-W*``0%>D"C`",HN'X@%NFYQ`.MMR24A4"4).$BW$NR!
M9+E<&2(/1H95HE&I9-3<&,D8FC,J=3<O0-L-T.:!!`CN`T*Q`=I&`"4=+$!0
M,*@$>L9PH1SYBQ.V(4IG/$`C?!ZA5EGUP'H4D!%N&(<38AT<;A;@`A#HX*VI
M8,=N'`E6OI(5`6:M#91T1*FPCG4!!"%%+U^4@,3)CA:NL9T#$!""5=B@`0E8
M`#L&0@5&(8$^GRT/"4:P$!+4;+&(E(X"=``>!)263YX%+6=-@8!B\B"OP@7>
M\N`'O+R*EK2^!8%0&$50F3)J$="!+@_H,X8'Y#;^.LI=0%U$4%Q?955.GWSM
M5AF1W05$!ZVFP*"_1"`"\MINM-U=GG898<OSD(MO_Y@'IAA55G)QU:LE*,%K
M35&7O#[V"H#5JW\(>I@]<$+!G<V(7'Q%WS)Z5CCK-1-6)S&&$/AK%"-XK85U
MM("-\B<2(J`.8Y?ZXEAI;E5,?16,;1R9%MV8<\'X3&"76K(MZ5C(GGF!BX=\
M9"0G6<E+CDQHG`I&,RZ9QZ29\F36LZ_*5-D_6>8R:+9LF2EKF1"2"8:6FVSE
MD0#E+F?^LIEN8>8WDPK.;?Y,E8,1@W6YV<M[AO.<>3SGS.Q9>X(^59G1[!E`
MASG03&9TG<6XU"@W&HW^OI5TI4\5@Q<`VM*;YG2G/?UI'3=UJ5"%L80$"&I&
M:UK'JD8UJUB]:#G#6M:<?C6A"\WF0;<:R4Z&]&8JIVM@!UO8PR9VL8U];,J(
MNM:EBK12B>*O!#1C!"ZVLZVMO9#?O%?/E='VLI/P&SB[0(_+HS0C&L0I*L=Y
M<#:(+G#*#9K.!#=6EM1CHH4[;D270MND0I*J1?#:=G?V'_YJBYFC<<Y_X($N
M8Q"W1N*@/#*#EP<C$(J\MPV9!1@8UY9)TWT-,+`OJ/O-\?:MH0,-@@*`5PEM
M,8L-GAR9?S/"XI#9M^W\V^6%./?B0U8V&DF]5!N\P`XN8-)?EEHFQB":79_^
MF>AC=IC&=P-D&5Z$UQXI`R_D6>YM8/;V8XI5F@880.*084S57]>SA:#"!@-C
M1`P(X!,%*(0!APG!=4*0CU2,TZ=Y?HS9QY;URI#`$5J'F'`!(!P;X%W3I#M5
M<GC,@.Y&\U%^0_-?=O)NA].13\<"\]@D'9JQ>['9+T;>!Q30`#.D50[618=*
MW(%P&TP'9]]IR0+,X@&^@<`#`WA[";CP+`.\5BTX???J/@""NQIX30?0^>"Z
M>=?4U3XZ[!F^$3BK`X6W00"VH&Y&4)_>,$5;*-$PY0<(NO:[@J`_@%&"`F!`
M59N/H0$1,8\#$O#!"Q_``4+3F'``^\N6>(!26)/^=&@"6](_=J`)2UB3Q>J_
M_-L4P2(*_#,%1\@]G%J.8&!``S.IMM@O-J(?W>"+U+N!2GB`KV(-1D`8)2"7
M#R"QR'#!S3,/&E&`&'`'2E`:UT"Z>E"8)M`;VVH7`5`E!;"_"72'"62$@^D:
M=B,*!O@3Y$.`U\*]>O@-!E`85-@Z4>(.2)`I=Y@BC8DV))@_:<"4$1!!'/("
M!]"XB4.`!"@Q(L@S*M&O!(B)E^C`UU&`X*.-/4`2(OR-X7L`=O@+\E,__EB]
M)""H-W($K2F!(+R"]O/`(>,UI?HY&$,>F("[$KB!`S`+0@HD0J!!P%B$`/B`
M&PB!T:@([`B'I*F;V0G^EH\:`%&*PH!+!510@$V,C_V!A1$8`+ZKD3\X(-%"
M`@@"IP(0@;G9)HTX/1TPQ5T`+Q<(`!?0`504)>S0Q;<+@YI9G`10C+>+A5\C
M`[HH@0(8"._Z&!$QBP+H+GQB#0+Z&)-IER8$@-AJ``=X@7&T@^-I1Q[(ADL8
MA,*)@7FA"JMJ)IRQ`7%T'CL($`YR@U5I$#S[!7!4$0UAA)-JA"L`@0%X`1!!
M`@#@@F`YEN[)C2KT@+Z@C!!P`&;H!,%XQS%`&+>X0[-0@!"(@7$*'$XH&H,,
M!]>Q`[X;BY=0"%<AQ;IS@EL<QUYQ`A<`DAN@II`RMP9H@"MX!(6X$SO0`_W^
M$88SJ,F=&@"?:$-(4)$`"*5[1)S!P(MK``!>`),0DXZ%)``]4*47R$C=(P-4
M((#N\BGQ6`::,`4DL()8R(--3`_`\`MI>('R&(,$X`2LZJ1Q3#)14ZK16RKD
M*189V@T28+'6X`T;&($&4`04Q(+S.("-:I!8$@,K>JT'V"BTB0$;("@\BHR_
M6,67<@R-?(RD80`'VJ@1X!'U.2"HLYT1Z8)8@A)P&HO1_#B8VBV9@ITRN1.R
M2:-U:0#06@3W6R&0D8@'DA,X(2'A<1L'D,YVL1Y1T,Z:J8N5>0!%<AC?K!(G
M2IX/$`&?0CZ^"1:#Z8P0.)YT\2U*001V<8'3<(_^8($>Z\RT09FN.,.?JE,A
M<&(X$;"%[I@(S^2\,D$>:7E/GQHW$>"G<"`=512#!9C-E_$5_1B`ILS`@EB$
MC&L".8#/Q0*+RU2">NH"9S(]OED=J<."^P29?R"_B`"G\1@)U:P5'4`^R;E.
ML#"1)#";_8@!-VE#%B.3$=N$_0*(46`^/'',1YO$&K.QR;PJ.6D&>@PJ&:&%
M2T&"<,@;!]J47A`&Q_C0!HC"&2*%VUJ)AMFRV'0,]TM._M.(5=P-5UB.N_D;
MUZ"5D4G.=E&(L5!3B;J"4F">S1L;HS.[R6RN!K@=ZT0>B8`">G2J_QFBA?A.
MMG&.;W`DD+$E`<C($AC^GF@!D8.B1S@8B'4Q.B<0`W/*S]WIEH6)5`X"%B00
MT`6R'8?3B<>(ANTZ4\]+&0PY5*^13N89H;]KU:MH#D90%@1``*Z,T8Q)&BMJ
M4Q=X`9P:@;\JF?`D*QL2EPO4AEUJAK6!E_:Y*O.+53I*FEHU$+,:C*:<S#B=
M4XR,.ZN3R8_1R3B],*(8U=>25P0(PCR;4->0U4A\M*ZCLBVM1-=P'P^0"_?0
M`1B((;29';?</*9\'<]#SE&0H1+8CS>M1^LJD8T`"0\5-^$0G%M0T+5``##Y
MC51E(GA26?'X#9P]2G@DA8]3&KZLD0=P#]P8&S&I(T9PT`,HV&1@!*QS#<S^
M@IYH[!NW^`9;:I?@V`^2E(U@^`T$,(N7JIX7H(MUX),FZB"),(X;D,D:T:/O
MS`)!H5#.HD>-P"PX8@X9'5K.>U3`$(,WA8R$X"S\FQ%EE0[@L5%VP8F(8005
MHE`/0@\\TX@7"$X1L*TQ]3PW=0R1[0U,6A2_60#]F9<&]!4=D*)_T,C<T,FK
M.BG@60"TD0Y.88"YY:R=V2\:)-W.N`L@R8(2.!L>4(3KQ`1#>I2*!4%\PDM2
MF)Y1$`&T044J[0+@$4TLW1RELH&();V%O2I4V!5NR<3<<`$"(`DHV,<%0(91
M"($W.`"4H@4&(%%?F!M4("U_P8XW6`!,H1A&^(O^KIE59@@[UXM9;B4!`:C"
M)G"7+;PEH:D[SQ*4B:*\IS!@/L&I7`*,TQN/I*&)T1+0CGD%X&$F4TM9E8!<
M3>`6?%N`N2,,_@&,\T6X1##AZR0,FA47W/"L8*+0&XC+R2J//7A*`E@5#NDF
M2:%;Q.0L&Q*!\>TFC.'5QEVW\"4,7N`3\"J!F'``V+T&_8OB<&*C;MJDURF`
M;BI?P^"Q5_"0IXE+!?`7H?FZO^626:T1HM._]X4!A"$)Q)F78*B=W0,G-TAC
M)4D`PR"`43`,&:787B4)`"BN($:]N@"\<P,'01'?$!`1FG`+^O4+5!!'UL@?
M[..%U/L+9-C@73",.WK^X\$@B/8$CG&J7"M^R2,#O5'+WJ72N<GU%=?X77#;
MKQ<(@>\!D1B89(W(("CY91=@S6O0@W6Y3!K99<>@J;836QK)6%+X*E+0&APT
M#O,,@?1<N]>9229I.PL3+M_BYEH)`36$0>P(`=>``:'Y77+&YB-JGEMP"HUA
M.$L"YC<CL;53#-M!$7U>ER(2`P)MEYGD$]8L9F/DH&_6F+QX+QHIQ:#BN],=
M@:^UYQWUCQK<JA!@A_^H%4,"C?VR`?@\J_N:MO<2@Q@(YWYFA'^KLEU>,$9A
MK&6,@84FT!OX-_ZKS3$0.C`9,W;&9E]I+F/^W1=0#(R%VN@`2#[IZ7_CK-_^
M!1-Z)I!UP3.?P"/W^8=I"X;FLYWWVJ\"XY-XK@T1,*UU*0&:_MI[GNJR-D8P
M(>IK)H7W*CGX`FMK?N4L1:/(1#6_HS-2T5]D<S7R($Y+DPV*IH@A8UA6P;>_
MEK2Y,T@X66Q4>TR?J[&'1;*N`J/*KK174[5AR>PZ4SIS\Y>ZP@S/UC(7]&SM
M8374WKG06>U94[3($"W[.C32QNS%AF773C99ANQ1RVW_\.T7`^Y1$SG>-A63
M&VZR2S>^-K80)C/BOK8;DVPRPE[0*6[KWC3AOF[MMN[LWF[.D6[,WFTP4N?G
M#I->%"`Z=K.-WK-.VIXK*,53NPS1.@R2Y&6-L#?^7(N"=38R,;L,.`NJ+WND
M^Z:Y;JK7:RO%98SO^"8PVJEK2B")!\"\V/M04J`(VN6Q&%##)-C3#1]P,X%M
M7^$;,X.S%`-MYXX,%^@F"'_N_V;4SAL!MK,Y'IMKVWFRA(AP"ID[^.&3']*:
M.2FN.5F%$U]N$!OQ7$MNA/@'\[LYI^LF,&$W!K!F05(:%(;$&Y-$O!;O+P(\
MR6BZ6]@Z'76Z16&/O;Z,=X4@3,*\TA`EGSA<,N)RMIV,!<@XGIK%J]O5RV!8
MAI6-]QJ!;HAQ7_EAC,0TJ)PV<]N7@1Z:KD-LRY`M#O<BT[,4GRJ\SF-TY_9R
M%P"`>-4:LVO0$C"(2^C^\^HT@`\0/"Y0@,"PBFM@$+ME%3C_C!%(9-!T`'S"
MLFL(@P\@`+,@=4Q`#P\`@//9!$@`]%)3E2/?L<^)*C1*`"#!<<&B'N?[`(J`
MZKD3BA:)=%#LK&ZJ"P48`#WJ=HJ!PF10#2NNZP!96]FX"T^@.`+Y(>=*"'F[
M<4H+<H/Y!#=O!Q33C:1V#'HZ]\[X$6)@5-/C`A$0`/JZ7"$?`3TXE'SOCN!T
M@KH@20H'>`6%<G"%%WH/Z@;@`K`1UJ$-!K-C=$?](]"Z@5[,L79Q`;,*K-=*
M2O,3@V?Q`'DQG@BGICS,^`R'(R,#%5DJZ)C6&)(`DR.BW;H@[VO0"[$JOMC^
MA922Q7'CD3?;P/%@410L2E7KB1Z&$.Q+D)Y*L<ZN%X;7*@4YF;C]B)$RVJLK
M*'/=P`GH.)2UA8S32'*-Z582"/C.4M"W`!HD4)_?C-EU,:D4_]F.L84?H<4C
M`^\ORFLPLA@2`'6T>!8F+X9I*P\T(`'BG1>"2-4!(%P&H"I+6(/]`GT=`("Z
M:0!,.8!)AL+`H?4AW(5I\85?0H64&W0(*B*7V`W`>GB:2-7/=]`%32.H/(**
M?8G1H)7'I]V74(0&L0W<FX1XDHZ_>H`X(KI1U!%!Z0HIU8BB+:+1P$AMSD-2
M]ZD#T$3@^-`HT)A$WB_+JX>E-[N-?XPVG"SE,(#^N^*4*S,-)$$3:=C*[_^1
M\>Q(("`A7""#;I&P/12E1H+G"GQ*B0?OJN,A2"4$#^2X.D(V`XET@/$,"=+'
MP$M>$;K1,'3(7O<>JXT74L`C8@8B*#)4Q&/G$@+G`6)3$.)R$,*S8#`B4F#C
MT?81X+*W1\)@XX5)PI.%2HKPQ^/A<>6R<#5[%;/P,68`4KL@PB!"NN?`Y/#D
M(C!597QUP/-!*QLR(A!"HLECZ8)0K%<R3:O'8Y-@;IS50%3M.KZP>@7C``N-
MGZ^_#WTC`'")G\"!//P!@$,PX;XT5Q@L6&`C!@P#?[(L&'%EP0L''FQX<N""
M00R$:V(5M.&B@302M_;^E+CEZIR"$`MNQ$"SI](52>1XL+0VPHI/%PI&Q+@A
M;$2!&#K,W>@4#88M4C]S2CMWX.<"!#%ZQ3@0<>*T,+(^*'#0-`LL'0=>Q+"1
MIMV+)SY;ZG(P("]&&S=@>"`P%E<($0KH(;A!I^W;-$3W9,G%I]Q.`@TJ*R@,
MS0!$%YU$J.&A8%Y=8W086.&E)7#9T%<>:%NJXT99'E#72,5<51=F!7P[Z1#4
MX(-'#[<8:D$7ZW""$7Q1._XB(($!`2*[S2NJE*EL!,R1B@A!R^.V#YB*E0=[
M)<$X8R0*]P&]_ERJ.3%PD>?!8!XU70M"#'!A@P*T&/(!`@WT4YL!4M&5VRO^
M/5DC`ED>7`/13?-%]IP"]^4S`AS[R;>'/#DY4(!H"IVXCP[_!(0BB@:1U"**
M]WPAG0((),"`.2*"YL(#;"3`70D,O'"+6B9]<``"#WC1'E6%Q;2+(0H`:446
M+[&2VGXC%.8:>%AJD4"8ZLDR```*Z.&*12Y,54J15_QDY'(?B$"8"S`0L!6.
MLE3C`7D(!"``,&`]-64"9S*P9DNYP?`9((*4D.0#TGPXH9<\Q)#`#9D68*.A
M-UQ)2BY-[?FE))N(8.(KL4"6Q7Y9P+G'83#DD6DW#_:Y0'VD/E#F$[/HX(6:
M;#8HP@"7#7`)`]H<R(`!A5XR(RP)Z`H+`C>&&1_^AHB-$H>N^_$*P!/6B@D#
M"+38R("&JC040F$6F6AE2],V(%H,%\Z8"SIZ0+;+AZ@`JX<"HYB##I8+K(F;
M75]*8ZY@EDZH5*="84&J'@]LB,]+LO$;+";9\O#"53&.O(=!+)(\D(H'H7QB
M6QDM@-DY.LZS0#W56-E`#()$$PN4*RE\I;T[]6>722X@I'-//T%,U@.$S?-'
M"=?==X,!NBHXE3@*'[V3("$@\`$,"#``A<CU??C!!\Q=6H`.<E"T$R:)7G%E
M%B#<J^G57_!Y#5TO2*L#W.>,1O&']I$24SY9,(`1#ZXU\$)KP-#MYAQ_7';?
MI'R"4)08(,!PW7?D+77^A=5LUAV-43&,($T7"JC!P'TZ_!&MIA71NMX-LAG3
M9RT#_)'5%0J(\,)U[4(]S6!"/4#+CHQSE5ZJA!.9P$9[79A?0ZN,<*"59/L$
M4DLPG"DR$^N0OD8,I[OY@5":7]'`=WR/4#0TO;-"S#XAY/CF]Z88O(H0"`53
M+".9RBZAC@+BXT4*)`@;MG0@!1B`,`<"H/``-``'%`%A/'``,1CP.RP8P&D)
M$`1G1%."`I0@)JYP%AY.AB,[6"$73<J%`?H@"!(,@!I@B<$`'C""ZO&!.^DB
MG)4F"`(07$(!S[/"#?ZSALDIX``4))4LE#B`$7B`;`>PP@>0Y02Y#:MR2/C^
MCI+B(`P&!.!6YR)A'J3QEQ`TH#"HNT*!1@""#Q`!'$DD0>+$H0X8],<#<."$
M"!ZP-20J40OU&4$`J'6K2%#Q`P"QP0^#:`,\>(*(A:D*K$J`F2R8+TRZ&$`#
M0'"`<41+!UL400,&X),=>@`LC`J59!"QB`GZZ%*7G%8)9)D'2'`F!%]L'LU<
M0(($'#(`+[@!M][D)A``8'4%&(%I2-$A$1#R78ZY(2$PX@"G4=%QG.3!"DFQ
M)&MV4E%N>@$!#GF+;X0`!`(8@0!Q00M.B>``D[/E.0K`N$76\A@%$%U]1OA-
M"P;.:=QH((H.Z-!],#"B^QA!2JH!B."P1U<DJ(_^$AHPCM5=87\E&($Y8E`9
MT)T-8VD;!!:*<0,/Q`\:^YO'FBZUBIO>X`,YJT5*=5&99_8O(#=!W`,<@-0'
M9$&.C3-G%@"$!3E^X*G<NJDKA0.%4_BD`0_X@Q]M,(^B4L4!]-K)`Q!EIQ=4
M=10[;0<)=&`>$C3``7\0ZQ[J@=0&A*`>1SVE2XU!5V/`H`$>V)T+.&*2<QPU
MJ77(@@[B4XR;0F$4@]4F+0;;#E8XH!BF(&I842A4%XSC!8V*P0-`>@41[$X$
M2V5`2?]P6)#X!!AZD.P50"";E&#U4DBM*E(C9]78V0`C'7U3(QFW0M.2PJZR
M\*JRH/$"PNJAN"63*;?^=,#39W;6CA_K;!;$RMS!?L"PIRP!#-1:"[;RU#S&
MN*D2%FL%$M#VMD<]+5ME&KE2Z*JM0J7H0$SV)?^6[!\P$K"!#XS@!"MXP1$%
M@:XHEN#AL<(X#![9"]A;X7S8H)\*3B`T+)IA%%TXQ`(&L((G6N$$>E@?*U:<
M0%H<X'4\AQ3J@'&,99RB&Z>,Q3JN,4%L[&)H`)G&1-;PR/1@XQ7/R@#@*+*0
M&PAD&-M@R(KS,8YUC(_9)63%5.8'P;H<Y"V+^1R[<S*/29RB%6$YHBHK,)K-
M_&+_@OG-=*ZSG>\LX#GC><]\[K,"39Q@%/MYT(0NM*%)K.=#*WK1C+8S1#O^
M3.`U&QA-9:9;V/H1@A"8(],>3C(_4`)G,[O`'#JHCPOR>V4H[^'!01YRIZ'P
MV`=3F<LSAG"12YWE.)^Y(*Q^<JT=@V1?/_G+R\UM8FV=:R>[X=B-;K:S\0QH
M!`LZQ'+8@Q-F.=]S&`"IG2@#4@6G0%")>4;F)-M-$STR<1MX`25P0:\9+"0$
MYU'2"JYV>NK#F@)6X@/O?K:__YUB-:/[1#:(-(/A"@*,N(``A:T%9FS0/8R$
M@"P-&,$(R*)!Q!'S8^X&P2I*<&EH@`KDC0*YKLH5<G([P```@FU71B&"2.PD
MX?K8<.-TX()-D`+E]5EYMG0PS\9UO!B@K@7!\OC^S!=X``:NO4%%.&UTHQ>/
M#%()><<Q8G)Z3*$6,?A.%E8.+ZA#0;Z.L=/6KX#'GJDM/0B`@0VJ_AF@:YKK
M-+=T?F-PDZG:X`/SD'LKU/H!X#+<L`S'C\5!H`<8G!TE(1B'XN/S>#&X#."4
MK_R)!9[@-E?X``E`9>.I$PMQWP,8.R(!4N<A[A@0('8&R!;G):69!M2&*K>X
M]@'(DRZ\2"6#A*2=218P`!+D8@`+6+D!&K`5<]Z0`71Y3@E&R``OW"``,RE%
M!GUD`Q!RF`VH%%05TH6II\9,]:Q?!9)D.H#!EB!PW_;]'`+W"QURE9]KJ`("
M8D\`H!_``TS$SPA5DGW^!,`BWK9R?U``MX<F>/(`"7`@"+``#U``:X(`Q`$+
M!\!R+F!*DH)XV[9R]1$IS,<#3H`DP/!%B%0`$S@)[+=R.O`"&4A%OZ15BS``
M9*-&IU48J/0!>N("`.!:>)"#9'-^#(@)`\!AEF>$1UA`CQ9H!J=@;U<0R'<<
MCI%*@R``998]X.,`C0,K>'<."4`>>G``H]`%&2$]IB`)61`RC;$(PO$'+]!Z
M4?@F[C$Z?[!%[\=N[`(-3:8%&%$`E?86/``#!:!6"N.$.M``7,0MAX$H(<@B
M?X@.P%``GQ$7+B!3\!,&JS0$YG05/_&&8VAXO&$Y&B5&,1."%509:R!492#^
M&\"R!".E+'0Q"OOAB7_#`!07!BP7/0\W*=\3AEO54N0P*]#4#8EU#PLP.1<!
MBHST-ZPP(PE0"9'S&S:@;DA(C=5X(@91A),6`"O#8$7`9%S$:BZ0`)9P#]RT
M"*<GC,?`9+_P)=!3%3M"%9#C)C-!-GJ`%`500J.`'G$X&ZEP/]5B@0A04#&&
M+^0A,D/#9)&HAGO@C0?`1<D!=+1P(1UD`!:H:1VC`-&5$O/P$]!S'--B3NP4
MA55!#!69D-EW3&IH$>MQ)>0&(E]'?R"B``$P`+3P'K"R%2QY"S-2%`1P?_?W
M(/=P<1!X``=0`'HDD@?`:DJY+OBQ3P&Y%%-A`S[^691FX"ZC:(U9J94OIF:7
MQXT*IH8M:1)%]P*AY#@!04P?@)95`@@2@E%1""IWR!X-$(P%`0[?TP@30H9P
M.!J]<Q60<1B9B&S1P"T,``P3.089,3<Y@1EB.0=.-SQD,5(2,CH!\P*(XE=?
ML)/)@1R$TY+U`2K$<`"[LSCK<3!LDA$!`0*;B3CSX1!D\0UXYTQFX"55D7W5
M!PBL"1HBT'RR\2'W8'H.@#&>I)N6TY3$<!@4<R6JN`?,V0V#N)71*9V.T95+
M^)4)=C3GI1G=T%26]#D)$!!JP!DO\`*1&(CDB8NWY4M$"(A&0CCL=@/J<"6_
MD'U<]#D12%8V(`*BP)?^D-*/^/1^@2!:KZ-E>U`@-]&'?X0?#:"?`2`5Y'8T
MZ*F;]\```"!4(+">Y"%3#8I2IR:(;C@.P1$#'B``;N-527FBBJD,,$`837DP
M?V,2*42>*L27!2$`'=$+.D``'84`(="")8`41!!/`2`"*.6C$5B>X["/U9(S
ME0B8SN5#(U"6BWDE!]!4>^@Q*MIV(G`+H-006UH8#'`*J#0:.M`HTXFF1UAP
M`+%@FM>-!R`PY+%/#R8V^:8$=#,E+!DFJ6(/($6"D=-54#`Y_$8)7_("Y`%Q
M$]@*#D!_2+%_)(`1#U!F.J``#P"ICH-VC1.H(0`D&!%SQH`(-:-8Z[`5'G#^
MJ0M00;>%`$Q`'H':7(,PD1TT-D3`"K/4)S&0/>TQ)N>@$N`14VTX.8?J.++Q
M`H.J!O8@1(%G1VJ@`*EJ3GG:&HF%#G@@%(+4HV]B+9?P%2)`%&\0$*"TJPTW
MK#<0?1"Q"(W3$5!`'LD$-H)Z!<**!P^F287Z!8`:)I$CK*UQ(VJ`708"K.?P
MEFDJL`"'C?3V9TPXL(4&`R?#8"TU9W*Y:(FC$-.8L!5KL8:FA-*&L(@F9PH$
M8P/'8UP8(\'V8^8T`/T&8\C78B!K8!([F!FC,+^V9V#&LA=KLW26L0<V;3=K
MLQZ!(F[G;,R6,D++LT5KM`L6;0?FID?+M$WKM$_^"[5L5IT:>YU1:[57B[59
MV[0`5K/_M8UNIK5A*[9C2[9&R+76";9EJ[9KR[9M6V<JDXUYMK%N2[=U:[=W
MRS(Y:V`[B[=]Z[=_Z[=)N[>1UK6`:[B'B[@5*[@E-K>)Z[B/"[DW"U&%ZV6-
M&[F7B[F96XV+ZU]\J[F?"[JANVAPB[26*[JGB[JIBV:<2U&>J[JO"[NQZU!Z
M*[=5*[NWB[NYFQ`%2[D29;I**[.Z>R*)%F49UKN2>V?'NV.%IKRUR["3]KO"
M*[W3"[NTV[F$VX3A]`#;"T2!I0?#0&IA=F,LVV)9F&S!VV.ZUFI`1&_$NP_N
MQ@_SMF/;NPA6(+\^Q6S^`W=.+ZL#[+L'SQ6\G\*K`Y-J!<R_H19C,)82D$G`
MGD8W1(L%YKL'05&\M484%?&R^%MN:"%LDD9K^)`2$,RKD9,_HQ*\YF`G4*``
MLM;!K3$QA<:Z$>6Z%+6#`&##`!``%7JAS3>[1\8*/&BP(:8#0%QA(P``J)8/
M!;`S!'&*"P``M`$86!("1ZQ`#P``CJ4X0.Q8G<</"``8+\"FAS;%;O>&)6O%
M24;$#7'%XBMCD-)O-#5--@``!;``S9L/4YQ?*P;&T!*W^T`"%JJ);ZP/IWAH
MUDM12ZM@3$$`?0AT`$`"VQLU4Y6;F=6<#B!\=`D%8Q!8WG4.0])!(V!ZK4#^
MR2XA%'3""D"4P]:4.PYPAQ!'B3U5R9<LGF/0`++!$G,'<;(\4@M0#3TR<7(,
M4ASLRJ0@)($5(5EUHH'%"C2Q"L,<%'`1+I0EII\1$B10`%&\<PQJ3O<Q)_:$
M'T]L`$L,"`!P<?U4S(G54L/L"8O8@CQ(A\)0"JZ5QM,P#A-B"AAFQ#>Z@TG$
M`)_!=/V,..W`4^H3.Z_"`&7ERC(URX?EJN=\#IN%R5=P`Q=#26JP=&=IR2&I
MS!!'5S!0)EKU$LIL"B6@Q8MCH<&A!S11#4GT`,`P6`#M%[,CT!%M#'C<``"`
M`/%Q6`S=,TAU;#%5BVIP<:UA4\(USH_LJE&5A6S^NG4?``*N`8C3+-%G!0,W
M<`#A`@,C^@<V@%3>TGCY0PJFO,X.<*;0AGE4F[8'ML@CA=,&$"Z8\,0*8"8%
MD'XY`0#109/C3!W??-5707PDC4R.[#@`4-8DK09Y<2F.+``#D`#;>%`^*0HP
M,,<(``!1_%1W_2>P-,4SR-<`(`U@C->`(4TS>0O21!U#[``DO0I6C&HDG0`$
M``=_3!2`0=)>C!`',`!73=8`0'I'3```,``K-``&8``#\"D'<=5N)L?%D```
M\`<!@$JPY,103#%3[)-O_<>V_0J`L8/KM]ANS:TV;#4-0'T`T*J>[=;U^,.W
M4`!F4B:KT"HX+#`'0=G^@&%)!5#<#[:#3';7!_#;(.#:;LUO]%W9XWQ_;UT"
M`:#=8*S@)D$``9``_Y#5;+J-48G3!-`ZGOW@>#''*''ACX#3[?T]&3'7`$`+
ME#239./6.WK?Q7T#(C!-DLW?XLR0%DK9.R3%;8W@E?W;\:$#>:$`P_W-60``
MMT!)"+#8C7S@I-C<K\VF1;X&E>U'PUW<'C$`^`T`)`+<.3=-.T@`/1[E02[8
M6++60#[<=DPR9XO6(7;-;#T.7_[-W0#(Z@#&9#/%)07(.T@>)`T,S```!V(#
M`<#>8(LL;F@`+^`?//#6E*0$A*T%"F+><%UFDFWG`(#GXZ#GY@0`10K$TF3^
MQ6%@Q*L#R#<`Q$",WXZAX(#(V]_,GQ"NZG0"R)0@V<GRQ#`>.2[^1,QWQ4-,
MXUF0`+=0D0YVQ08`&!5*&^(\Q;3>@EX@V?,%XUR]1A5:']-]TXM`SAWDW$*^
M@R,^Q&1#UU#`IGK0YCMX+D^,VTU!?%@BV<U#Q4`\:C!.5R8.&K5NZ3RPUF\]
MZS&PZGL`X[2.=YNNZ$7BZK-NE`4Q516:!:DNV5]D0O-<H5/VYW)L!48<,E%\
M[BI2<=.D[^7N8U/\[Y.S5("\UDI\!22/!0$`&R;]PV0#Y?!:[VM-#T`\Q<4`
MQ'"^!L:M`P$P5P#@FYD4ZX1=\,=.&["T@R=SZBC^SZ]^1KI>F=8&9O)3/`IP
M/MVH@,,OO,?@#JE4C,<K7SJ`W$&"<.U$-D?:BPQA`.72Q-4X;,/!O>I.;`Y7
MOX,6I_543.H,RJ8[2-XVO(UR#XU0W@"`$?8V>L-`3-)P8!`W?%1K_*YM_\10
M'^4W?'\[`_.@^@O#4ZG2(/5/W.9[X/C2A(&#/^*D+B1/\/335.U3O(W;F."W
M0.IV,<2WL-9%3PIM#L:]+><W3!*U#]=-`<0+0``.$/&,/\Y1+PC_<,,.H.\(
MQ-:C($T3?@E`O*8W#'R5@_`JH_8+(`"L/\]N/\0YH_;;N$]1[-8WK$P:S_@>
MYO&S3@J.?^_?@_`YT=[^R`+7/VSW)\/^@(&&J[Z#-`_[.S/^-@P$!T.!I^/Q
M0@`7#Z0,,(X,`*]`X+D`H>.Q>BT`!J+MF%PVG]'IHTZ05;_AQUO;$+?#"T0D
M`$8E2HV,'@#$C%X`%/9*1I2N`#QX2`!`>!@&$@9L>$H"'#)Y;#2W2@P,7%Q*
M2W@`%O9L!OM@;&`F*P&,C@X3DTHDE[`@)4=B$)D`!A]`EY)>B@"@.#U%BP(2
M>&Y<=&X&%`8:>*JOEQM!7&@_>!*FF'D.!G1TLA%N=0+J;&+&;$I!=`P.T.6Q
MQ6/(F"20I+P8@*"(BQMC$B`@0,)6/@53I/!@-(('C#X"B&#YMN:9'QZ'M&S^
M(4"$EI8%4]P9<3&M)8^71@`X&&1#1TX;;C**`-"L0)T`#+%U=+-%*"4I,8B)
M847-&C8=`F]XT`$(G+59-NPY@K*%*X`&/Y/9(*HGYI4]4-W<U!$#UUMB6G"Q
M6TF0@!$"=<9H>VFCP:V?WZ:^0"=T[19:4)I(A2*0X#NWA35]L)%D'(P#?7G\
M-8FR"!<B\&Y<;':'=>MK;5*Z9CT'`&#9LKOL64+`RDL>'@`@,``@GTPP!@)8
M8<>C\/`#D;*P2<3CXG3>9`98"3W`6:LF,&Z`2=")%J67#W,=%Z!\Z)'"!P`\
M/S0`N96+"`H,N,'X6DGJQ=;X+;X#`BAA@0!TX*S^B0,(5,4=^,X"H)H!II!D
M`!=*J&V>$#(L"@`B;H*(N'1&O,ZWW(YH@CX`K`&.00%4*4T2`AZ*80`!AJ,$
MN`)@0`Z3.ES\`HI`IKH.B]C^4P`+\RK4,`!T#(EKBIX<:((`^!@@ALD]FKD.
M.`0(-&>I-0@XJ@T8[EIE+!?#=,$>"F'XX$,;Y&0P`!<6%+(((WSK"8K[\K,A
M-TD,V%`HN%Q:ISTCDD`T0+VLR)"W1K90H!H"N`..`'6\"RZ`=_C;J]+@*-2B
M2#T(12``$&S([@L.P7"!D1@.F505(\>DHK=++;O-5S1H0_)7-=BH;=C60*#D
M)`<T23:29!)LP('5CFC^"00/'GJ!V5$8$(,'$1XP@@0'C)!B"2:>&V,$;]<]
MP@..7-CV%08^T,$&!Y8@(9DM4+I6$VVG*:';*$$(`=LC1)!V"8"/>(`B6\X=
MHX0&&B!!!X>+>$`,$BBV^(@0&E#6A09$T/>($1CXQ0&2C8"AXA`H*8'&`/$\
MHF8F*#$9Y@"UA<$!;R/IF(Q[8]/A@P:H!>$LHQMX()]-&G#AW2TNILC9>ZF]
MY@&G'\@7DF4;"*&N>_,-EP>,E8:!!%:G?7;99I7EN&)0V@[L`P]*<."&&QKH
MXP&.CI#;XU>B+D)I300W0F"I'P[\Z[\19@!?G/FE6`N?0YE\!$@8SH79&R;^
MWR)>N(]XY8%IY/B`@=-3Q/<#P%]H.I_1*1]#!'S;QO@#94^R/!`/&@`<98_D
MW5J4G;$>X^JCG3[6>:IA*^WY,VBS;?KKR2!-MAM&R&Z+#QP@HR[G#^&]C/%/
MRA6._;)#'_O62)@.>_?AH/_]^_'/7__]^>_?_^F#U;_J_<\UZ(-!``J!AO'A
M(DH%>%HD4'<^8IEA?`?DB/W(<,`$!HA^+?O0`Q48F#,$(H14$]\87)"U-V`P
M0"<LH`E9*#T1NG"&,ARA"QEHAQC:\`X=E"`%6\A#(.X/@^Y;H`G3L$,D#A&&
M]2.@;(IEOOP5RWI/M.(5H8C%(#Y1B5I\8?]\Z$7^,8Z1C&6L7_3X-T`SKI&-
M;73C&^$81SG.D8YEL`$:B4@'*]K/B"(`81J*,X(^X&(SQ1&B$7MX0SN&(!\C
M:$8)8G0$2$JPB^,+Q0UC((+QB2!B?/QA"6D8B=6@SY-+9.(5O'7)2?+07M<8
M!AQL0`)9.C*4AQQ##$:`'C1D$G"@*)DLGQ8#$.BR+BS\8PU-:`,1Z'*&.SSB
M*;>(3!-FTG[%"4$?HIG-.I:1-I3HHJ_4^$;2Q/``K?#3&"QXFU*V)@8!X$B1
MM&.:YX5``&%<3A$&$+[G5=(_4^2!)TYRI]#H86@#H,21A$@&+`"`H07R%6?2
M8(,R%>!X#+6H%D00`&S^.I$!=?@FE^J8A$&:D`$L`4`OMYG28@D+?W<TEO\@
MF<D^D""7/,BD"*;A`A(@]`K7-(,D#I`-L\0@!)K@GB9<(((1H.ZH)5BF31WY
MU,VL1IF(RX8?)?DP&]0T!C&2U5+5--`Q%&4SNBQ!"+*F`ZR^H)=.?8@-X//4
MLU)KI_S9`@GZ4`(7R)0,O'R@,B-V`PY)3).YV"E'E$F,L9!@L*!8JBS5U<M,
M-LZQ^;!!C%Y`@LQNY1%7,8`R-\H#.2U@%EEXP5.+H%1FTL(!,!A!6*I55'ZI
M%JJGM:I(A^93T3[C@4DH!PC6XU@=J$U6@<-JZ42@"A@,8``>>X%L:ZM)M8;^
M8!Q9&X&LFK$9RHX`I2-HG%XSV0P2R'6O(A!O33O26/"*8*,[A>A-\['<`91@
MJZ)(*BYT"MB[)C>E8UPI&/7X45\5(`#P60B%%)"A`03`#0X``P'<(*<`.-2$
M\`G.*CST#EJ(`#@+'L!&L9"="R<A+$UH`Q1N$("^1:<DX6D%*`!`D<%001VF
M@L)UMC`<`E]HMPN.9'EL<@L>S$,``3BM16&0!!^3B+GM(4DK"&SAB"F8P5K@
M!(4,H(,2"(`.\)A'``1`$2F8A1$@*<D7*,20)""@#=^`09D^%8-6G7@,`TA&
M$Y:`@`4X>*$G515\!(I/ACHM/A!FB`Z^?("ZE`_^%`6.`@#:@(X.3SB3$GJ.
M.IH<,6,PN`$ZH%!.2K,<7C"",`R%@A22DP\2<)E%+P&##@K3!DHTX2@N$$"3
M^]&/+=!&"1)E,!1B`&<!R`+.`\A'E,&`@#1300`&5O:%.2%K*AR%H4O`-(5B
M$&(&ZXNA!4`HH`,@9A8Q6),$N/54^JO%`*91C_XK@`"@8PUUG!4ZG6;1V4Z*
M!8XX(`#G:W%\!`27$1Q``'0!X2$8(B=9G50ID&'X"-9CC71P1Q*J,$(YVU$`
MO)[4#:<*T'!"P0I]_Q/>*F'(`%HQB"48@#L9R1!'&M#<1Y"H&42:#+PS%)N:
M2>(;1XD$:1<2B42HO#+^S!D1<^LMVF,KBB,#(`*;.Z(`A3"$%A?\IWT*D`P`
MY$U11.FW)&)#&BR$3QWI*+D`PF<<B\98([60PF7%`!SN,EP2D%!'S1MNC!*D
M*2].UK<D[L4'?.>#03P0`$-&H("K6($13@'`?AB>A,LQDT@2#SHQXM=O&"0@
M!N.Q08H98@!X2T+>4Q!]O(>L45"3FD#0<>3,U8&FG)7D.H<8@<*++@59F.4P
M-HU@N@GX7_Y1\7]=((UO0E"`BT1("_IFQ((9K.GN3+\)<&$OA28R!K''F!'5
M=<:0AN-5XC`@GJ(]``D0X($%A,``-?&X2K13@`,(!?J-,(('^L)V426AU'O^
M@/X3R,')IJ_V<B7YEN\G\")]D&3_`*#4<*(57.PD$``_IB!4B*"?4FS"*&0L
M-N%"#"`$@JK?@J(1]F*<TH<2CL_T(*W=TB<![B8_;"%*M,`!E.^D?$$W0.IC
M%H7W"M#O3HK4"N,AI.!&8B57NH`K;(\1:DX=<L*(2@(L)JP-%@#EJ,8_,L+X
MI$17%-`F"@32P(P0/B-]:*H1(`H$:G`RK$#?PO`M"N,(2J(P$.'W@,]_`DC`
M7".<^$<@$&H!T&Y$>#`9&&$,0>`%((F42J(G.L51L.$BK.X0PF<CNL_UE"(9
M/B`[TH4'["SKT*D`TD]0.I$0PDI4CH#EC.#PFH+^$$N@+F``[4`C`>H)WV"M
M`B<ALV"@"3AB$/#NG$K0#03!#^TM+5Z`&-+"VEYQ$&(1)ZC.+,(C?'Q#*)9`
M(((N'GX"`6"@%Q[('Q(@$0P@`:PA(W"K"Q!*!ATA42KC%#3+,99B$&)`3OJ@
M^RQ%*>9N'&Y1\`*'X<X!`1_%R=1AJQHP"&UAIS1+&)7!)("C'8="";=@'>]-
M?/X-`5`QV`XM&X)NR+A#(%*0+[;P0$2B&BW&`*S@$,9P'NG$#V^,"&R/#XW`
MP8XQK'P)Z>;0BNIP?_!P?PC0/`!0`2X""I#C`89#"PH,!!)@`>HA[8K@UL1F
M*AHE*KI'=2@E?<R"P+[^A1[GP1/>01AI85\J40"D;QZ:81YBP/U:`<=&,3ZD
MP"</`"CEYP@@)#T,0`J^H3"0ACZ`DK22XP$HA%H0,30^DA>-;@%RDCD"X`$(
M+/`$,P!*JRW-(LC*)2?4@5D`@``<H,A`ZCJ2P`'4860>@2<US<'$@#.#K.T2
MH$>LH"8\R`#VKA:0+R<^H``2"`LFC,%HQ-/RZ<(@!#[F+KOJDD(T;2J1KB9"
MS0LWT!4*PS@4``0.(!D:(#`'<QX\H%5F\SG8(08*@%X"X,4"`]VDP`,$$P:$
MH@$NDQ$4H,;T\@0_$PNWA.5`@`$.X`:PT"<)P"X;<!#\LB2&PP.P`*=JPRW^
M/_.<#@`!DH\]5.@EITC:V.VE^J<!@.W\1"L!;J"D0D!U0*$!SE)!-T_^1D`'
M#H`#-Z$MTP$=2."S]H&^%D#^@"9]/F`!0C,2#N!I=,`#"N`L1`L!C``$9-01
M$F%\4.9D6B$&3+-#*T%#)<<,O67S_J&7&,4`&@<&%,``O$4'1E3.$L!"H\X%
M5Q0BG`+8>G0-'!1"D2`5$.8?8D1)/S!%$B`0/L``/@`!T(']4@8!NLH`\@%!
M)4D(E,5%"V!;'$/Q.H)!F:!,SX8`\B9!(PD)"&"8D#1&CW0Z-RH&$"`B&O5I
M"*,`M,*F$N``)J8<JI12J32T6I0`8)1'!Y4$#B#^(@!"7`Y@,_QT$_`C`<Z%
M_2S5IB;07AJ``.IE0XL#!(8`1LL``7C'`X9@6TI`"%(B6(,J"A*4(C[`&N0T
M!A0T34&AI`R`$I;U53>/2O-A1$4`0ADU-"ET2;TE68T@`2A!!/!#`68*3@44
MP-0'?V9RFSP`'8Y%>Z!(3E`J7>WU7O$U7_7UC=8MCXS%#O'GF<Z@.5>HEHPC
M`4%)A(9C))+(5SZJB*0)FAIV@A*I8BE6G;XH8A.VEH8HAD@IA`#VA#Y6AS:6
MA4:68SUV7P4(C_2G7546#NC"5_#A96FV9FWV9G%6AZ(G9._`97/V9X$V:(5V
M:(EV#/I5?XBO:)5V:9G^MFF=5HZB:&4-]&FIMFJM]FJQ%IQ8-G]\-FN]]FO!
M-FR'5OC\M8K$]FS1-FW5=@Z[*:&NIVO7-F[E=F[I]G_(MF59L&[U=F_YMF_5
M:6O9-6_]=G`)MW#[]F@'=&H-=W$9MW'!]FZY5G`==W(IMW*'-B9;EL',UG(Y
MMW,]]UXQ-W(5]W-)MW1--XZB=O@D]W19MW5=EXL`]W[@]G5IMW9M5VO75797
M]W9YMW=]%UAB]WUF]W>)MWA?][]X5F='UWB9MWE/%W$#]T.<=WJIEW135R9W
MMWJU=WO]%GKO)VFY-WS%=V\A-WHW=WS1-WW!UGO?!WS5]WWA]VJ1%WN7-W[^
M[?=^A;9\OS=[\;=__5=E0S=@^?=_";B`V39XL<>ESM>`&;B!Z6A^D7:`'7B"
M*9B,V!=[AK>"-7B#[1:!KX?XDI>#17B$[]"#`4B"23B%5=AA=W9_%'B%83B&
MCR6`][=^9?B&<7B$3/AY,CB'?3B&VW;X-/>'B;B(BS)WA1>%C7B)-=BE6$IW
M;9B)I5B#]3>)HWB*L;B!VS:$S^B*L_B+_[>*,5B)P;B,X?>"WY:,S7B-QU>,
MT]B+V3B.Q3=JN?@->EB.\9AZT7AZW#>/_7B.=]AY[OB/"=EW]WB?`JR0%5F/
MI:V.U6"0%SF26]>-I^>%)?F2B9>2$1F.,;F32??^D`59C3UYE"E7DYVG'CB9
ME%79<6G8BA=XE6%Y<EMYC%,YEFVY;Z\W@FOYEGF9;DUYAD6YEX59;4$9F'=Y
MF)%9;(MY6"`YF9W9:R$X<5_YF:DY;)?Y5YJYFK6Y:7.9:X=XF\%9;'^9F8,Y
MG,TY:*^9A8_YG-D99^F8?J>YG>49:-/Y-@;(D><YG].MGK>GG/7YG]-UG'^E
MCP&ZH&OVG?%VG0UZH;>)GTM8H1DZHN/(H5=(%G;-GR4ZH]M(H.V@!!Y``1C`
MIPA:HTDZI2@Z#5BE="@AFTNZI<4HFITGN>SE:C#:I6T:=I%XH$%`!$IF#1+Y
MIH':C6999J-`UU@ZJ)'^.J&?>%BT@+IN[S4@.JFE>GY:>'IP2@OH!*KC>:JY
M6JGOYP'T#&FTNJO)>H\"V9BWNJS5.I1SVE?&96N"9ZS7>JX3%V&?QSM%``0^
M0!6.FJ[].@V&6ITBJ*__NK#%YZS).:H->[&A6HI.^2L]0A-&FK$I>X40^PXL
M00'`!!T(N[+]FJ/C`$/(H+,]>ZZ=6%W3NK0K>XNOIQF$R6-(6[7+&K3A0`L\
M@!`IP9)E>[</NZUO8Q"A!"]^FK=Y^Z31X+1B1+)KFKC)FK9[R*B6F[FY.K"'
MQ0:6(+:E&ZFI6S;B!;JP.[N!NIN=1Z]#(`242J[!6[6=6PUT[1HX.[K3.ZC^
MC?L,I&81&(`B[CF^/7N^SP`&3D$4)EN__QJFW[89OEO`29J_DR@?#AS!,UJ\
MCV6K%*!N4#FU'7RJ%9P,7N<42F"EX?O"27J]TT!L2@<2&AS$%YJUIR<&?@9D
M^N#$4;R@13RB0@$78#S&_WG&W^"RT!O'YSK#B>7#?7RA=9R"OO(KH5NQASRB
MM[LU,KM2T:%5E'S)4[RJGT>G>MO"J;RD(=R5MURMB[P,8L`^;:!@KN&;O[RK
M@7P+/``&]BP;CEC+TURBUSQ%ROQ"DUS.YYRA"7Q83HNFS*O']UR[+QMW"6K0
MD;K+]TD.A!S1S[G.J:?1'3V<(=T,;GS2GQFAI1G^T^6[T.U9TCF]FBN]#"X]
MU(<YS.T8U$W=F37=?%?=I4=]M%7]U4_=TRTVP&F]H"$]!N9&R\8:GW-]F%7\
M>?8:9C9#T(.=R&W]#4B\!!3@O:<\V9,9U5$(%^BMU*5=E6.]=)8`S;/=H*G]
M#'`)'*+]VWNYR5NC+L:=P2[1W`$:W6\C!BC"V]U=GQ4=G.*G:WRZW.L]EL/=
M73@)0[!ZUOO=DR&=Q$$!VO6\X(5]V=7`9T0`9`R<X!G^DON<F>?"QBF^XB,9
MTI5&T["=XPOYWF^#D3[@`5(ZY$7^C_\="7#!NY!]Y;<9TG\/A&7>G%O]6/K@
MM8U`Y6]>C@_^-S#$P_G^_><[WN'3X`,4HPBTP.>-?HU;GKBJ)>:??MH;^7HV
MP[52(L6*ONH)&=+M,UJS%12PS.NUV>-%:PF(?N'-'I-WG6KP>^/;WHQS?EA:
M*3#H?>Z%&=)59Y@NNNOU/HX]7@=(0#M?7.X#/XM;OKU?X+H1/_&GN.Y_Y?><
M'O*->-NA!_`M'XQ;G@8G$$U!X?$W__*1'@VRU5YX@NI'?Y2'78`U?_4CO_2I
M)]]7([]A?Y5;_@,XJ1>:7O1O/X?1OG04_O=A.>H=P*D*I_*)'XBM_'G6\4+7
M(.^7_Y+AW8E&X`%T8K"4?_I5F.1E`^%O8.VY?Y1;?EUN(`8>H/=??_R!7_;^
MSR`$%J!PXIS].QG2;\\!/("_;)_^%_GB?:6]@>`&XMT$``,OJ5PRF\XG-"J=
M4JO6*S:KW7*[WB\X+!Z3R^8S.JU>%@$A,RD4@SW>;>0ZK]_S^_X_8*#@(&&A
MGH[1D%G)R,A+$N*1X21EI>4E9J;F)B=9Y%M9C(B"@XL-D1%>YRIKJ^LK;*SL
M8!LHF8>I#<P'JN3L+W"P\#!Q<6#DD`Z9R"F/BT>OJO$T=;7U-79KK9F-0\C'
MP^E-@&^V^3EZNOKZU3::,F0J^SQ]O?T][*?>'7Z__S_`@&:0\8"7AI_`A`H7
M,@SH;DTD:0W9O7`!`XL.92Y<?+%1PB"6&!R7Z&C^!D6D$Y!/8I3(HE)'"9-?
M5$+RI`1&RR4N'DV\]U`-PI[J;!P`8)2!%1@#.!XX\"4$@(M:%@`PJ*/`&YI*
MJ&J-HJQ!@*XDH[QP4]`KI@8"0!(H(-3>SS01WZHS`.`!"04`H/&P02(&I)@X
ME3D``$+'1AXB/4JU6#!FDA<E`"=Q(0H`S\"3*\=@V0SFC095E4!MT*S$R)H,
M`'@TZ0(R$\DC<4(BH8LC#!>(I2HNP3M&1;,D?2NQW'J)#<LE;O#`2=ERWX_1
M=2NVR-$C9&4Q2/!6(CL)[<=7W?8ED9JN.8)BQ01%CVV$824/.(XP<M<9``0#
M`"PH:W3$`0/P0%4"__'^4``!/)3U!E0`",`150/LEYD-^Y'S@0Y'%`!``1D5
M14``825QPWX`.,"#74?(M)I=`HS`0V$J+L%`B``XM5IS!-@X@%L$&NA"B2+P
M\````6QHBS,E+E`0AQL:H(PR(!29('P.<L0?#U+"<)51)Z[&7PD!&"$`"4D:
M)20\-))S(P`Y<LAA7QO>YUXV<:%A@SQT6J,,5!P99`,`"?#@`0"6`8`4`FWV
M>6""J[T0PZ$\M*4@`"/``("0#13@@HD\%/6(=@[H`"D2DA06`U0O&F$0IT/H
MU1D`"JB&*0\!'/!!5"@*"DE^U?&`(U7`2;*:10`TP$.G(A3::V%($D"`#B3^
M`,"+J9B=!=4;)=#:@(`+"*A`@@0X=:D+A4%8*`\?`7JBLLW<T"M*P`(PAR3B
M-@=`F7I:8^<9<ZVG[R^+)A&"#E"!:BR@0U#%@\&2-MIFADL^BU\C`#QK!+$,
M6^O=`0H$4.J24-D@&G.K&;0@LDC].EH2)@\H`%7/ALA<$H0&H`!@"Q=`'H(#
MMHEL`Y!*N)]H0W":%:6@[(QLR!MKS)&4!$@XK[:2/E"K`,_>59@R+^Q7P(N<
M#B"U<(,6B;//!Y(WJ9A:JPSP-/KDT1[<Q5RJ@#+:,J!MF9!Z`.@;"S?<L\D9
M(C5Q623`Y\$((I2`:YF$9J:MD)-B*>7(\_)0X,G^M`:P:P("S*AY`@/H%4+C
M)(!D`P@ZZB#:@0+R,/;*&2%\*`DBD"`M--K:<BE?`PAZN=.+0N5![B-D-,`#
M!#QB8^[,B&90"7J!`"@#R<MD0PC[O=YF`;(/4.H!T7=7]S#J090G^L80RB,Y
M+1D00.L!W'"IPFTJRX`-/7/%-(KVHA<19"@!)&"``P!E`!#LQT\:4P"AG$(\
MD<0*5R("3WY@`!4&%.TL*S,`H1C`J0;DA1=*<(`!];*R+-VE0$CX7Z3:,@(/
M**!_`0B!79"T&@\DZDI+DA*H-/8(0"E@!`UH@#*H@@>/B0`$"+"!RTJP0"E!
M0X8/J.$)4U@5V$G)`87^00(3G7B>]@6#7V:@&QF%(0(#$``!(PF-Z0`#`P*\
MR`-/X@%8#B@K.R:A`-!P@0$*``*P.<,`8S.:`0[P@`)TAP$#:(`3;0!"'HR`
M`!<1`0$4P(`#@.0#`;B:"';VHIH\``$A$(`#F!-*'HTR"20P)"'M2)@!?("-
M@T*"#@QPM1B4C@"BB@&X/$!()>C@`^/STR0KR1ME5L:0!%#$"`;`EY%):`$W
MJ*4R;."M1S*'EQ(2E1)>R2,AR;*8CTS`DJ@Y@`7()(V_D-L:T.C.>78B!$M"
MA$3HJ4\_F+$,\MPG,?[UKYEPX25=H(DRE&*4I5AAH.\`Z$24T89DQ)-]$+W^
MJ"4VTDZ,<G0@1D"27.3AT(Z2M*0F=04\@6+1D[*TI2[E1#_)\,^7TK2F-N5#
M2D-:CIORM*<^E>E'/7B0E?ZTJ$8]JA2V,=(NS!2I3GUJ3PDR-Z)"M:I6?6E.
MWT'5JW*UJQB-Z1B:ZM6QDA5]63V#6,NJUK6^1:D5W2E;XRK7GH!5#/Z:JUR7
MBE*\>D$955($1'04@,SPM;"&M0>ARK8&T0!@``2\@0YN(-G)0I:R):'L9"-K
MV<Q2U@::U2QF06L#SF*VLI*];&E!>UK2GG:TJ0TM:R4[6M6JMK6?+:UI;^#:
MW&X6MIG=;6]96]O7`C>VN1TN;W6;W-J"%KFT+>[^:H.K6L]&U[?*K6YPE4O;
MUZ86M=:M;FUGFUW;8I>UNW4N;C/KW?$V%[?/=:]UT?M;^$J7OJVU+W@[>UON
M7C>YX(7N<F.[WO+Z5[*X*M)&[Y0B!XE)`"%RL``@_.`'0UC"#183A3%\80=?
MN,,1SK"'.?SA#']8Q!8N\80W?.(5:QC%(29QBTT,XA'36,8;3G&)62QC&TNX
MQS?^L8LK'.,A[QC&&`XRB75LY"#SN,DS]O&+@7SD*3.9R$MV,HNC7.,GMYC*
M1U:RE)&L8BN'^<1))C.2Q9QC-(-YRUIV\IF++.4QOUC$1RY2I_3JA1LLV"A^
M_C.@`RWH01.ZT(8^-*+^$ZWH13.ZT8Y^-*0C+>E)4[K2EKXTIC.MZ4USNM.>
M]O.)^N#7$"0@D09(9%-,?>I3'\#4J6[UJF/MZE6GFM:LCC6L:XWK7<_ZU;*V
M-:R!C6I5_[K5P;ZUL8WM:F4?.]>\UK6MHZWL72>;V,4F]JN;O6QKRWK:PSYV
MK[U][5S[FMK?_K6P6:UM:Y/[VM+>-K.9/6QAEWO<W88WOM>M;W"S&]G:KC:_
MT]T4<8>;V^96-[?C;7"!UQO9YT;WK!'^;FGS6]_X1C?!%:[Q;9]Z`2'(R6%#
M+O*0@\2A>CY$7U,^%D*<?*`GIX*>37X)@ZX<"B^O>4U8CA&8#V3G4[BY&H!6
MGG-B,D$K0A\YTI.N]*4SO>E.?SK4HR[UJ5.]ZE:_.M:SKO6M<[WK7O\ZV,,N
K]K&3O>QF/SO:TZ[VM;.][6Y_.]SC+O>YT[WN=K\[WO.N][WSO>]3"`(`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
